



(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 21 December 2000 (21.12.2000)

PCT

(10) International Publication Number WO 00/77222 A1

(51) International Patent Classification⁷: 15/52, 9/02, 9/04, C12P 19/62

(21) International Application Number:

C12N 15/53,

PCT/EP00/06227

- (22) International Filing Date: 14 June 2000 (14.06.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 99201893.7

14 June 1999 (14.06.1999) EP

- (71) Applicant (for all designated States except US): DSM N.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MARTIN, Juan Fransisco [ES/ES]; Avda. de a Facultad NO. 13-4A, E-24004 Léon (ES). APARICIO, Jesus F [ES/ES]; C/Came-no Miranda, nd 9-1dB, E-33013 Oviedo (ES). COLINA, Angel Jose [ES/ES]; Paseo de Salamanca, nd 19-2dC, E-24009 Léon (ES).
- (74) Agents: MATULEWICZ, Emil, Rudolf, Antonius et al.; DSM N.V., DSM Patents & Trademarks, Office Delft (994-0760), P.O. Box 1, NL-2600 MA Delft (NL).


- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL. IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENES ENCODING ENZYMES IN THE BIOSYNTHESIS OF PIMARICIN AND THE APPLICATION THEREOF



(57) Abstract: A polynucleotide comprises the nucleic acid sequence set out in SEQ ID NO: 5, 7 or 9 or a homologue or fragment thereof or a sequence complementary thereto. Polynucleotides of the invention may be used for modifying the biosynthesis of pimaricin and also in the biosynthesis of new compounds.



GENES ENCODING ENZYMES IN THE BIOSYNTHESIS OF PIMARICIN AND THE APPLICATION THEREOF

Field of the invention

The invention relates to novel genes encoding enzymes which are fundamental in the biosynthesis of pimaricin. The invention further relates the application of said gene for modifying the biosynthesis of pimaricin. It also relates to the biosynthesis of new compounds.

10

15

20

25

30

35

5

Background of the invention

Polyketides, such as pimaricin (in the literature also referred to as natamycin, see for its structure Fig. 3A), form a large and highly diverse group of natural products. Members of the said group include compounds having antibacterial, antifungal, anticancer, antiparasitic and immunosuppressant activities.

Despite their structural diversity, these metabolites are believed to be synthesized by micro-organisms by a common pathway in which units derived from acetate, propionate or butyrate are condensed onto a growing chain by a polyketide synthase (PKS). The process resembles fatty acid biosynthesis, except that the β -keto function introduced at each elongation step may undergo all, part or none of a reductive cycle comprising β -ketoreduction, dehydration and enoylreduction. Structural variety of polyketides arises from the choice of monomers, the extent of β -ketoreduction and dehydration, and the stereochemistry of each chiral center. Yet further diversity is produced by functionalization of the polyketide chain by the action of glycosylases, methyltransferases and oxidative enzymes.

Modification of complex biomolecules, such as polyketides, is increasingly an important way of obtaining biologically active compounds with improved or altered properties. Currently, these modifications are usually introduced by chemical methods in a directed or random (e.g.

15

20

25

30

35

in combinatorial chemistry) manner. A drawback of these chemical methods is that they are often performed under relatively harsh conditions and furthermore, they lack selectivity and/or sensitivity. Particularly, in the case of complex biomolecules having multiple functionalized, reactive groups, precautions have to be taken in order to avoid undesired side reactions. These precautions include for instance the introduction of protective groups before a desired chemical conversion. Consequently two additional process steps are involved, as the protective groups must be removed afterwards.

Bioconversion of simple organic compounds, i.e. compounds with no or single reactive centers, has been known for some time and has been widely applied. Examples are the oxidation of long chain alkanes using alkane hydroxylation systems of Pseudomonas, and epoxidation of alkenes using enzyme systems from various micro-organisms. However, for the specific modifications required in the biosynthesis of complex molecules, for example, β -lactam antibiotics, polyketide antibiotics, anticancer agents, or peptide antibiotics, the large amounts of reactive groups present in those molecules are problematic for even the simplest treatments, such as hydrolysis of specific bonds. More complicated treatments frequently completely destroy the molecule.

Summary of the invention

The present invention is based on the identification and isolation of three genes which encode enzymes which facilitate specific oxidative conversions in the biosynthesis of pimaricin. The present invention thus provides the means to perform specific conversions in complex biomolecules, in particular in polyketides, without applying the harsh conditions often related to chemical modifications. The said conversions can be carried as part

25

of a biosynthesis of said biomolecules, for instance in micro-organisms.

Surprisingly, it has been found that the expression of polynucleotides of the invention in different microorganisms, can lead to the biosynthesis of different biomolecules. It has further been found that expression of the said polynucleotides may be switched off (or knocked out) in Streptomyces which is usually used for the biosynthesis of pimaricin. In this embodiment, no pimaricin is produced by said Streptomyces, but instead a modified biomolecule is produced. In addition, it has been found that the polynucleotides may be overexpressed in Streptomyces, leading to an increase in the biosynthesis of pimaricin in the said Streptomyces.

- According to the invention there is thus provided a polynucleotide comprising:
 - i) a nucleic acid sequence set out in SEQ ID NO: 5, 7 or 9 or a sequence complementary thereto; or
 - ii) a homologue or fragment of a sequence defined in i).
 The invention also provides:
 - a polypeptide encoded by a polynucleotide of the invention which is preferably isolated and/or purified;
 - a polypeptide obtainable by a polynucleotide of the invention in a cell which is a *Streptomyces* (including e.g. *S.natalensis*) cell or a cell of a heterologous species
 - a polypeptide comprising the amino acid sequence set out in SEQ ID NO: 6, 8 or 9 or a homologue or fragment thereof:
- 30 a recombinant cell comprising at least one additional copy of a polynucleotide of the invention, wherein the cell naturally possesses at least one said polynucleotide;
- a recombinant cell, wherein a polynucleotide of the
 invention which naturally occurs in the cell has been inactivated;

30

35

- a recombinant cell comprising a polynucleotide according to the invention which polynucleotide does not naturally occur in that cell or where the polynucleotide is heterologous to that cell;
- 5 a method for overexpressing a polynucleotide encoding a polypeptide according to the invention in Streptomyces cell which method comprises:
 - i) attaching a promoter sequence to the said
 polynucleotide;
- ii) transferring the resulting promoter-polynucleotide complex into the said cell; and
 - iii) maintaining the resulting cell under conditions
 suitable for expression of the said polynucleotide;
- a method for inactivating a polynucleotide encoding a

 15 polypeptide according to the invention in a Streptomyces
 cell which method comprises disrupting the coding
 sequence of the said polynucleotide;
 - a method for expressing a polynucleotide encoding a polypeptide according to the invention in a heterologous cell which method comprises:
 - i) attaching a promoter sequence to the said polynucleotide;
 - ii) transferring the resulting promoter-polynucleotide complex into the said cell; and
- 25 iii) maintaining the resulting cell under conditions suitable for expression of the said polynucleotide;

invention and isolating the said pimaricin;

- a method for producing pimaricin which method comprises maintaining a recombinant cell according to the invention under conditions suitable for obtaining expression of the additional copy of a polynucleotide according to the
- a method for producing a biomolecule which method comprises maintaining a recombinant cell according to the invention under conditions which would be suitable for obtaining expression of the inactivated polynucleotide

25

35

had it not been inactivated and isolating the said biomolecule;

- a method for producing a biomolecule which method comprises maintaining a recombinant cell according to the invention under conditions suitable for obtaining expression of the polynucleotide which does not naturally occur in the cell and isolating the said biomolecule;
- a biomolecule obtainable by a method of the invention for producing a biomolecule;
- 10 use of a recombinant cell of the invention in the production of pimaricin;
 - use of a recombinant cell of the invention in the production of a biomolecule;
- a vector containing a polynucleotide of the invention
 which is capable of expressing a polypeptide of the invention;
 - a cell harbouring a vector of the invention; and
 - a method for producing a polypeptide of the invention, which method comprises maintaining a recombinant cell
- according to the invention under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide.
 - use of a isolated and/or purified polypeptide according to the invention for the oxidative modification of a methyl group of a suitable compound.

Brief description of the drawings

Figure 1: Physical map of part of the Pimaricin biosynthetic cluster.

- Genes: locations of the genes encoding polyketide synthases and oxidative genes involved in Pimaricin production (not drawn to scale);
 - Probes: 0.7 indicates the location of the 0.7 kb fragment used to identify the extent of polyketide synthase encoding regions; 3.3 indicates the location of the 3.3 kb fragment used in polyketide synthase gene disruption;

Cosmids: sizes and numbers of available cosmids covering the chromosomal region encompassing the oxidative genes.

Figure 2: Detailed physical map of the chromosomal regions including the oxidative genes.

Figure 3A: Molecular structure of Pimaricin.

Figure 3B: Molecular structures of Pimaricin derivatives with a reduced oxidation state of C4 and C5 and/or the carboxyl group at C12.

Figure 4: Molecular structures of Amphotericin B and 15 Nystatin

Figure 5: 5 illustrates the conversion of the triketide lactone to it oxidized form by the action of pORF1 and pORF2

20 <u>Description of the sequence listings</u>

polyketide synthase gene

- SEQ ID 1 shows the nucleotide sequence and derived amino acid sequence of a first Pimaricin biosynthesis associated polyketide synthase gene
- SEQ ID 2 shows the amino acid sequence of a first Pimaricin 25 biosynthesis associated polyketide synthase SEQ ID 3 shows the nucleotide sequence and derived amino acid sequence of a second Pimaricin biosynthesis associated
 - SEQ ID 4 shows the amino acid sequence of a second Pimaricin biosynthesis associated polyketide synthase
 - SEQ ID 5 shows the nucleotide sequence and derived amino acid sequence of ORF1, an oxidative gene involved in Pimaricin biosynthesis
 - SEQ ID 6 shows the amino acid sequence of an oxidation
- enzyme pORF1 involved in Pimaricin biosynthesis
 SEQ ID 7 shows the nucleotide sequence and derived amino

acid sequence of ORF2, an oxidative gene involved in Pimaricin biosynthesis

SEQ ID 8 shows the amino acid sequence of an oxidation enzyme pORF2 involved in Pimaricin biosynthesis

- 5 SEQ ID 9 shows the nucleotide sequence and derived amino acid sequence of ORF3, an oxidative gene involved in Pimaricin biosynthesis
 - SEQ ID 10 shows the amino acid sequence of an oxidation enzyme pORF3 involved in Pimaricin biosynthesis
- 10 SEQ ID 11 shows a synthetic oligonucleotide (forward primer) for isolation by PCR of the ermE promoter of Saccharopolyspora erythraea
 - SEQ ID 12 shows a synthetic oligonucleotide (reverse primer) for isolation by PCR of the ermE promoter of
- 15 Saccharopolyspora erythraea

SEQ ID 13 shows a synthetic oligonucleotide (forward primer) for isolation by PCR of the N-terminal region of ORF1
SEQ ID 14 shows a synthetic oligonucleotide (reverse primer) for isolation by PCR of the N-terminal region of ORF1

20

25

30

35

Detailed description of the invention

Three open-reading frames (ORFs) were identified from the Pimaricin producing microorganism Streptomyces natalensis. The three ORFs are associated with polyketide synthese genes and each ORF has been shown to be essential for pimaricin biosynthesis.

The functionality of the Pimaricin PKS associated genes was initially pursued by comparing their derived amino acid sequences with those present in public databases like EMBL, Genbank, NBRF/PIR, or Swissprot.

Surprisingly, ORF1 appeared to resemble cholesterol oxidases from several Streptomyces species. The close association of ORF1 with the Pimaricin PKS suggests an oxidative step in Pimaricin tailoring. A methyloxidase encoding gene has not been observed previously in a polyketide biosynthesis gene cluster.

Based on similar analyses, ORF2 and ORF3 resemble cytochrome P450 dependent monooxygenases from various sources. With respect to the biosynthesis of bioactive compounds, P450 dependent monooxygenases have been identified before in association with polyketide gene 5 clusters, e.g. in the Erythromycin and Rapamycin biosynthesis gene clusters. However, only in the Erythromycin case has a specific enzymatic action on Erythromycin precursor compounds been proven. Essentially all known cases of tailoring oxidation steps act on 10 secondary carbon atoms (methylene groups). Oxidation of primary carbon atoms (methyl groups) to carboxylic acid function in polyketide biosynthesis, as has presently been found, is unprecedented. Nothing is known about the 15 molecular basis of epoxide formation in polyketide products, though epoxides are present in a few known structures.

Thus, the invention provides a polynucleotide which comprises:

20 i) a nucleic acid sequence set out in SEQ ID NO: 5, 7, or 9 or a sequence complementary thereto; or

25

ii) a homologue or fragment of a sequence defined in i).

Polynucleotides of the invention may comprise DNA or
RNA. The invention also provides double stranded
polynucleotides comprising a polynucleotide of the invention
and its complement.

Homologues of a nucleic acid sequence set out in SEQ ID NO: 5, 7 or 9 are polynucelotideds which do not share 100% sequence identity with a sequence set out in SEQ ID NO: 5, 7 or 9, but which do encode polymentides having a

- 5, 7, or 9, but which do encode polypeptides having a similar enzyme activity to a polypeptide encoded by a nucleic acid sequence set out in SEQ ID NO: 5, 7 or 9. Thus a homolog of a polypeptide encoded by SEQ ID NO: 5 will typically encode a polypeptide which has methyl oxidase or
- 35 methyloxidase-like activity. A homologue of a polypeptide encoded by SEQ ID NO: 7 or 9 will typically encode a

polynucleotide which has cytochrome P-450 monocxygenase activity or cytochrome P-450 monooxygenase-like activity. A homologue of the invention will generally have at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the sequence of SEQ ID NO: 5, 7 or 9 over a region of at least 60, more preferably at least 100 contiguous nucleotides or most preferably over the full length of SEQ ID NO: 5, 7 or 9 (for determination of sequence identity see D.J. Lipman, W.R. Pearson. 1985.

10 Science 227, p1435).

15

35

Any combination of the above mentioned degrees of sequence identity and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher sequence identity over longer lengths) being preferred. Thus, for example a polynucleotide which has at least 90% sequence identity over 60, forms one aspect of the invention, as does a polynucleotide which has at least 95% sequence identity over 100 nucleotides.

The sequence of SEQ ID NO: 5, 7 or 9 may be modified 20 by nucleotide substitutions, for example from 1, 2 or 3 to 10 or 25 substitutions. The polynucleotide of SEQ ID NO: 5, 7 or 9 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends. The modified polynucleotide 25 generally encodes a polypeptide which has methyl oxidase or cytochrome P-450 monooxygenase activity. Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for 30 example as shown in the Table below.

Polynucleotides of the invention include fragments of a sequence set out in SEQ ID NO: 5, 7 or 9. Thus, polynucleotides of the invention may be used as a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labeled with a revealing label by conventional means using radioactive or non-radioactive

10

labels, or the polynucleotides may be cloned into vectors (M.A. Innis et al..1990. PCR Protocols, Academic Press Inc).

Such primers, probes and other fragments will preferably be at least 10, preferably at least 15 or at least 20, for example at least 25, at least 30 or at least 40 nucleotides in length. They will typically be up to 40, 50, 60, 70, 100, or 150 nucleotides in length. Probes and fragments can be longer than 150 nucleotides in length, for example up to 200, 300, 400, 500, 600, 700 nucleotides in length, or even up to a few nucleotides, such as five or ten nucleotides, short of the full length of the sequence of SEQ ID NO: 5, 7 or 9.

5

10

15

20

25

30

35

Polynucleotides such as DNA polynucleotide and primers according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques.

Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook et al, 1989, Molecular Cloning: a laboratory manual.

A polypeptide of the invention comprises the amino acid sequence set out in SEQ ID NO: 6, 8 or 10 or a substantially homologous sequence, or a fragment of the said sequences and typically has methyl oxidase or cytochrome P-450 monooxygenase activity. In general, the naturally

occurring amino acid sequence shown in SEQ ID NO: 6, 8 or 10 is preferred.

A polypeptide of the invention may comprise:

- (a) the polypeptide sequence of SEQ ID NO: 2, 4, 6, 8,
- 5 10 or 12; or

10

15

20

25

(b) a homologue or fragment thereof.

A homologue may occur naturally, for example, in a bacterium and will function in a substantially similar manner to the protein of SEQ ID NO: 6, 8 or 10, for example it acts as a methyl oxidase in the case of a homologue of SEQ ID NO: 6 or a cytochrome P-450 monooxygenase in the case of a homologue of SEO ID NO: 8 or 10.

Homologues can be obtained by following the procedures described herein for the production of the polypeptides of SEQ ID NO: 6, 8 or 10 and performing such procedures on a suitable cell source e.g. a bacterial cell. It will also be possible to use a probe as defined above to probe libraries made from bacterial cells in order to obtain clones encoding homologues. The clones can be manipulated by conventional techniques to generate a polypeptide of the invention which can then be produced by recombinant or synthetic techniques known per se.

A homologue of a polypeptide of the invention preferably has at least 80% sequence identity to the protein of SEQ ID NO: 6, 8 or 10, or more preferably at least 90%, at least 95%, at least 97% or at least 99% sequence identity thereto over a region of at least at least 40, preferably at least 60, for instance at least 100 contiguous amino acids or over the full length of SEQ ID NO: 6, 8 or 10.

The sequence of the polypeptide of SEQ ID NO: 6, 8 or 10 and of homologues can thus be modified to provide polypeptides of the invention. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10 or 20. substitutions. The modified polypeptide generally retains activity as a methyl oxidase or cytochrome P-450 monooxygenase. Conservative substitutions may be made, for

WO 00/77222

CT/EP00/06227

example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

12

ALIPHATIC	Non-polar	G A P
	Polar-uncharged	CSTM
	Polar-charged	D E K R
AROMATIC		H F W Y

5

Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides. Such fragments typically retain activity as a methyl oxidase or cytochrome P-450 monooxygenase.

10

15

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus, in a further embodiment, the invention provides a method of making polypeptides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell.

20

25

Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence, such as a promoter, "operably linked" to a coding sequence is positioned in such a way that

13

expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

10

15

20

25

Vectors of the invention may be transformed into a suitable host cell to provide for expression of a polypeptide of the invention. Thus, the invention provides a process for preparing a polypeptide according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector encoding the polypeptide and recovering the polypeptide.

Each of the genes ORF1, ORF2 and ORF3 can be used for various purposes separately or in combination. This will be discussed in detail below.

Targeted inactivation of one or more of the present genes, e.g. through marker insertion or replacement with a non-functional gene equivalent, interferes with at least one (oxidation) step in the Pimaricin biosynthetic route. This results in the production of modified Pimaricin molecules characterized by a different oxidative state. For example, molecules can be created lacking the epoxide function at carbons C4 and C5, or molecules with a modified oxidation state of the carboxyl group at C12 resulting in an aldehyde, alcohol, or methyl group at this position.

Disruption of chromosomally encoded genes can be accomplished by gene replacement strategies. Gene replacement is preferably carried out using suicide plasmid vectors or defective phage vectors carrying modified target genes and detection or selection marker genes. The various elements useful for such strategies, and how to employ them, are described below.

Target gene modification can be accomplished by disruption of a coding sequence by insertion or deletion of nucleotides or nucleotide stretches. Such insertions or deletions may be of any suitable size. Preferably, they are of a size of at least 2 nucleotides, for example up to 5, up to 10, up to 25 or up to 50 nucleotides in length, excepting deletions which are multiples of 3. Alternatively, the

14

coding region of the target gene may be replaced by that of a (marker) gene. This confers an easily detectable phenotype on cells transformed with such a construct. Suitable examples of replacement genes are lacZ, xylE, Green Fluorescent Protein, and genes for the biosynthesis of antibiotics, such as erythromycin, apramycin, hygromycin, and thiostrepton, and metabolite analogues, such as fluoroacetamide.

Transfer of a disrupted target gene to a Pimaricin 10 production host, resulting in in vivo gene inactivation, can be accomplished by using e.g. suicide vector systems, a defective phage containing a fragment internal to the coding region of the target gene, or a variant of the gene inactivated through deletion or insertion of DNA stretches 15 as described above, and optionally a detection or selection marker. Suicide vectors and defective phages are characterized by their inability to propagate autonomously in the strain to be transformed and thus cannot be stably maintained by themselves. For Streptomycetes in general 20 several suicide systems are available and suicide vectors can be chosen from the group of extrachromosomal element based cloning vectors available for E. coli, which cannot replicate in Streptomyces species, including for example pBR322, pUC, CoID, RSF1010, RK2 and vectors derived from 25 these plasmids. Similarly, Streptomyces plasmids characterized by a limited host range can be selected that are incapable of stable maintenance in the desired host strain. Examples of such narrow host range plasmids are SLP1.2 and SCP2, and cloning vectors derived from these plamids. Still another possibility is to use temperature 30 sensitive variants of Streptomyces wide host range plasmids. These plamids are characterized by their inability to replicate above a certain (restrictive) temperature. Besides non-replicative plasmids, defective phage vectors have been 35 developed based on the Streptomyces phage phiC31 and have proven extremely useful for genetic analysis. In this

15

regard, it is noted that an extensive overview of known Streptomyces genetic engineering techniques may be found in Hopwood et al. (D.A. Hopwood, M.J. Bibb, K.F. Chater, T. Kieser, C.J. Bruton, H.M. Kieser, D.J. Lydiate, C.P. Smith, J.M. Ward, H. Schrempf, Genetic Manipulation of Streptomyces: A Laboratory Manual, The John Innes Foundation, Norwich, England, 1985).

5

10

15

20

25

30

35

The above mentioned suicide constructs can be introduced in a desired host cell using transformation procedures with isolated DNA, by conjugation from a donor microorganism, e.g. an *E. coli* or *Streptomyces* strain harboring the construct, or via transfection by phage particles. All of these methods are well within the knowledge of the person skilled in the art.

Upon introduction of such a construct in the microorganism of interest, e.g. Streptomyces natalensis, stable maintenance of the introduced genetic information is only possible by integration of the construct in the host chromosome, preferably by homologous recombination with the chromosomal copy of the target gene. Strains having integrated the construct in the chromosome can be detected by the expression of a co-introduced marker. In case of a detection marker, transformed colonies can be screened for acquired properties such as conversion of a colorless substrate into a colored compound (applicable with e.g. the genes lacZ, or xylE) or fluorescence (by expression of e.g. Green Fluorescent Protein). Alternatively, a marker can be used which allows selection of transformed strains by acquired resistance to e.g. antibiotics or toxic metabolite analogues. The latter method usually is employed more frequently because only cells with the acquired resistance will be able to grow in media containing the antibiotic or toxic metabolite analogue. If an internal fragment of the target gene is used for the construction of the suicide vector or defective phage, integration of the construct into the chromosomal copy of the target gene will result in

16

inactivation immediately. If the suicide construct or defective phage contains the complete target gene or a fragment including the N-terminal or C-terminal coding region, though inactivated through smaller insertions or deletions, only integration of the construct will result in the presence of an active and inactive copy of the gene, separated by vector DNA. For obtaining a strain with only an inactive copy, a second homologous recombination has to take place removing the vector sequences and the active copy of the target gene. Strains having undergone this second homologous recombination can be detected by the loss of the acquired property encoded by the co-introduced marker gene.

10

15

20

25

30

35

Another application of the present genes from the Pimaricin gene cluster lies in overexpression of one or more of these genes in the natural host, Streptomyces natalensis. The expression of the individual genes within the cluster is tightly regulated by the cell physiology and/or cluster specific regulatory genes. This internal control may be appropriate for production of the antibiotic in the natural environment, but is undesirable for industrial production. Overexpression of all genes of the cluster by introduction of additional gene copies or altering the controlling elements (e.g. promoters or regulatory genes) can boost antibiotic production considerably. This has been shown for e.g. Actinorhodin production by Streptomyces coelicolor. A similar effect can be obtained by overexpression, specifically of those genes encoding enzymes representing rate limiting steps in antibiotic biosynthesis.

Additional copies of each of the present genes from the Pimaricin biosynthesis gene cluster or homologues or fragments thereof, either separately or in different combinations, can be introduced into *Streptomyces natalensis*. This increases the efficiency of the oxidative reactions leading to biosynthesis of the natural Pimaricin molecule, and results in strains displaying improved Pimaricin production. This increase may be in the form of

17

increased Pimaricin titre in the culture broth or a higher product yield on substrate consumed. Of course, enhanced expression of certain genes can also be combined with inactivation of other genes, thus effecting improved production of variants of Pimaricin as described above.

5

10

15

20

25

30

35

Strains containing additional copies of target genes can be obtained through introduction of complete genes including expression signals (promoters and optionally enhancers) into the host chromosome. Suitable techniques include suicide vectors and defective phage, as described above. Alternatively, autonomously replicating DNA molecules derived from phage genomes or extrachromosomal elements, for example plasmids, can be used to carry the additional genes. Suitable cloning vectors include those derived from plasmids pIJ101 and SCP2. Other vectors can be constructed based on the plasmid naturally occurring in Streptomyces natalensis, as disclosed in GB patent application nr 2210619, using selection and/or detection markers similar to those employed for the pIJ101 derived vectors, such as pIJ702, pIJ486, with or without added markers as described above.

For gene expression, a large variety of promoters efficiently directing transcription of genes in Streptomyces is available. An example of a constitutive promoter is the ermE promoter, which directs expression of the erythromycin resistance gene from Saccharopolyspora erythraea. By contrast the agarase gene promoter from S.coelicolor, the promoter of the glycerol utilization operon, or the tipA promoter are examples of promoters inducible by specific substrates. Using techniques known in the art additional promoters can be obtained, e.g. promoters endogenous to S.natalensis (see J.M.Ward, G.R.Janssen, T.Kieser, M.J.Bibb, M.J.Buttner, M.J.Bibb. 1986. Mol.Gen.Genet. 203: 468-478).

The degree of overexpression can be manipulated by the choice of the promoter, by the amount of inducing compound, or by the choice of the autonomously replicating vector systems. Depending on the vector derivative used,

18

predetermined plasmid copy numbers can range from 1 or 2 to about 500. It is well within the expertise of the normal person skilled in the art to adjust the vector system to the desired degree of overexpression.

5

10

15

20

25

30

35

Both of the above uses of polynucleotides of the invention, i.e. inactivation to obtain new variants of Pimaricin and overexpression to increase Pimaricin productivity, can also be applied to strains producing structurally similar bioactive compounds for instance polymer antibiotics such as Amphotericin B (Streptomyces nodosus), Nystatin (Streptomyces noursei) (see Figure 4) to obtain variants of these compounds and/or to improve productivity Using the present genes to inactivate the corresponding genes in Streptomyces species other than Streptomyces natalensis will result in new derivatives of, inter alia, nystatin and amphotericin B which are altered in their oxidative state.

A further application of the polynucleotides of the invention is the heterologous expression and exploitation of the enzymatic activity encoded by one or more of the said polynucleotides. Using similar vector systems as employed for overexpression of the oxidative genes in S.natalensis, other microorganisms, preferably Streptomycetes species for instance the strain Streptomyces lividans or Streptomyces coelicolor, can be genetically transformed and thus acquire new oxidative enzymatic activity. This route is particularly useful for application of the enzymatic activities of polypeptides of the invention to the oxidative modification of other, preferable bioactive, compounds. Examples include secondary metabolites, antibiotics and anticancer agents etc., which often are highly functionalized chemical entities. Thus, it is possible to introduce one or more of the polynucleotides of the invention into a host producing such bioactive compounds naturally, or one which has acquired the genetic information to produce compounds by recombinant DNA technology. A strain having acquired a gene

35

or genes encoding oxidative enzymatic activity from the Pimarcin biosynthetic gene cluster will then be able to introduce, for example, epoxide functions or alcohol, aldehyde, or carboxyl groups into metabolites previously not modified in such a way. In this way it is possible to 5 oxidize a methyl group which is not part of an linear alkane. A methyl group forming part of an aliphatic ring of an organic compound or biocompound can be oxidized by one or more of the polypeptides of the invention. The polypeptides 10 of the invention can be isolated or purified from rDNA transformed hosts in which one or more of the polynucleotides of the invention are introduced. Preferably the polynucleotide are heterologous to the host. But also the transformed host as such may be used for the oxidative conversion. Thus, an approach has been provided, which 15 allows for the creation of new variants of bioactive compounds not obtainable by chemical means (exemplified in Example 6 below).

The invention will now be demonstrated by the 20 following, non-restrictive examples.

Examples

Example 1. Isolation and identification of Pimaricin biosynthetic genes.

Streptomyces natalensis strain ATCC27448 was grown in YEME medium (D.A. Hopwood, M.J. Bibb, K.F. Chater, T. Kieser, C.J. Bruton, H.M. Kieser, D.J. Lydiate, C.P. Smith, J.M. Ward, H. Schrempf, Genetic Manipulation of Streptomyces: A Laboratory Manual, The John Innes Foundation, Norwich, England, 1985) at 30°C for 3 days. Mycelium was harvested and total DNA was extracted and purified essentially as described by Hopwood (ibid.).

Total S.natalensis DNA was subjected to partial digestion with the restriction enzyme Sau3AI and size

20

fractionated on 0.8% agarose gel. Fragments of 30-40 kbp were isolated, inserted into BamHI digested cosmid Supercosl and subsequently introduced in E.coli strain XL1-Blue MR according to protocols suggested by the supplier (Stratagene, La Jolla).

Thus, a cosmid library of S.natalensis DNA in E.coli was obtained. The cosmid library was screened for the presence of polyketide synthase (PKS) related sequences by hybridization with radioactively labeled fragments from 10 known PKS genes from the Rapamycin biosynthesis cluster from Streptomyces hygroscopicus (T.Schwecke, J.F.Aparicio, Y.Molnár, A.König, L.E.Khaw, S.F.Haydock, M.Oliynyk, P.Caffrey, J.Cortés, J.B.Lester, G.A.Böhm, J.Staunton, P.F.Leadlay. 1995. Proc. Natl. Acad. Sci. USA 92: 7839-7843).

Several clones were isolated which contained sequences hybridizing to a fragment containing the KS module 5 of rapB.

Complete DNA sequence determination of a number of neighbouring NotI fragments from Cos9 was performed after cloning the fragments in pBluescript. Computer assisted analysis of the DNA sequences revealed the presence of genes clearly identifiable as PKS gene modules on the basis of nucleotide and derived amino acid sequence homology with established PKS genes and proteins involved in the biosynthesis of erythromycin and rapamycin, as well as with fatty acid synthase genes and proteins, which catalyze a similar set of reactions. The complete nucleotide sequences and derived amino acid sequences of two Pimaricin PKS genes are given as SEQ ID numbers 1-4.

Using a 0.7 kb NotI fragment from Cos9 as a probe, the extent of the PKS related genes on the cosmid map was established as indicated in Figure 1.

20

25

30

Example 2. PKS genes are essential for Pimaricin biosynthesis

A completely sequenced 3.3 kb NotI DNA fragment (see Figure 1) (in pBluescript), encoding part of a S.natalensis 5 PKS as deduced form the organizational and structural sequence similarities with known PKS, was excised by SacI from the sequencing vector. The fragment was subcloned into the phage vector KC515 (M.R.Rodicio, C.J.Bruton, K.F.Chater. 10 1985. Gene 34: 283-292) and introduced in S.lividans to obtain infectious particles (recombinant phage) containing the S.natalensis PKS fragment. Infection of S.natalensis using this recombinant phage population and selection for resistance to the antibiotic viomycin, allowed the isolation 15 of lysogens, originated through integration of the recombinant phage DNA into the S.natalensis chromosomal DNA by homologous recombination of the PKS regions.

None of 20 lysogens tested displayed antifungal activity as analyzed by an agar plate bioassay using Candida utilis as the indicator organism. Detailed analysis of one of the lysogens by Southern hybridization studies confirmed that integration of the recombinant phage DNA into the S.natalensis chromosomal PKS locus had indeed occurred.

Culturing the lysogen with the disrupted PKS gene in standard production medium (25 g/l soya peptone, 0.5 mM ZnSO₄, 20 g/l glucose, pH 7.5) followed by extraction of the culture broth with butanol, and UV spectrophotometric analysis indicated that no traces of Pimaricin were produced by this lysogen (J.F.Martín, A.L.Demain. 1975. Biochem. Biophys. Res. Commun. 71: 1103-1109).

20

25

30

Example 3. Detailed sequence analysis of non-PKS genes: preliminary identification.

Full sequence analysis of the regions flanking the PKS genes of Example 1 revealed the presence of additional

22

open reading frames (ORF) potentially encoding proteins functional in Pimaricin biosynthesis.

Homology comparison of the deduced amino acids sequences of the ORFs indicated the involvement of several in oxidation/reduction reactions. ORF1 showed a clear homology with previously identified cholesterol oxidases and ORF2 and ORF3 were similar to cytochrome P-450 monooxygenase proteins. Also, genes encoding accessory proteins for the P-450 enzymes seem to be present i.e. ferredoxin type. Complete nucleotide sequences of the respective genes and derived amino acid sequences are added as SEQ ID numbers 5-10. Detailed information on the chromosomal regions enompassing the three open reading frames (ORF's) is presented in Figure 2.

15

10

5

Example 4. Functional characterization of non-PKS genes involved in Pimaricin biosynthesis.

To define the involvement of the accessory genes/proteins in Pimaricin biosynthesis, both ORF1 and ORF3 20 were disrupted and the effect on Pimaricin production established. Similar strategies as described in Example 2 for the PKS disruption were employed for the non-PKS genes. ORF1 : a 7kb SphI fragment containing the complete ORF1 was cloned into pUC19, the resulting plasmid was digested with 25 BqlII, the cohesive ends were filled in by treatment with Klenow polymerase and religated. This new plasmid was used as a source for DNA for the gene replacement. The 2.9 kb BamHI-PstI fragment from the plasmid was cloned into the BamHI-PstI sites of KC515. The recombinant phage was 30 propagated in S.lividans, and used to infect the wildtype S. natalensis strain. Lysogens were obtained by selection for thiostrepton. The second recombination event was searched for by the loss of thiostrepton resistance. The insertion 35 and subsequent loss of the phage as well as the final structure of the disruptred gene was confirmed by Southern

23

hybridization.

ORF3: disruption was accomplished by insertion of a 667 bp PvuII-SmaI fragment internal to ORF3 in HinCII cut pUC19; The fragment was excised using BamHI and PstI and ligated into similarly digested phage vector KC515.

Transformation of the ligation mixture to S.lividans yielded recombinant phage Ø6D4-1particles. After transfection of S.natalensis, lysogens were isolated as described above.

Disruption of ORF3 in S.natalensis mutant D4 was confirmed by Southern hybridization

Example 5. Analysis of ORF1 and ORF3 gene disruptants of S.natalensis.

15

20

10

5

Strains with disrupted ORF1 and ORF3 were analyzed for pimaricin production using the bioassay with *C.utilis*. For both disruptants the production of an antifungal activity was strongly reduced as compared with the wild-type strain *S.natalensis* ATCC27448.

Both strains were cultured in pimaricin production medium (see Example 2) and the culture filtrate was analyzed by combined liquid chromotography/mass spectroscopy (LC-MS) analysis.

Disruptants in ORF1 did not contain any pimaricinlike molecule in the culture filtrate.

In the case of the ORF3 disruptant a single Pimaricin-like molecule was detected in the culture filtrate having molecular mass of 649.75 indicating the loss of exactly 1 oxygen atom. The exact structure was determined by NMR spectroscopy to be identical to Pimaricin except that the epoxide function at was replaced by a double bond; the structure with a double bond between C₄-C₅ (displayed in Figure 3b (top)) is the expected biosynthetic precursor for the epoxidation.

24

Example 6. Overexpression of ORF1, ORF2, and ORF3 in S.natalensis.

Separate overexpression of ORF1, ORF2 and ORF3 was achieved by placing each gene under the direction of the ermE promoter from Saccharopolyspora erythraea (M.J. Bibb, G.R. Janssen, J.M. Ward. 1985. Gene 38: 215-226). A useful derivative of this promoter, having a number of cloning sites attached was obtained by PCR using the following oligonucleotides: SEQ ID 11:

AAACTGCAGCTCTAGAGGCGGCTTGCGCCCGATGCTAGTC

SEO ID 12:

AAACTGCAGCTCTAGATGCCCGGGTATCGATCGTCGACGGCATGCGGATCCTACCAACCGGCACGATTG

15

30

35

10

The 225 bp PCR fragment obtained was digested with PstI, purified by agarose gel electrophoresis and inserted into PstI digested pUC19, yielding pUCermE

ORF1 was inserted in pUCermE as a 2.2 kb SphI-ClaI fragment encompassing the complete coding sequence. For ORF2 a 3.5 kb ClaI-NruI fragment was used, and for ORF3 a 2.8 kb SalI-KpnI fragment was used. Each ermE promoter-ORF combination was subsequently excised as a PstI fragment, inserted in PstI digested phage vector KC515 and introduced in S.natalensis essentially as described in Example 4.

Recombinant S.natalensis strains were thus obtained which overexpressed one of the three genes. Each strain showed improved levels of Pimaricin production of 10 -15 % after growth under standard production conditions (see Example 2).

Example 7. Expression of S. natalensis ORF1, ORF2, and ORF3 in S. coelicolor and S. lividans

ORF1 and ORF2: A 223 bp NdeI-EcoRI fragment,

10

15

corresponding to the 5'end of ORF1 from the ATG to the first EcoRI site was obtained using the Polymerase Chain Reaction such that an NdeI site was created coinciding with the ATG initiation codon of ORF1. The oligonuleotides used for this PCR were 5'-AGGATTACCCATATGTTCGAGAACCAGCAT-3' (forward; SEQ ID NO 13) and 5'-GCATGAGCGTGGGAATTCCG -3" (reverse; SEQ ID NO 14). The PCR product was digested with Ndel and EcoRI cloned into similarly digested vector pT7-7 (S. Tabor, C.C. Richardson. 1985. PNAS 82, 1074) to yield plasmid pJA56.

pJA56 was digested with *EcoRI* and *SmaI*, and ligated to an *EcoRI-NruI* fragment encompassing ORF1 and ORF2, yielding plasmid pJA57.

pJA57 was digested with NdeI and ligated to NdeI-digested pIJ6021 (E .Takano et al. 1995. Gene 166,133). The resulting plasmid was named pJA58. Both ORF1 and ORF2 are now under the direction of the thiostrepton inducible tipA promoter. Plasmid pJA58 was transformed into strain S.coelicolor A(3)2 and S.lividans 1326.

ORF3: The ORF3 expression vector has been constructed by cloning a 3.7 kb KpnI fragment containing the complete ORF3 into the unique KpnI site of pHZ1351 (Bao et al.. 1997. ISBA Meeting abstract 4P15). The resulting plasmid (pJA50) was transformed to strain S.coelicolor A(3)2 and S.lividans 1326. Expression of ORF3 is directed by its own promoter.

Example 8. Activity of cell-free extracts of S. coelicolor expressing ORF1, ORF2, and ORF3.

- 30 S.coelicolor strains expressing the genes ORF1 and 2, and ORF3, respectively, thus producing the active proteins pORF1, pORF2, and pORF3 were grown in YEME medium (Hopwood et al., ibid). For induction thiostrepton was added to 0.005mg/l. Incubation was for 48 hrs. at 30°C.
- 35 Cell-free extracts were prepared as follows:

 Mycelium was harvested by centrifugation at 5000xg/4°C for

26

10 minutes and washed with 1 volume of 50mM Tris-HCl pH 7.5, 1mM DTT, 10% glycerol. The mycelium was resuspended in 0.2 volume of 50mM Tris-HCl pH 7.5, 1mM DTT, 10% glycerol; 1 tablet of protease inhibitor cocktail (Boehringer Mannheim) was added per 25 ml of extract. Cell extracts were prepared by sonication. After sonication cell debris were removed by centrifugation at 10000xg / 4°C for 10 minutes.

5

25

Activity assays for the cell-free extracts were

10 performed using S.coelicolor cell-free extract (100-1000μg total protein); 0.5 μmol NADPH; 5 μmol glucose-6-phosphate; 0.5 U glucose-6-phosphate dehydrogenase; 22μg spinach ferredoxin; 0.05 U spinach ferredoxin NADP+ reductase. As substrate for the oxidation activities triketide lactone

15 (TKL, see Figure 5; M.J.B. Brown et al. 1995. J.Chem.Soc. Chem.Comm. 1517; C.M. Kao et al.. 1995. J.Am.Chem.Soc. 117, 9105) was added. After allowing to react for 60-90 minutes, the products were extracted twice with an equal volume of ethylacetate, and analysed by thin layer chromatography, LC-20 MS, and NMR spectroscopy.

It appeared that pORF3 was inactive on this specific substrate, but that the combined action of pORF1 and pORF2 resulted in a TKL derivative having the methyl group completely oxidized to the carboxylic acid function (see Figure 5).

27

Claims

- 1. A polynucleotide comprising:
- 5 (i) a nucleic acid sequence set out in SEQ ID NO: 5, 7 or 9 or a sequence complementary thereto; or
 - (ii) a homologue or fragment of a sequence defined in (i).
- A polynucleotide according to claim 1 consisting
 essentially of the nucleic acid sequence set out in SEQ ID
 NO: 5, 7 or 9 or a sequence complementary thereto.
 - 3. A polypeptide encoded by a polynucleotide according to claim 1 or 2.
 - 4. A polypeptide obtainable by expressing a polynucleotide according to claim 1 or 2 in a cell which is a Streptomyces cell or a cell of a heterologous species.
- 20 5. A polypeptide comprising the amino acid sequence set out in SEQ ID NO: 6, 8 or 9 or a homologue or fragment thereof.
- 6. A recombinant cell comprising at least one additional copy of a polynucleotide according to claim 1 or 2, wherein the cell naturally possesses at least one said polynucleotide.
- 7. A recombinant cell according to claim 6, wherein the cell is one which naturally produces pimaricin or a related molecule.
 - 8 . A recombinant cell according to claim 7 which is a Streptomyces natalensis cell.

PCT/EP00/06227

- 9. A recombinant cell, wherein a polynucleotide according to claim 1 or 2 which naturally occurs in the cell has been inactivated.
- 5 10. A recombinant cell according to claim 9, wherein the cell is one which naturally produces pimaricin or a related molecule.
- 11. A recombinant cell according to claim 10 which is a 10 Streptomyces natalensis cell.
- 12. A recombinant cell comprising a polynucleotide according to claim 1 or 2 which polynucleotide does not naturally occur in that cell or where the polynucleotide is heterologous to that cell.
 - 13. A recombinant cell according to claim 12, wherein the cell is one which does not naturally produce pimaricin.
- 20 14. A recombinant cell according to claim 13 which is a Streptomyces lividans or Streptomyces coelicolor cell.
 - 15. A method for overexpressing a polynucleotide encoding a polypeptide according to any one of claims 3 to 5 in a Streptomyces cell which method comprises:
 - (i) attaching a promoter sequence to the said polynucleotide;

- (ii) transferring the resulting promoter-polynucleotide complex into the said cell; and
- 30 (iii) maintaining the resulting cell under conditions suitable for expression of the said polynucleotide.
 - 16. A method for inactivating a polynucleotide encoding a polypeptide according to any one of claims 3 to 5 in a
- 35 Streptomyces cell which method comprises disrupting the coding sequence of the said polynucleotide.

29

- 17. A method for expressing a polynucleotide encoding a polypeptide according to any one of claims 3 to 5 in a heterologous cell which method comprises:
- 5 (i) attaching a promoter sequence to the said polynucleotide;
 - (ii) transferring the resulting promoter-polynucleotide complex into the said cell; and
- (iii) maintaining the resulting cell under conditionssuitable for expression of the said polynucleotide.
 - 18. A method for producing pimaricin which method comprises maintaining a cell according to any one of claims 6 to 8 under conditions suitable for obtaining expression of the additional copy of a polynucleotide according to claim 1

or 2 and isolating the said pimaricin.

- 19. A method for producing a biomolecule which method comprises maintaining a cell according to any one of claims
- 9 to 11 under conditions which would be suitable for obtaining expression of the inactivated polynucleotide had it not been inactivated and isolating the said biomolecule.
- 20. A method for producing a biomolecule which method
 25 comprises maintaining a cell according to any one of claims
 12 to 14 under conditions suitable for obtaining expression
 of the polynucleotide which does not naturally occur in the
 cell and isolating the said biomolecule.
- 30 21. A biomolecule obtainable by a method according to claim 19 or 20.
 - 22. Use of a recombinant cell according to any one of claims 6 to 8 in the production of pimaricin.

- 23. Use of a recombinant cell according to any one of claims 9 to 14 in the production of a biomolecule.
- 24. A vector containing a polynucleotide according to5 claim 1 or 2 which is capable of expressing a polypeptide according to any one of claims 3 to 5.
 - 25. A cell harbouring a vector according to claim 24.
- 10 26. A method for producing a polypeptide according to any one of claims 3 to 5, which method comprises maintaining a cell according to claim 25 under conditions suitable for obtaining expression of the polypeptide and isolating the said polypeptide.

27. Use of an isolated or purified polypeptide according to any one of claims 3 to 5 for the oxidative modification of a methylgroup of a suitable compound.

20

Figure 1





Figure 2






Figure 3a

$$\begin{array}{c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

Figure 3b

$$H_3C$$
 H_3C
 H_3C

Figure 4

Figure 5

Triketide lactone

Oxidized triketide lactone

SEOUENCE LISTING

<110> DSM N.V.

<120> Genes encoding enzymes in the biosynthetis of pimaricin and applications thereof

<130> S-2959

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 5544

<212> DNA

<213> Streptomyces natalensis

<220>

<221> CDS

<222> (1)..(5544)

<400> 1

atg gtg ccc gtc cac aca gat gac tac gcg atc cag ccg ccc gcc gac 48
Met Val Pro Val His Thr Asp Asp Tyr Ala Ile Gln Pro Pro Ala Asp

acc gcg cat gga ggg ggt ggc ttc aca ctg cct gct gtg ttc gag gcc 96
Thr Ala His Gly Gly Gly Phe Thr Leu Pro Ala Val Phe Glu Ala

gcc gtg gaa tcc gcc ccc gac gca gtg gcc ctc gtc gac ggc acc gtt 144 Ala Val Glu Ser Ala Pro Asp Ala Val Ala Leu Val Asp Gly Thr Val 35 40 45

cct gga cct ggg cgc atg tgg cgc gca gac gtc gat gcg ctg gcc cgc 192
Pro Gly Pro Gly Arg Met Trp Arg Ala Asp Val Asp Ala Leu Ala Arg
50 55 60

ggg ttg cag gag tcg ggt atc gca ccc ggt gac gtg gtg gcg gtg cgg 240 Gly Leu Gln Glu Ser Gly Ile Ala Pro Gly Asp Val Val Ala Val Arg 65 70 75 80

ctg ccg aac tgc ggg agg ttt ccc acc ctg cac ctg gcc gtc gcg gcc 288 Leu Pro Asn Cys Gly Arg Phe Pro Thr Leu His Leu Ala Val Ala Ala

gtc gga gcg gta ctg ctg ccc atc cac cag ggc acc ccg ctc ccg gag 336 Val Gly Ala Val Leu Pro Ile His Gln Gly Thr Pro Leu Pro Glu 100 105 110

gtc gac gcg ctg ctg acc cgg gcg gaa ccc gcc ctt ctc gtc ctg tcg 384 Val Asp Ala Leu Leu Thr Arg Ala Glu Pro Ala Leu Leu Val Leu Ser 115 120 125

gcc gcc ggg agc gac ggc ctg gcg acg gcc cgt tcg ctt ctg gag agc 432 Ala Ala Gly Ser Asp Gly Leu Ala Thr Ala Arg Ser Leu Leu Glu Ser 130 135

1

	ccg Pro														480
	tcc Ser														528
	gac Asp														576
	gtc Val														624
	tcg Ser 210														672
	aac Asn														720
_	gtc Val		_	_	_	_	_		_				_		768
	cac His								_	_	_				816
	gac Asp														864
	gtg Val 290														912
	agg Arg														960
	Gly aaa	_	_	_				_	_		_	_		_	1008
	gac Asp														1056
	acc Thr														1104
	agc Ser 370														1152

WO 00/77222			PCT/EP00/06227
-------------	--	--	----------------

														ttg Leu		1200
_				_	-	_		_	_	_	_	_		acc Thr 415	_	1248
			-				_				_	_		gac Asp		1296
														ej aaa		1344
														ttt Phe		1392
														ctc Leu		1440
														atc Ile 495		1488
														gac Asp		1536
														tcc Ser		1584
														aac Asn		1632
														tac Tyr		1680
														gtg Val 575		1728
														ttc Phe		1776
														ggc		1824
														ctc Leu		1872
gcc	acc	ctg	gcc	ttc	gac	tcc	ccc	act	ccg	cga	gcc	gtc	gcg	cgc	gtc	1920

wo	00/77	222)								P	CT/EP	0/06227
Ala 625	Thr	Leu	Ala	Phe	Asp 630	Ser	Pro	Thr	Pro	Arg 635	Ala	Val	Ala	Arg	Val 640	
ctg Leu	gcc Ala	gag Glu	cag Gln	gag Glu 645	gag Glu	ccg Pro	tcc Ser	cag Gln	gac Asp 650	gag Glu	ccg Pro	agg Arg	gag Glu	aac Asn 655	ccg Pro	1968
														cgg Arg		2016
														gcc Ala		2064
														gac Asp		2112
														tac Tyr		2160
cgc Arg	gaa Glu	ggc Gly	ggc Gly	ttc Phe 725	ctg Leu	cac His	gac Asp	gcg Ala	ggc Gly 730	gac Asp	ttc Phe	gac Asp	gcg Ala	ggc Gly 735	ttc Phe	2208
														cag Gln		2256
														atc Ile		2304
														gcg Ala		2352
gac Asp 785	cgc Arg	ggc Gly	tat Tyr	gga Gly	acc Thr 790	agc Ser	gcg Ala	tcc Ser	gcc Ala	gcg Ala 795	ccc Pro	agc Ser	gca Ala	tgg Trp	gag Glu 800	2400
agc Ser	atg Met	ctc Leu	atc Ile	acc Thr 805	gjà aaa	acc Thr	gcc Ala	ggc	agc Ser 810	gcg Ala	gtc Val	tcg Ser	eja aaa	cgc Arg 815	atc Ile	2448
														acc Thr		2496
tcc Ser	tcg Ser	tcc Ser 835	tcc Ser	ctc Leu	gtc Val	gcc Ala	ctg Leu 840	cat His	ctg Leu	gcc Ala	tgc Cys	cgg Arg 845	tcg Ser	ctg Leu	cgc Arg	2544
tcg Ser	ggc Gly 850	gag Glu	acc Thr	gac Asp	ctg Leu	gcg Ala 855	ctg Leu	gcc Ala	ggc Gly	ggc Gly	gtc Val 860	acc Thr	gtc Val	atg Met	gcg Ala	2592

acc ccg gcg ccc ttc gca cac ttc tcc cgg ctg cgc gcg ctg tcc ccc Thr Pro Ala Pro Phe Ala His Phe Ser Arg Leu Arg Ala Leu Ser Pro

865					870					875					880	
gac to Asp So																2688
tcg ga		ly.														2736
cgc a: Arg A:	sn G															2784
cag ga Gln As 9:																2832
cag cg Gln A: 945	-			_	_	_	_	_	_	_		_	_	_	_	2880
gac g Asp V			_								_	_			_	2928
ccc a		lu														2976
gtg g	lu A					Leu					Ser					3024
aca co Thr G	ln A				Gly					Ile						3072
ctg c Leu A 1025				Val					Leu					Pro		3120
gcc a Ala L			Asp					Ser					Thr			3168
cgg c		rp.					Gly					Ala				3216
tcg t Ser P	he G	199 31 y 175	ctc Leu	acc Thr	ggc	Thr	aac Asn 1080	gcg Ala	cac His	gtg Val	Ile	ctg Leu 1085	gag Glu	gag Glu	gcg Ala	3264
ccg g Pro G 10	ly G				Ala					Glu						3312
cgg to Arg C				Ser					Pro					Asp		3360




WO 00/77222

gcc gcg ccc tgg g Ala Ala Pro Trp V 11				
cag gcg ctc cgc c Gln Ala Leu Arg L 1140	eu Ala Asp Gln			
gcc cag gat gtc g Ala Gln Asp Val A 1155				
cac cgg gcc gtc g His Arg Ala Val V 1170			n Met Leu Ala A	
gca aag cgg ttc g Ala Lys Arg Phe G 1185			y Val Thr Pro A	
gat tcc gcg ccg g Asp Ser Ala Pro G 12				
cag cgc agc ggc a Gln Arg Ser Gly M 1220	et Gly Arg Ala			
gga cgg gcg ctg g Gly Arg Ala Leu G 1235				
cgc cca ctg acc t Arg Pro Leu Thr S 1250			y Ser Glu Glu A	
gcc cgt ctc gac g Ala Arg Leu Asp A 1265			a Leu Phe Ala V	
cag gtc gcc ctg t Gln Val Ala Leu T 12	yr Arg Leu Phe	gag tcc tgg ggg Glu Ser Trp Gly 1290	c gtg gtg ccg g y Val Val Pro <i>I</i> 1295	/sp /ac 3888
cag ctg gtg ggg c Gln Leu Val Gly H 1300	is Ser Val Gly			
ggc gtg ctc ggc c Gly Val Leu Gly L 1315				
agg ctg atg ggc g Arg Leu Met Gly A 1330	cg ctg ccg ccc la Leu Pro Pro 1335	ggc ggt gcg atg Gly Gly Ala Med 1340	. Val Ala Val A	egc 4032 Arg
atc acg gaa ccc g Ile Thr Glu Pro G 1345	aa gtg acc cca lu Val Thr Pro 1350	tgg ctc gcg gag Trp Leu Ala Glu 1355	ı Leu Thr Asp (gag 4080 Slu 860



gtg tcg ato Val Ser Ilo	c gcg gcc gt e Ala Ala Va 1365	c aac ggt il Asn Gly	ccg cac Pro His 1370	tcc ctc c Ser Leu V	gtg ctc gcg /al Leu Ala 1375	Gly
gcc gag gcc Ala Glu Ala	c ccg ctc gt a Pro Leu Va 1380	ıl Ala Leu	acg gac Thr Asp 1385	cgg ctc g Arg Leu A	gcc gcc gcc Ala Ala Ala 1390	gga 4176 Gly
	c egg ege et r Arg Arg Le		Ser Thr	Ala Pro F		
atg gac ccc Met Asp Pro 1410	e atg ctg ga o Met Leu Gl	g gag ttc u Glu Phe 1415	cgc gcg Arg Ala	gtc gtc c Val Val A 1420	egc acg ctg arg Thr Leu	tcc 4272 Ser
tac gcc gcc Tyr Ala Ala 1425	g ccc gcc gt a Pro Ala Va 143	l Pro Leu	Val Ser	acc gtc a Thr Val T 1435	hr Gly Arg	ccg 4320 Pro 1440
	gag gag go Glu Glu Al 1445					
	gtc cgc tt Val Arg Ph 1460	e Lys Asp				
	ggg ttc ct Gly Phe Le			Glu Pro A		
atg atc gad Met Ile Asp 1490	gag tgc ct Glu Cys Le	g gag tcc u Glu Ser 1495	gcc gac Ala Asp	ggg cag c Gly Gln P 1500	ecc ggg acc Pro Gly Thr	gcc 4512 Ala
ctg gtg ccg Leu Val Pro 1505	g agt ctg cg o Ser Leu Ar 151	g Ala Gly	Val Pro	gag cgg g Glu Arg A .515	sp Ala Leu	ctc 4560 Leu 1520
acc gcg gto Thr Ala Val	gcc cgg gt Ala Arg Va 1525	g cac gcc l His Ala	cag ggc Gln Gly 1530	gtt ccc g Val Pro V	tc gac tgg al Asp Trp 1535	gac 4608 Asp
	ccc ggg gc Pro Gly Al 1540	a Glu Ala				
gcc gcc gac Ala Ala Asp 1555	cgc cag tg	g ttc cgc	ttc gtc	ccc gac c	ag ggc gcg	ccg 4704
oto aco oto		1560	Phe vai		65 65	
		1560 c tcg ctg	cac ctg	gag ggc g	cc gcc cac	ctc 4752
Leu Thr Leu 1570 cgc gac gtg	gcc gac cg	1560 c tcg ctg g Ser Leu 1575 t cgc acc s Arg Thr	cac ctg His Leu gcc gac Ala Asp	gag ggc g Glu Gly A 1580 ggc cgg t	cc gcc cac la Ala His gg gtg aaa rp Val Lys	ctc 4752 Leu atg 4800



Arg Leu Met Asp Ala Glu Ser

<210> 2

1845

<211> 1848 <212> PRT <213> Streptomyces natalensis Met Val Pro Val His Thr Asp Asp Tyr Ala Ile Gln Pro Pro Ala Asp Thr Ala His Gly Gly Gly Phe Thr Leu Pro Ala Val Phe Glu Ala 25 Ala Val Glu Ser Ala Pro Asp Ala Val Ala Leu Val Asp Gly Thr Val Pro Gly Pro Gly Arg Met Trp Arg Ala Asp Val Asp Ala Leu Ala Arg Gly Leu Gln Glu Ser Gly Ile Ala Pro Gly Asp Val Val Ala Val Arg Leu Pro Asn Cys Gly Arg Phe Pro Thr Leu His Leu Ala Val Ala Ala Val Gly Ala Val Leu Leu Pro Ile His Gln Gly Thr Pro Leu Pro Glu Val Asp Ala Leu Leu Thr Arg Ala Glu Pro Ala Leu Leu Val Leu Ser 120 Ala Ala Gly Ser Asp Gly Leu Ala Thr Ala Arg Ser Leu Leu Glu Ser Val Pro Ser Leu Arg Gly Val Leu Leu Ala Gly Ala Ser Gly Asp Gly Glu Ser Gly Ser Val Gly Gly Glu Ser Gly Ser Gly Arg Arg Ser Leu Asp Gly Leu Leu Ala Gly Trp Ala Gly Ser Gly Pro Arg Pro Val 185 Asp Val Thr Pro Asp Met Pro Leu Val Leu Val Pro Ser Ser Gly Thr Val Ser Ala Arg Pro Lys Leu Cys Val His Ser His Asp Gly Leu Leu 215 Ser Asn Thr Ala Ala Val Thr Ala Glu Ala Ala Asp Ala Phe Asp Gly Pro Val Leu Thr Ala Cys Pro Met Thr His Leu Phe Gly Leu Gln Ser 250 Leu His Ala Ala Leu Phe Ala Ala Cys Thr Gln Val Leu Leu Thr Gly 260 Trp Asp Val Asp Arg Phe Leu Glu Gln Ala Arg Glu His Gly Pro Arg

WO 00/77222

PCT/EP00/06227

Val	Val 290	Phe	Ala	Val	Pro	Ala 295	Gln	Leu	Arg	Asp	Val 300	Val	Thr	Arg	Leu
Ala 305	Arg	Thr	Gly	Glu	Pro. 310	Ala	Gly	Phe	Thr	Pro 315	Tyr	Gln	Val	Arg	Thr 320
Ala	Gly	Ala	Ala	Val 325	Ala	Pro	Ala	Leu	Ala 330	Val	Arg	Val	Arg	Ala 335	Val
Leu	Asp	Cys	Glu 340	Leu	Val	Val	Val	Trp 345	Gly	Met	Ser	Glu	Ile 350	Gly	Thr
Gly	Thr	Arg 355	Thr	Arg	Ala	His	His 360	Pro	Asp	Gly	Cys	Val 365	Gly	Glu	Pro
Val	Ser 370	Gly	Val	Asp	Val	Arg 375	Val	Val	Asp	Glu	His 380	-	Gln	Glu	Cys
Ala 385	Ala	Asp	Glu	Arg	Gly 390	Glu	Leu	Gln	Tyr	Arg 395	Gly	Pro	Gly	Leu	Phe 400
Arg	Gly	Tyr	Phe	Arg 405	Glu	Pro	Glu	Leu	Thr 410	Arg	Ser	Ala	Leu	Thr 415	Asp
Asp	Gly	Trp	Leu 420	Arg	Thr	Gly	Asp	Leu 425	Ala	Thr	Val	Asp	Ala 430	Asp	Gly
Val	Val	Val 435	Leu	His	Gly	Arg	Ala 440	Ala	Glu	Leu	Ile	Asn 445	Thr	Gly	Gly
Arg	Lys 450	Phe	Ser	Ala	Gly	Glu 455	Val	Glu	Gly	Leu	Leu 460	Ser	Gly	Phe	Thr
Asp 465	Leu	Gly	Pro	Leu	Ala 470	Val	Val	Gly	Ala	Pro 475	Asp	Asp	Arg	Leu	Gly 480
Glu	Tyr	Pro	Cys	Leu 485	Val	Val	Thr	Asp	His 490	Ala	Asp	Gly	Thr	Ile 495	Gly
Leu	Ser	Glu	Val 500	Thr	Ala	Phe	Leu	Arg 505	Arg	Leu	Gly	Leu	Ala 510	Asp	His
Lys	Ile	Pro 515	Leu	Glu	Leu	Val	Thr 520	Val	Arg	Glu	Leu	Pro 525	Phe	Ser	Pro
Ala	Gly 530	Lys	Leu	Asp	Arg	Gly 535	Ala	Leu	Lys	Arg	Leu 540	Leu	Ala	Asn	Leu
Ala 545	Glu	Val	Ser	Val	Pro 550	Ala	Arg	Leu	Gly	Ala 555	Val	Pro	Pro	Tyr	Thr 560
Ala	Glu	Glu	Ala	Leu 565	Asp	Leu	Val	Arg	Asp 570	Cys	Val	Gly	Arg	Val 575	Leu
Arg	Tyr	Gly	Gly 580	Ala	Ala	Val	Pro	Phe 585	Pro	Pro	Asp	Lys	Asp 590	Phe	Phe
Ser	Pro	Asp 595	Lys	Asp	Phe	Arg	Gln 600	Leu	Gly	Leu	Asp	Ser 605	Ile	Gly	Ala

Val Arg Leu Arg Asn Leu Leu Arg Glu Glu Thr Gly Leu Pro Leu Pro 615 Ala Thr Leu Ala Phe Asp Ser Pro Thr Pro Arg Ala Val Ala Arg Val 635 630 Leu Ala Glu Glu Glu Pro Ser Gln Asp Glu Pro Arg Glu Asn Pro Ala Asp Gly Ala Asp Pro Val Ala Ile Val Gly Met Ala Cys Arg Leu 665 Pro Gly Gly Ala Asp Ser Pro Asp Ala Leu Trp Glu Leu Leu Ala Asp 680 Gly Thr Asp Ala Met Ser Pro Phe Pro Thr Asp Arg Gly Trp Asp Leu 695 Asp Arg Leu Phe Asp Glu Asp Ala Asp Arg Pro Gly Thr Ser Tyr Ala Arg Glu Gly Gly Phe Leu His Asp Ala Gly Asp Phe Asp Ala Gly Phe Phe Gly Leu Ser Asp Gln Glu Ala Thr Ala Thr Asp Pro Gln Gln Arg Leu Leu Glu Ala Ala Trp Glu Thr Phe Glu Arg Ala Gly Ile Asp Pro Gln Ser Leu Arg Gly Ser Arg Thr Gly Val Phe Thr Gly Ala Met Asp Arg Gly Tyr Gly Thr Ser Ala Ser Ala Ala Pro Ser Ala Trp Glu Ser Met Leu Ile Thr Gly Thr Ala Gly Ser Ala Val Ser Gly Arg Ile Ala Tyr Thr Tyr Gly Leu Glu Gly Pro Ala Leu Thr Val Asp Thr Ala Ser Ser Ser Leu Val Ala Leu His Leu Ala Cys Arg Ser Leu Arg Ser Gly Glu Thr Asp Leu Ala Leu Ala Gly Gly Val Thr Val Met Ala Thr Pro Ala Pro Phe Ala His Phe Ser Arg Leu Arg Ala Leu Ser Pro Asp Ser Arg Ser Met Ala Tyr Ala Asp Ala Ala Asn Gly Ser Ala Trp Ser Glu Gly Ala Gly Leu Leu Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His Arg Val Leu Ala Leu Val Arg Gly Ser Ala Val Asn 915 920 925



- Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Ser Gly Pro Ala Gln 930 935 940
- Gln Arg Val Ile Arg Gln Ala Leu Ala Asp Ala Gly Leu Thr Pro Gln 945 950 955 960
- Asp Val Asp Ala Val Glu Gly His Gly Thr Gly Thr Pro Leu Gly Asp 965 970 975
- Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Gln Arg Pro 980 985 990
- Val Glu Arg Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly His 995 1000 1005
- Thr Gln Ala Ala Gly Val Val Gly Val Ile Lys Thr Val Leu Ala 1010 1015 1020
- Leu Arg His Gly Val Leu Pro Gln Thr Leu His Val Asp Ala Pro Ser 025 1030 1035 1040
- Ala Lys Val Asp Trp Ser Ala Gly Ser Val Arg Leu Leu Thr Glu Ala 1045 1050 1055
- Arg Pro Trp Pro Arg Glu Ser Gly Arg Thr Arg Arg Ala Gly Val Ser
- Ser Phe Gly Leu Thr Gly Thr Asn Ala His Val Ile Leu Glu Glu Ala 1075 1080 1085
- Pro Gly Glu Ala Ala Gly Ala Arg Ala Glu Val Pro Glu Glu Ala 1090 1095 1100
- Arg Cys Ala Ser Ser Pro Ala Arg Leu Pro Glu Pro Pro Gly Asp Ala 105 1110 1115 1120
- Ala Ala Pro Trp Val Leu Ser Ala Arg Ser Arg Ala Ala Leu Arg Ala 1125 1130 1135
- Gln Ala Leu Arg Leu Ala Asp Gln Val Ala Ala Asp Pro Gly Leu Arg 1140 1145 1150
- Ala Gln Asp Val Ala His Ala Leu Ala Thr Ser Arg Thr Leu His Arg
- His Arg Ala Val Val Ser Gly Ser Asp Arg Ala Gln Met Leu Ala Ala 1170 1175 1180
- Ala Lys Arg Phe Gly Leu Gly Glu Arg Thr Ala Gly Val Thr Pro Asp 185 1190 1195 1200
- Asp Ser Ala Pro Gly Leu Leu Ala Phe Val Phe Ser Gly Gln Gly Ser 1205 1210 1215
- Gln Arg Ser Gly Met Gly Arg Ala Ala Glu Ala Phe Pro Val Phe 1220 1225 1230
- Gly Arg Ala Leu Gly Glu Val Cys Ala Ala Leu Asp Pro Leu Leu Thr 1235 1240 1245
- Arg Pro Leu Thr Ser Val Met Trp Ala Ala Pro Gly Ser Glu Glu Ala

1250

1255

PCT/EP00/06227

1260

Ala Arg Leu Asp Asp Thr Thr Tyr Thr Gln Pro Ala Leu Phe Ala Val 1270 1275

Gln Val Ala Leu Tyr Arg Leu Phe Glu Ser Trp Gly Val Val Pro Asp 1290 1285

Gln Leu Val Gly His Ser Val Gly Glu Ile Ser Ala Ala His Val Ala 1305

Gly Val Leu Gly Leu Arg Asp Ala Cys Thr Leu Val Ala Ala Arg Ser 1320

Arg Leu Met Gly Ala Leu Pro Pro Gly Gly Ala Met Val Ala Val Arg

Ile Thr Glu Pro Glu Val Thr Pro Trp Leu Ala Glu Leu Thr Asp Glu

Val Ser Ile Ala Ala Val Asn Gly Pro His Ser Leu Val Leu Ala Gly

Ala Glu Ala Pro Leu Val Ala Leu Thr Asp Arg Leu Ala Ala Gly 1380

His Lys Thr Arg Arg Leu Met Val Ser Thr Ala Pro His Ser Pro Leu

Met Asp Pro Met Leu Glu Glu Phe Arg Ala Val Val Arg Thr Leu Ser

Tyr Ala Ala Pro Ala Val Pro Leu Val Ser Thr Val Thr Gly Arg Pro 1430

Leu Thr Gly Glu Glu Ala Arg Asp Pro Asp His Trp Val Arg His Val 1445

Arg Gln Ser Val Arg Phe Lys Asp Ala Ile Gly Arg Leu Arg Asp Glu

Arg Val Thr Gly Phe Leu Glu Leu Gly Ala Glu Pro Ala Leu Thr Pro 1475

Met Ile Asp Glu Cys Leu Glu Ser Ala Asp Gly Gln Pro Gly Thr Ala

Leu Val Pro Ser Leu Arg Ala Gly Val Pro Glu Arg Asp Ala Leu Leu 1515

Thr Ala Val Ala Arg Val His Ala Gln Gly Val Pro Val Asp Trp Asp 1530

Ala Val Leu Pro Gly Ala Glu Ala Ser Val Thr Val Arg Gly Leu Pro 1545

Ala Ala Asp Arg Gln Trp Phe Arg Phe Val Pro Asp Gln Gly Ala Pro 1560

Leu Thr Leu Ala Asp Arg Ser Leu His Leu Glu Gly Ala Ala His Leu 1575 1580



Arg Asp Val Gly Gly Cys Arg Thr Ala Asp Gly Arg Trp Val Lys Met 1595 1600

Gly Val Leu Tyr Arg Thr Asn Asn Leu His Ala Leu Thr Asp Ala Asp 1605 1610 1615

Leu Ala Lys Leu Gln Arg Leu Gly Ile Arg Thr Asp Phe Asp Leu Arg 1620 1625 1630

Met Pro Gly Glu Arg Ala Lys Ala Pro Asn Arg Val Pro Thr Gly Ala 1635 1640 1645

Arg Tyr Ile Val Ala Asp Ala Phe Asp Ala His Leu Arg Asp Gly Leu 1650 1655 1660

Ser Leu Ser Glu Arg Asp Leu Glu Arg Leu Arg Glu Ala Arg Leu Ser 665 1670 1675 1680

Gly Leu Asp Glu Ala Glu Gln His Ala Leu Val Leu Ala Leu Val Leu 1685 1690 1695

Ala Glu Thr Ser Ala Val Leu Gly Gly Gln Glu Thr Pro Gly Glu Glu 1700 1705 1710

Pro His Gly Glu Glu Gly His Arg Thr Phe Lys Glu Met Gly Ile Asn 1715 1720 1725

Ser Leu Asn Ala Val Glu Leu Arg Asn Arg Leu Ile Ala Ala Thr Asp 1730 1735 1740

Leu Arg Leu Pro Ala Thr Leu Val Tyr Asp Tyr Pro Thr Pro Lys Ala 745 1750 1755 1760

Val Val Arg Leu Val Arg Glu Arg Leu Ala Arg Pro Ala Ser Pro Ala 1765 1770 1775

Arg Asp Val Ala Ser Val Val Ala Glu Leu Glu Ser Leu Leu Thr Ala 1780 1785 1790

Gly Ala Glu Val Ser Glu Glu Thr Ala Ala Arg Leu Lys Ala Val Thr 1795 1800 1805

Ala Val Ser Thr Gly Thr Thr Gly Ser Gly Ser Gly Thr Gly Ala Gly 1810 1815 1820

Ser Gly Gly Ala Leu Asp Leu Val Ser Ala Ser Asp Glu Glu Leu Phe 825 1830 1835 1840

Arg Leu Met Asp Ala Glu Ser 1845

<210> 3

<211> 20394

WO 00/77222

<212> DNA

<213> Streptomyces natalensis

<220>

<221> CDS

<222> (1)..(20394)

	0> 3 tcq	aac	gag	qaq	aaq	ctq	cac	gag	tac	ctc	aaσ	cac	aca	atc	aca	48
			Glu													
gac Asp	ctt Leu	cac His	gag Glu 20	act Thr	cgt Arg	cag Gln	caa Gln	ttg Leu 25	gac Asp	gag Glu	acc Thr	gag Glu	gcg Ala 30	aag Lys	cag Gln	96
			ctc Leu													144
			ccc Pro													192
			tcc Ser													240
			gac Asp													288
			cat His 100													336
			gag Glu													384
_			tgg Trp						_			_	_			432
			agc Ser													480
			gag Glu													528
			aat Asn 180													576
ctg Leu	gly aaa	ctg Leu 195	gaa Glu	ggc Gly	cct Pro	gcc Ala	ctg Leu 200	acc Thr	gtg Val	gac Asp	acg Thr	gcc Ala 205	tgc Cys	tcc Ser	tcg Ser	624
			gcc Ala													672
tgc Cys 225	gcc Ala	atg Met	gcc Ala	ctg Leu	gtg Val 230	ggc	ggc Gly	gcg Ala	acc Thr	gtg Val 235	atg Met	tcc Ser	acg Thr	ccg Pro	cag Gln 240	720

WO 00/77222		PCT/EP00/06227

					tcc Ser						_		_		_	768
_	_	_			gcc Ala	_	_	_					_			816
					gtc Val											864
					gtg Val											912
					acc Thr 310											960
atc Ile	cgc Arg	cag Gln	gcg Ala	ctg Leu 325	acc Thr	ggc Gly	gcg Ala	ggc	ctc Leu 330	gcc Ala	gcc Ala	tcg Ser	gac Asp	atc Ile 335	gac Asp	1008
					ggc											1056
gcg Ala	cac His	gcc Ala 355	ctg Leu	ctg Leu	gcc Ala	acc Thr	tac Tyr 360	999 Gly	cag Gln	cag Gln	cgc Arg	gcc Ala 365	gcc Ala	gac Asp	cgg Arg	1104
					tcc Ser											1152
					ggc Gly 390											1200
					acc Thr											1248
					aac Asn											1296
					ccc Pro											1344
					cac His											1392
gcc Ala 465	gaa Glu	ccg Pro	gcc Ala	ccc Pro	gaa Glu 470	ccg Pro	gcc Ala	gcc Ala	cgg Arg	ccg Pro 475	ggc Gly	gcg Ala	ctg Leu	ccc Pro	tgg Trp 480	1440

WO 00/77222									F	CT/EP0	0/06227
atc ctg tc Ile Leu Se											1488
ctc ggc cg Leu Gly Ar			Arg A	-		_	_	_	_	_	1536
gcc cat gc Ala His Al 51	a Leu Ala										1584
gtc gtc gc Val Val Al 530					Arg						1632
gcc gcg gg Ala Ala Gl 545	-	-			_		_	_	_	_	1680
gcc gcc ag Ala Ala Se											1728
atg ggg cg Met Gly Ar		_	Ala H				_	_	_		1776
gac gcg gt Asp Ala Va 59	l Cys Ala										1824
gac atc gto Asp Ile Val					Glu .						1872
cag acc gc Gln Thr Ala 625											1920
ttc cgg cto Phe Arg Le											1968
cac tcc ato His Ser Ilo			Ala A								2016
ctc cac gad Leu His Asp 679	Ala Ala										2064
gcg ctg ccc Ala Leu Pro 690					Val						2112
gag atc cgo Glu Ile Arc 705											2160
gcc gcc aa	ggg ccc	gat tcc	acc g	tc att	tcg	ggc	gac	gaa	cag	gcc	2208

wo	00/77	222)								F	CT/EP	00/06227
Ala	Ala	Asn	Gly	Pro 725	Asp	Ser	Thr	Val	Ile 730	Ser	Gly	Asp	Glu	Gln 735	Ala	
														acc Thr		2256
										_		_	_	gac Asp	_	2304
_		_			_	_	_	_		_				gcc Ala		2352
														gaa Glu	-	2400
														acc Thr 815		2448
														acc Thr		2496
														cag Gln		2544
														cgc Arg		2592
														gcc Ala		2640
														ccc Pro 895		2688
														tgg Trp		2736
														gcc Ala		2784
														ctc Leu		2832
														tcc Ser		2880

ggc agc ttc ctg ccc acc ctc tcc tcc tgg cgc agg cag cgc agg acc Gly Ser Phe Leu Pro Thr Leu Ser Ser Trp Arg Arg Gln Arg Arg Thr

			1 € 1721 00700	
	965	970	975	
	Asp Arg Phe		eac tgg gcc ccg cgc 29° His Trp Ala Pro Arg 990	76
acc gcc tcg ggc Thr Ala Ser Gly 995	Gly Pro Thr	gcc acc ggg cac t Ala Thr Gly His :	ngg ctc gtc gtc ctg 302 Trp Leu Val Val Leu 1005	24
		Pro Trp Thr Ala A	egc ctc ctg gac gcg 30° Arg Leu Leu Asp Ala 020	72
ctg aac gac cag Leu Asn Asp Glr 1025	ggc ctg cac Gly Leu His 1030	acc gac gta cgc g Thr Asp Val Arg (1035	gaa ctg ccc gcc gac 312 Glu Leu Pro Ala Asp 1040	20
			gac ggc gtg ctc tgt 316 Asp Gly Val Leu Cys 1055	68
	Asp Glu Arg		gc cct ccg tac cgg 321 Cys Pro Pro Tyr Arg 1070	16
cgc ggg ctg gcc Arg Gly Leu Ala 1075	Ala Thr Thr	aac gct gct gcg o Asn Ala Ala Ala A .080	egc cct gag ggc gcg 326 Arg Pro Glu Gly Ala 1085	64
		Cys Val Thr Arg	ge gee gte gee gte 331 Hy Ala Val Ala Val .00	12
			rca cag aca tgg ggc 336 la Gln Thr Trp Gly 1120	60
			gc tgg ggc ggg ctc 340 er Trp Gly Gly Leu 1135	80
atc gac ctg ccc Ile Asp Leu Pro 1140	Asp Asn Leu	gac gga cgg gcc g Asp Gly Arg Ala \ 1145	tc tcc gcg ctg ctg 345 al Ser Ala Leu Leu 1150	56
	Gly Glu Glu		tc cgc ccc gcc ggg 350 al Arg Pro Ala Gly 1165	04
		Arg Ile Thr Pro G	gc ggc gac acc ggc 355 ly Gly Asp Thr Gly 80	52
gac cgg tgg agc Asp Arg Trp Ser 1185	acc cac ggc Thr His Gly 1190	acc gtc ctg gtc a Thr Val Leu Val 7 1195	cc ggc ggc acc ggt 360 Thr Gly Gly Thr Gly 1200	00
Ala Leu Gly Ala	cac ctc gcc His Leu Ala 1205	cac tgg ctg gcc g His Trp Leu Ala A 1210	ac gcc gga gcc gaa 364 sp Ala Gly Ala Glu 1215	48



His Leu Val				ccc ggc gca ccg Pro Gly Ala Pro 1230	3696
			Gly Val Lys	gtc acc ctc gcc Val Thr Leu Ala 245	3744
	Ala Ala Asp			gtc ctc gcg gac Val Leu Ala As p	3792
				gcc gcg ggc gta Ala Ala Gly Val 1280	3840
		Asp Ala Leu		cgc ttc gag acc Arg Phe Glu Thr 1295	3888
Val Leu Arg				cac gaa ctc acc His Glu Leu Thr 1310	3936
			Leu Phe Ser	tcg atc gtc ggc Ser Ile Val Gly .325	3984
	Asn Ala Gly			gcc aac gcc tac Ala Asn Ala Tyr	4032
				ctc ccg gcc acc Leu Pro Ala Thr 1360	4080
		Gly Gln Ala		cac gac agc gac His Asp Ser Asp 1375	4128
Ala Ala Asp				atg gcc gcg gcc Met Ala Ala Ala 1390	4176
			Ala Gln Gly	atg aca cag gtg Met Thr Gln Val .405	4224
	Asp Ile Asp			gcc ctg acc gcc Ala Leu Thr Ala	4272
				gca cgc cgc gcg Ala Arg Arg Ala 1440	4320
		Pro Arg Arg		ccc ctg cgc gac Pro Leu Arg Asp 1455	4368

wo	00/77	222												F	PCT/EP0	0/06227
cgg Arg		Gly					Ala					Ala				4416
atg Met	Val					Ala					His					4464
acc Thr 1					Arg					Gln						4512
atg Met 1505	Ala	_	_	Leu	_				Ser	-		_		Leu		4560
ctg Leu			Thr					His					Ala			4608
gcc Ala		Leu					Leu					Pro				4656
gtt Val	Gln	_			_	Āla		_	_	_	Val					4704
atg Met 1	_	_	_		Pro					Ser			-	_		4752
cgg Arg 1585	Leu	_	_	Glu			_	_	Ile					Ala		4800
cgg Arg			Asp	_	_			Tyr			_		Asp		_	4848
ggc		Ser					Gly					Gly				4896
ttc Phe	Asp					Gly					Glu					4944
gac Asp 1	_	_	_		Leu		_	_		Trp				_	_	4992
gcg Ala 1665	Gly			Pro					Gly					Val		5040
gcg Ala			Asn					Gly					Ala			5088

gac gaa gcc ggc gga cac cgg ctc acc ggc aac gcg atg agc gtc gtc 5136

WO 00/77222	•	PCT/EP00/06227
Asp Glu Ala Gly Gl	y His Arg Leu Thr Gly Asn A	la Met Ser Val Val
1700	1705	1710
	c tac acc ttc ggc ttc gag g r Tyr Thr Phe Gly Phe Glu G 1720	
	c tcc tcc tcg ctg gtg gcc c s Ser Ser Ser Leu Val Ala L 1735 17	eu His Met Ala Ala
	g ggc gaa tgc tcc ctg gcg g n Gly Glu Cys Ser Leu Ala V 1750 1755	
acg gtg atg gcc ac Thr Val Met Ala Th 176	c ccg tcc tcc ttc gtg gag t r Pro Ser Ser Phe Val Glu Pi 1770	ne Ala Arg Gln Arg 1775
ggg ctg gcc ccc ga	ggc cgc tgc aag ccg ttc g	og gog god god gad 5376
Gly Leu Ala Pro As	Gly Arg Cys Lys Pro Phe A	la Ala Ala Ala Asp
1780	1785	1790
	e gag ggc gtc ggc ctg ctg c r Glu Gly Val Gly Leu Leu Le 1800	
agc gac gcc cgc cg: Ser Asp Ala Arg Arg 1810	a aac ggc cac cag gtg ctc go g Asn Gly His Gln Val Leu A 1815 18:	la Val Val Arg Gly
tcg gcg gtc aac cag	g gac ggc gcg tcc aac ggt c	eg agc gca ccc agc 5520
Ser Ala Val Asn Gli	n Asp Gly Ala Ser Asn Gly Le	eu Ser Ala Pro Ser
1825	1830 1835	1840
ggc ccg tcc cag cag	g cgg gtg atc cgg cag gcc c	ng gcg aac gcc cgg 5568
Gly Pro Ser Gln Gln	n Arg Val Ile Arg Gln Ala Le	Bu Ala Asn Ala Arg
184	1850	1855
gtg gcc gcc tcc gag	g gtc gac gcc gtg gag gcc ca	ac ggc acg ggc acc 5616
Val Ala Ala Ser Gli	1 Val Asp Ala Val Glu Ala H:	is Gly Thr Gly Thr
1860	1865	1870
acg ctc ggt gac ccg	g atc gag gcc cag gcg ctg ct	ng gcc acc tac ggc 5664
Thr Leu Gly Asp Pro	o Ile Glu Ala Gln Ala Leu Le	eu Ala Thr Tyr Gly
1875	1880	1885
cag gag cgg ccg ctg Gln Glu Arg Pro Let 1890	g ctg ctc ggc gcg gtg aag to 1 Leu Leu Gly Ala Val Lys Se 1895 190	er Asn Leu Gly His
acc cag gcc gcc gcc	ggt gtg gcg ggc gtg atg as	ag atg gtg ctg gcg 5760
Thr Gln Ala Ala Ala	Gly Val Ala Gly Val Met Ly	vs Met Val Leu Ala
1905	1910 1915	1920
atg cgg cac ggc atg	ctg ccg cgc acc ctg cac gt	cc gac gag ccc acc 5808
Met Arg His Gly Met	Leu Pro Arg Thr Leu His Va	al Asp Glu Pro Thr
1925	1930	1935
ggg cat gtc gac tgg	acc gcg ggc gcg gtc gag ct	g ctc acc gag cac 5856
Gly His Val Asp Trp	Thr Ala Gly Ala Val Glu Le	eu Leu Thr Glu His

1940		1945	1950	
acg gac tgg ccc Thr Asp Trp Pro 1955	Glu Thr Gly			
ttc ggc atc agc Phe Gly Ile Ser 1970				
gcc gaa cag ccc Ala Glu Gln Pro 1985		Gln Pro Ser		
ccg gcc acc gct Pro Ala Thr Ala		_	Ala Ser Asp Gly	
ccg ctg ctg ctc Pro Leu Leu Leu 2020				
gcc cgg ctg cac Ala Arg Leu His 2035	Ser His Leu			
gac gcc gcg tac Asp Ala Ala Tyr 2050				
gcg gcc gtc cgc Ala Ala Val Arg 2065		His Glu Ala		
gcc ctg gct gcg Ala Leu Ala Ala			Val Asp Thr Gly	
cac acc ggc cgg His Thr Gly Arg 2100				
atc gga atg ggc Ile Gly Met Gly 2115	Arg Glu Leu			
gcc ttc gac acc Ala Phe Asp Thr 2130				
ctg cgg gac gtg Leu Arg Asp Val 2145		Glu Asp Glu		
gtc tac gcc cag Val Tyr Ala Gln			Glu Val Ala Leu	
ctc gtg gag tcc Leu Val Glu Ser 2180	Trp Gly Val			His Ser

gtc ggc gag atc gcc Val Gly Glu Ile Ala 2195	gcc gcg cac g Ala Ala His V 2200	Val Ala Gly Val	ttc tcg ctg gcc 6624 Phe Ser Leu Ala 2205	4
gat gcc tgc gcg ctg Asp Ala Cys Ala Leu 2210	gtg gcg gca o Val Ala Ala A 2215	egc gga cgg ctg Arg Gly Arg Leu 2220	atg cag gcg ctg 6672 Met Gln Ala Leu	2
ccc gcc ggc ggc gcg Pro Ala Gly Gly Ala 2225	atg gcg gcg a Met Ala Ala I 2230	atc cgg gcg acg Ile Arg Ala Thr 2235	gag gac gaa gtc 6720 Glu Asp Glu Val 2240	D
ctc ccg cac ctg gcg Leu Pro His Leu Ala 2245	gac agc gtc t Asp Ser Val S	ceg atc gcg gcc Ser Ile Ala Ala 2250	gtc aac ggc ccg 6768 Val Asn Gly Pro 2255	3
tcg tcg gtc gtc gtc Ser Ser Val Val Val 2260	Ser Gly Ala G	gag cac gcc gtg Glu His Ala Val 265	ctc tcc atc gcc 6816 Leu Ser Ile Ala 2270	5
gcg cac ttc gag ggc Ala His Phe Glu Gly 2275	gcg ggc cgc a Ala Gly Arg I 2280	ys Thr Thr Arg	ctg cgg gtc tcg 6864 Leu Arg Val Ser 285	1
cac gcc ttc cac tcc His Ala Phe His Ser 2290	ccg ctc atg g Pro Leu Met A 2295	gac ccg atg ctg Asp Pro Met Leu 2300	gcc gac ttc cgc 6912 Ala Asp Phe Arg	2
gcc gtc gcc gag ggc Ala Val Ala Glu Gly 2305	ctg acc tac g Leu Thr Tyr G 2310	gc gag ccg gag Sly Glu Pro Glu 2315	ctg gcc gtc gta 6960 Leu Ala Val Val 2320)
tcg aac gtc acc ggc Ser Asn Val Thr Gly 2325	caa ctc gcc a Gln Leu Ala T	cc ccg gac cag Thr Pro Asp Gln 2330	ctg cgc acc ccc 7008 Leu Arg Thr Pro 2335	3
gag tac tgg gtg acc Glu Tyr Trp Val Thr 2340	His Val Arg A	reg geg gtg ege la Ala Val Arg 145	ttc gcg gac ggg 7056 Phe Ala Asp Gly 2350	5
ata cgg gct ctg ggg Ile Arg Ala Leu Gly 2355	gcg gaa ggg g Ala Glu Gly V 2360	al Thr Arg Phe	ctc gaa ctc ggc 7104 Leu Glu Leu Gly 365	Ī
ccg gac ggc gtc ctg Pro Asp Gly Val Leu 2370	tcg gcc ttg g Ser Ala Leu A 2375	cc agg gag tcg la Arg Glu Ser 2380	gca ccg gac gac 7152 Ala Pro Asp Asp	2
gcc gtg tgc act ccc Ala Val Cys Thr Pro 2385	gtg ctg cgc a Val Leu Arg L 390	ag gac cgc tcc ys Asp Arg Ser 2395	gag gcg gcg acc 7200 Glu Ala Ala Thr 2400)
ctc ctc gcg gcc ctg Leu Leu Ala Ala Leu 2405	acg cac ctg c Thr His Leu H	ac gta cac gga is Val His Gly 2410	acc gag atc gac 7248 Thr Glu Ile Asp 2415	ļ
tgg acc gcg ttc ctc Trp Thr Ala Phe Leu 2420	gcc ggc cgc g Ala Gly Arg A 24	sp Ala His Ala	gtc gac ctg ccc 7296 Val Asp Leu Pro 2430	;

			•	C1/E1 00/0022
	cag cac cag cgg Gln His Gln Arg 2440	Phe Trp Pro		
ege ace ggt gae Arg Thr Gly Asp 2450		Gly Leu Glu		
ctg ctg agc gcc Leu Leu Ser Ala 2465			Glu Gly Leu Leu	
acc acc cgc ctc Thr Thr Arg Leu	-			_
gtc atg ggc tcg Val Met Gly Ser 2500	Val Leu Leu Pro			-
ctc cgc gcc gcc Leu Arg Ala Ala 2515		Cys Asp Arg		
ctg gcc gcc ccg Leu Ala Ala Pro 2530		Glu His Gly		
ctg cgg gtg ggc Leu Arg Val Gly 2545			Arg Thr Leu Thr	
cgc tcc agg gcg Arg Ser Arg Ala				_
acc ggc gtc ctc Thr Gly Val Leu 2580	Ala Glu Gly Glu			_
ttc cac acc gag Phe His Thr Glu 2595		Ala Asp Ala .		_
tcc ggc ctc tac Ser Gly Leu Tyr 2610		Ala His Gly		
cac ttc cag ggg His Phe Gln Gly 2625			Gly Asp Glu Val	
gcc gag gtc gcc Ala Glu Val Ala				
gga ctc cat ccg Gly Leu His Pro 2660	Ala Leu Leu Asp			
aac gga gtg gac	cgc ggc gtc gtg	ccg ttc tcc	tgg gag agc gtc	gcg 8064

WO 00/77222

PCT/EP00/06227




2675	urg Gly Val Val 2680		rp Glu Ser Val Al 2685	a
ctg cac gcc acc g Leu His Ala Thr G 2690			rg Val Val Arg Hi	
agc ggc gac acg g Ser Gly Asp Thr V 2705				0
gtc gcc tcc atc g Val Ala Ser Ile G 27				-
ttg gcg ggc ggc g Leu Ala Gly Gly A 2740				
cag tgg aac ccc g Gln Trp Asn Pro V 2755		Pro Ala Gly A		
gcg acg ctc ggc t Ala Thr Leu Gly S 2770			sp Gly Tyr Pro As	
ctg gcg tcc ctg g Leu Ala Ser Leu A 2785				.1
ccg gtg gaa gcc g Pro Val Glu Ala G		val Val Ala A	sp Asp Val Val Gl	
20		2810	2815	
gcg acg cac gca a Ala Thr His Ala 3 2820	acg gec gec egg	geg etg gae e	tg gcc cgg tcg tg	
gcg acg cac gca a	acg gcc gcc cgg Thr Ala Ala Arg	g gcg ctg gac c g Ala Leu Asp L 2825 c tcg cgc ctg g a Ser Arg Leu V	tg gcc cgg tcg tg eu Ala Arg Ser Tr 2830 tg ttc gtg acg cg	p t 8544
gcg acg cac gca a Ala Thr His Ala 7 2820 ctg gcc gat gac c Leu Ala Asp Asp A	acg gcc gcc cgg Thr Ala Ala Arg cgg ttc gcg gcc Arg Phe Ala Ala 2840	g gcg ctg gac cg Ala Leu Asp L 2825 c tcg cgc ctg g a Ser Arg Leu V	tg gcc cgg tcg tg eu Ala Arg Ser Tr 2830 tg ttc gtg acg cg al Phe Val Thr Ar 2845 cg gtg tgg ggt ct la Val Trp Gly Le	Eg 8592
gcg acg cac gca a Ala Thr His Ala 3 2820 ctg gcc gat gac c Leu Ala Asp Asp A 2835 ggc gcg gtg tcc g Gly Ala Val Ser 6	acg gcc gcc cgg Thr Ala Ala Arg cgg ttc gcg gcc Arg Phe Ala Ala 2840 ggt gcg gat ctc Gly Ala Asp Let 2855	g gcg ctg gac cg Ala Leu Asp L 2825 c tcg cgc ctg ga Ser Arg Leu V c gcg ggt gcg ga Ala Gly Ala A 28	tg gcc cgg tcg tg eu Ala Arg Ser Tr 2830 tg ttc gtg acg cg al Phe Val Thr Ar 2845 cg gtg tgg ggt ct la Val Trp Gly Le 60 tc ggt ctg gtg ge	g 8592 su 8640
gcg acg cac gca a Ala Thr His Ala 3 2820 ctg gcc gat gac c Leu Ala Asp Asp A 2835 ggc gcg gtg tcc g Gly Ala Val Ser c 2850 gtg cgg tcg gcg c Val Arg Ser Ala I 2865 ctg gat gac gat g Leu Asp Asp Asp A	acg gcc gcc cgg Thr Ala Ala Arg agg ttc gcg gcc Arg Phe Ala Ala 2840 ggt gcg gat ctc 3855 atg tcg gag cac tcg tcg gag cac 2870 gcc gaa ctg gcg	g gcg ctg gac c g Ala Leu Asp L 2825 c tcg cgc ctg g a Ser Arg Leu V c gcg ggt gcg g a Ala Gly Ala A 28 c ccg ggc cgc t s Pro Gly Arg P 2875	tg gcc cgg tcg tg eu Ala Arg Ser Tr 2830 tg ttc gtg acg cg al Phe Val Thr Ar 2845 cg gtg tgg ggt ct la Val Trp Gly Le 60 tc ggt ctg gtg ga he Gly Leu Val As 288	Eg 8544 Eg 8592 Eu 8640 Ep 8688
gcg acg cac gca a Ala Thr His Ala 3 2820 ctg gcc gat gac c Leu Ala Asp Asp A 2835 ggc gcg gtg tcc g Gly Ala Val Ser c 2850 gtg cgg tcg gcg c Val Arg Ser Ala I 2865 ctg gat gac gat g Leu Asp Asp Asp A	acg gcc gcc cgg Thr Ala Ala Arg Egg ttc gcg gcc Arg Phe Ala Ala 2840 ggt gcg gat ctc 3855 Etg tcg gag cac Leu Ser Glu His 2870 gcc gaa ctg gcg Ala Glu Leu Ala 885	g gcg ctg gac c g Ala Leu Asp L 2825 c tcg cgc ctg g a Ser Arg Leu V c gcg ggt gcg g a Ala Gly Ala A 28 c ccg ggc cgc t b Pro Gly Arg P 2875 g ctg gtg cca c a Leu Val Pro A 2890 c ggt ggt gag g	tg gcc cgg tcg tcg eu Ala Arg Ser Tr 2830 tg ttc gtg acg cg al Phe Val Thr Ar 2845 cg gtg tgg ggt ct la Val Trp Gly Le 60 tc ggt ctg gtg ga he Gly Leu Val As 2886 gg gtg ttg gcg tc rg Val Leu Ala Se 2895	g 8544 g 8544 g 8592 g 8640 g 8688 g 8688

2915 2920 2925

					-					•					
acg gt Thr Va 293	ıl Leu			Gly					Leu						8832
cgt ca Arg Hi 2945			Val					Arg					Val		8880
ege eg Arg Ai		Pro					Ala					Thr			8928
cgg ca Arg Hi	s Ser					Ala					Asp				8976
gcg gc Ala Al					Leu					Arg					9024
gtg ca Val Hi 301	s Thr	-	_	Val	_	_	_		Val			-	_		9072
ccg ga Pro Gl 3025			Ser			_	_	Pro	_		_		Ala		9120
aac ct Asn Le		Glu					Leu					Phe			9168
ttc to Phe Se	r Ser					Ile					Gln				9216
gcg gc Ala Al					Leu					His					9264
gcg gg Ala Gl 309	y Leu			Ala					Gly						9312
Gly Gl 3105			Gly					Val					Ser		9360
ggc ag Gly Ar		Āla					Arg					Leu			9408
gcc gc Ala Al	a Leu					Āla					Val				9456
tgg go Trp Al	g tcc a Ser 3155	ctg Leu	cgc Arg	gcc Ala	Gln	ggc Gly 3160	gag Glu	gtg Val	cca Pro	Pro	ctg Leu 165	ttg Leu	cgc Arg	ggc Gly	9504

WO 00/77222		PCT/EP00/06227
	t gcc cgg cgc tcg gcg gtc ggc gg g Ala Arg Arg Ser Ala Val Gly Gl 3175 3180	
	g gga cgc ctg agc gga cgg gga ac l Gly Arg Leu Ser Gly Arg Gly Th 3190 3195	
	g gac ctg gta cgg gcc cag atc gc u Asp Leu Val Arg Ala Gln Ile Al 5 3210	
	g gag acg atc gag tcc acc cgt gt o Glu Thr Ile Glu Ser Thr Arg Va 3225	
	c ctg acc gcg gtc gaa ctc cgc aa r Leu Thr Ala Val Glu Leu Arg As 3240 324	n Arg Leu Asn
	g cgc ctt tcg gcc acc gcc gtc tt u Arg Leu Ser Ala Thr Ala Val Ph 3255 3260	-
	c gtc gac ttc ctg ctg gac gag ct u Val Asp Phe Leu Leu Asp Glu Le 3270 3275	
	g ctg ccg gcg ccg gtg ccg tca cc u Leu Pro Ala Pro Val Pro Ser Pr 5 3290	
	c gtg atc gtc ggc atg agc tgc cg l Val Ile Val Gly Met Ser Cys Ar 3305	
Gly Val Gly Ser Pro	c gag gac ctg tgg cgc ctg gtg tc o Glu Asp Leu Trp Arg Leu Val Se 3320 332	r Glu Gly Val
	c ttc ccc acc gac cgt gga tgg ga p Phe Pro Thr Asp Arg Gly Trp As 3335 3340	
	c ccc gag gcg ctc ggc acc tcg ta p Pro Glu Ala Leu Gly Thr Ser Ty 3350 3355	
	c gag gcg gcg gag ttc gac ccc ga s Glu Ala Ala Glu Phe Asp Pro As 3370	
	g geg etg geg ace gae gee eag ca u Ala Leu Ala Thr Asp Ala Gln Gl 3385	
	g gag gcc atc gag cgc acg ggc at p Glu Ala Ile Glu Arg Thr Gly Il 3400 340	e Asp Pro Ala



tcg ggt gtg gcg ggt gtc atc aag atg gtg ctg gcg atg cgg cac ggt 10992

Leu Leu Gly Ser Val Lys Ser Asn Ile Gly His Ala Gln Ala Ala

3640

3635



																2 00,0022
	Gly 3650		Ala	Gly		Ile 3655	Lys	Met	Val		Ala 3660	Met	Arg	His	Gly	
	Leu			Thr					Glu					gtc Val		11040
			Gly					Leu					Glu	tgg Trp 3695		11088
		Glu		_	_	_	Ala		_			Phe		gtc Val	-	11136
	Thr					Ile	_		_		Gly	_	_	gcg Ala	_	11184
Asp					Ala					Pro				gca Ala		11232
	Leu			Arg					Leu					gcg Ala		11280
_			Leu	-	_		_	Asp		_			Arg	gac Asp 3775		11328
		Ser					Arg					His		gcg Ala		11376
	Trp					Asp					Ala			gca Ala		11424
Ala					Asp					Glu				ggc		11472
	Arg			Phe					Gln					ctg Leu		11520
			Glu					\mathtt{Tyr}					Asp	gca Ala 8855		11568
		Val					Asp					Arg		ctg Leu		11616
	Val					Asp					Asn			gcg Ala		11664
														ctg Leu		11712

3890 3895 3900 gaa tog tgg ggc atg ogc ocg gac tto gtg gog ggg cat tog atc ggt Glu Ser Trp Gly Met Arg Pro Asp Phe Val Ala Gly His Ser Ile Gly 3905 3910 gag gtc gcc gcg gcc cat gtg tcg ggt gtc ttc tcg ctc ccg gat gcc Glu Val Ala Ala Ala His Val Ser Gly Val Phe Ser Leu Pro Asp Ala tgt gcg ctg gtg gcg gcc cga ggc cga ctg atg cag caa ctg ccc tcc 11856 Cys Ala Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gln Leu Pro Ser gge gge geg atg atg geg ate egg geg ace gag gae gag gte ett eeg 11904 Gly Gly Ala Met Met Ala Ile Arg Ala Thr Glu Asp Glu Val Leu Pro cat ctg gcg gaa ggc gtc tcg ctc gcg gcg gtc aat ggc ccg tcg tcg 11952 His Leu Ala Glu Gly Val Ser Leu Ala Ala Val Asn Gly Pro Ser Ser 3970 3975 gto gtg ato tog ggo goo gag gao gog gtg otg goo ato gog gog cae 12000 Val Val Ile Ser Gly Ala Glu Asp Ala Val Leu Ala Ile Ala Ala His 3985 ttc gcg ggg gag ggg cgc aaa acc acc cga ctg cgg gtc tcg cat gcc 1204B Phe Ala Gly Glu Gly Arg Lys Thr Thr Arg Leu Arg Val Ser His Ala ttc cac tcg ccg ctc atg gaa ccg atg ctg gag gaa ttc cgc gcg gtg 12096 Phe His Ser Pro Leu Met Glu Pro Met Leu Glu Glu Phe Arg Ala Val 4025 gtg aca egg etg tee tte gge acg eeg ate eee gte gte tee aac 12144 Val Thr Arg Leu Ser Phe Gly Thr Pro Thr Ile Pro Val Val Ser Asn 4040 ctg acg ggc cgc ctc gcc gaa ccc gaa cag ctc gcg cac gcc gac tac Leu Thr Gly Arg Leu Ala Glu Pro Glu Gln Leu Ala His Ala Asp Tyr 4055 tgg gtc cgg cac gtc cgc gag gca gtg cgc ttc gcg gac ggg ata cag 12240 Trp Val Arg His Val Arg Glu Ala Val Arg Phe Ala Asp Gly Ile Gln 4065 4070 geg etg egg geg gaa ggg gtg acg egg tte etg gag ete gge eeg gae Ala Leu Arg Ala Glu Gly Val Thr Arg Phe Leu Glu Leu Gly Pro Asp 4090 ggt gtg ctg tcg gcg atg gcc cgc gag tcg gca tcg gac gac gcc gtg Gly Val Leu Ser Ala Met Ala Arg Glu Ser Ala Ser Asp Asp Ala Val 4105 ctc gcg ccc gta ctg cgc agg gac cgg ccc gag gag acg gcg ctg ctg Leu Ala Pro Val Leu Arg Arg Arg Pro Glu Glu Thr Ala Leu Leu 4120 ggc gcc ctg gcg cag ctg tac gtc cgg ggt gcg cac gtg gac tgg acg Gly Ala Leu Ala Gln Leu Tyr Val Arg Gly Ala His Val Asp Trp Thr 4135

PCT/EP00/06227

WO 00/77222

gtg ccg ttc gcc ggt Val Pro Phe Ala Gly 4145			
gcg ttc cag cac gag Ala Phe Gln His Glu 4165	Arg Phe Trp Pro		
ggc gat gtg cgg tcc Gly Asp Val Arg Ser 4180		Ser Ala Gly His	
ggc gcg gcg gtg gaa Gly Ala Ala Val Glu 4195			
cgg ctg tcg gtg tcc Arg Leu Ser Val Ser 4210			
ggc tcc gtc ctc gtg Gly Ser Val Leu Val 4225			
gcg gcc gac gag gcc Ala Ala Asp Glu Ala 4245	Gly Cys Asp Leu		
gca ccg ctg gtg ctg Ala Pro Leu Val Leu 4260		Ala Ala Val Gln	
gcg gtg ggc gag ccc Ala Val Gly Glu Pro 4275			
gca cgt gag ggc gag Ala Arg Glu Gly Glu 4290			
acc tcg ggc gcc gaa Thr Ser Gly Ala Glu 4305			
aag ggc gcg gag ccc Lys Gly Ala Glu Pro 4325	Val Asp Val Ala		_
gat gcc ggg ctc acc Asp Ala Gly Leu Thr 4340		Phe His Gly Leu	
tgg aag ctc ggt ggg Trp Lys Leu Gly Gly 4355			
acc gac ggc gac gca Thr Asp Gly Asp Ala 4370			-

WO 00/77222		PCT/EP00/06227
	g gaa gcg ggc gga gtc a Glu Ala Gly Gly Val 4395	
Ser Trp Ala Gly	g acc ggc gcc tcg cac a Thr Gly Ala Ser His : 4410 4	
	g ctg tcg gtc gcg atc g a Leu Ser Val Ala Ile . 5 4430	
	g gag tcg ctg gtg ata l Glu Ser Leu Val Ile . 4445	
	c gac cgt gac gcc ctc a Asp Arg Asp Ala Leu : 4460	
	g gac gaa cgc gtc gag r Asp Glu Arg Val Glu 4475	
Thr Gly Pro Glu	g acg tac gcg gat ctg g g Thr Tyr Ala Asp Leu . 4490 4	
	g gtc ctg gtc gcg ccg r Val Leu Val Ala Pro 5 4510	
	a cac gcc gcg acc gtc l His Ala Ala Thr Val 4525	
	c gac gac cgg ttc gcc a Asp Asp Arg Phe Ala 4540	
	g gcc ttc ggc gcg gat a Ala Phe Gly Ala Asp 4555	
Ala Ala Ala Val	c tcg gca cag tcg gag g Ser Ala Gln Ser Glu . 4570 4	
	c ggc gac gcc gat acg p Gly Asp Ala Asp Thr 5 4590	
	g ccc gaa ctg ctg gtg u Pro Glu Leu Leu Val 4605	
	 c cgg gcg cag tcc tcg l Arg Ala Gln Ser Ser 4620	_

gtg acg tgg gat ccg tcc ggt acg gtc ctg atc acc ggc ggg acc ggt 13920

WO 00/77222	PCT/EP00/06227
Val Thr Trp Asp Pro Ser Gly Thr Val Leu Ile Thr Gly 4625 4630 4635	Gly Thr Gly 4640
ggg ctg ggc cgt agt gtc gcc cgg cac ttg gtg agc gag Gly Leu Gly Arg Ser Val Ala Arg His Leu Val Ser Glu 4645 4650	
cgc agt ctg ctg ctg gtc agc cgc cgt ggt ccc gcg gcc Arg Ser Leu Leu Val Ser Arg Arg Gly Pro Ala Ala 4660 4665 4	
ggg gag ttg gtg gcc gaa ctc agg ggc agt ggc gcc gag Gly Glu Leu Val Ala Glu Leu Arg Gly Ser Gly Ala Glu 4675 4680 4685	
gag gct tgt gat gtg acc gat gcg gtg gcg gtg gcc gat Glu Ala Cys Asp Val Thr Asp Ala Val Ala Val Ala Asp 4690 4695 4700	
cgg cat cgg atc agt gct gtg gtg cat acg gcc ggt gtt Arg His Arg Ile Ser Ala Val Val His Thr Ala Gly Val 4705 4710 4715	
ggt gtg gtg gag tcg ctg acg ccg gag cgg ctt gcg gtg Gly Val Val Glu Ser Leu Thr Pro Glu Arg Leu Ala Val 4725 4730	
ccg aag gtg gat gcg gcc tgg aac ctg cac gag gcg acc Pro Lys Val Asp Ala Ala Trp Asn Leu His Glu Ala Thr 4740 4745 4	
gat ctg gat gcg ttt gtg gtg ttc tcg tcc gtg gca ggc Asp Leu Asp Ala Phe Val Val Phe Ser Ser Val Ala Gly 4755 4760 4765	
agt gcg ggt cag gcc aat tac gcg gcg ggt aat gct ttc Ser Ala Gly Gln Ala Asn Tyr Ala Ala Gly Asn Ala Phe 4770 4775 4780	
ctg gcg tat cac cgt cgg gcg gtg ggt ctg ccg gcg gtg Leu Ala Tyr His Arg Arg Ala Val Gly Leu Pro Ala Val 4785 4790 4795	tcg ctg gcg 14400 Ser Leu Ala 4800
tgg ggc cct tgg tcg cag gac ggt ggt atg acc ggc acc Trp Gly Pro Trp Ser Gln Asp Gly Gly Met Thr Gly Thr 4805 4810	ttg agc gac 14448 Leu Ser Asp 4815
gcc gat gtc cag cgc atc gcc cgg cag ggc atg ccg ccg Ala Asp Val Gln Arg Ile Ala Arg Gln Gly Met Pro Pro 4820 4825 4	ctg acc gtc 14496 Leu Thr Val 830
gag gag ggt ctg gcc ctc ttc gac gcc gcg ctc ggc agc Glu Glu Gly Leu Ala Leu Phe Asp Ala Ala Leu Gly Ser 4835 4840 4845	gcc gaa ccc 14544 Ala Glu Pro
atg gca ctc ccg gtc cgc ctg gac ctg gcg gcg ctg cgg Met Ala Leu Pro Val Arg Leu Asp Leu Ala Ala Leu Arg 4850 4855 4860	gca caa ggc 14592 Ala Gln Gly
gag ccc cag cca ctg ctg cgc ggc ctc atc cgg acg agg Glu Pro Gln Pro Leu Leu Arg Gly Leu Ile Arg Thr Arg	

WO 00/77222

PCT/EP00/06227

4865	4870	487	5	4880
tcc ggc gcc gcc Ser Gly Ala Ala			n Arg Leu Ala	
tcc acg gcg gag Ser Thr Ala Glu 4900				
atc gcg acg gtc Ile Ala Thr Val 4915	Leu Gly His			
cgg gcc ttc cag Arg Ala Phe Gln 4930				
cgt aac ctg ctc Arg Asn Leu Leu 4945			g Leu Pro Ala	_
gtg ttc gac tac Val Phe Asp Tyr			a Ala His Leu	
gaa ctg ttc ggc Glu Leu Phe Gly 4980				
gtg ccc ggc ctg Val Pro Gly Leu 4995	Pro Ser Leu			
atg agc tgc cgc Met Ser Cys Arg 5010	ttc ccc ggc Phe Pro Gly 5015	ggc gtc gcc tc Gly Val Ala Se	g ccg gag gac r Pro Glu Asp 5020	ctg tgg 15072 Leu Trp
cgc ctg gtg gcg Arg Leu Val Ala 5025			r Ala Phe Pro	
cgg ggc tgg gag Arg Gly Trp Glu			o Glu Arg Glu	
atc gcc acc cgt Ile Ala Thr Arg 5060				
ccc gag ttc ttc Pro Glu Phe Phe 5075	Gly Met Ser			
cag cag cgg ctg Gln Gln Arg Leu 5090				
ggt atg gac ccg Gly Met Asp Pro 5105	_		g Thr Gly Val	-

					1 (1721 00/0022/
	tac cac gac to Tyr His Asp Ty 5125	r Ser Thr	-		
Glu Gly Tyr	cag ggc agc gg Gln Gly Ser Gl 5140				
	acc ttc ggt to Thr Phe Gly Ph		Pro Ala Val		
	tcg tcc ctg gt Ser Ser Leu Va 517	ıl Ala Leu			
	gag tgc tcg ct Glu Cys Ser Le 5190			Val Thr Val	
	ctg acc ttc gt Leu Thr Phe Va 5205	ıl Glu Phe			
Ala Asp Gly	cgc tgc aag go Arg Cys Lys Al 5220				
	ggc gcc gga at Gly Ala Gly II		Leu Glu Arg I		
	ggg cac cgc at Gly His Arg Il 525	e Leu Ala '			
	ggt gcg tcc aa Gly Ala Ser As 5270			Asn Gly Pro	
	gtg atc cgg ca Val Ile Arg Gl 5285	n Ala Leu i			
Ala Asp Val	gac gcg gtg ga Asp Ala Val Gl 3300				
	gag gcc cag gc Glu Ala Gln Al		Ala Thr Tyr (
	cgg ccg ttg ct Arg Pro Leu Le 533	u Leu Gly			

PCT/EP00/06227

WO 00/77222

cac gcg caa gcg gct tcg ggt gtt gcc ggt gtc atc aag atg gtg ctg His Ala Gln Ala Ala Ser Gly Val Ala Gly Val Ile Lys Met Val Leu

v. o oo			1 6 1/21 00/0022
Ala Met Arg His	ggt gtg ctg cct Gly Val Leu Pro 5365	c cgg acg ctg ca Arg Thr Leu Hi 5370	st gtc gac gag ccg 16128 .s Val Asp Glu Pro 5375
	Asp Trp Ser Ala		ng ctg ctg acc tcc 16176 nu Leu Leu Thr Ser 5390
gag gcc gag tgg Glu Ala Glu Trp 5395	ccg cag ggc gag Pro Gln Gly Glu 5400	ı Gly Pro Arg Aı	gc gcg ggc gtc tcc 16224 gg Ala Gly Val Ser 5405
tcc ttc ggc atc Ser Phe Gly Ile 5410	agt ggg acg aac Ser Gly Thr Asn 5415	gcg cat gtg at Ala His Val II 542	c ctg gag cag ccc 16272 e Leu Glu Gln Pro
Glu Pro Val Ala 5425	Ala Glu Thr Glu 5430	Ser Ile Thr Pr 5435	c gac acc gca ccg 16320 To Asp Thr Ala Pro 5440
Asp Ala Ala Glu	Asp Glu Ala Ala 5445	Asp Ser Gly Th 5450	g ccg gtg ccg gca 16368 r Pro Val Pro Ala 5455
Leu Leu Ser Gly 5460	Arg Ser Ala Ser	· Ala Leu Arg Al 5465	c cag gca gca cga 16416 a Gln Ala Ala Arg 5470
Leu Leu Ser Arg 5475	Leu Asp Gly Asp 5480	Pro Gly Pro Ar	g atc act gac gtc 16464 g Ile Thr Asp Val 5485
Ala Tyr Ser Leu 5490	Ala Thr Gly Arg 5495	Ser Ala Phe Pr 550	
Ile Leu Ala Ala 5505	Asn Arg Ala Asp 5510	Leu Leu His Se 5515	g ctg tcc gcc ctg 16560 r Leu Ser Ala Leu 5520
Ala Glu Gly His	Thr Glu Ala Pro 5525	Ala Val Val Al 5530	a cag gac cga gcc 16608 a Gln Asp Arg Ala 5535
Arg Ser Gly Lys 5540	Leu Ala Phe Leu	Phe Ser Gly Gl 5545	g gga tcg caa cgc 16656 n Gly Ser Gln Arg 5550
Leu Gly Met Gly 5555	Arg Glu Leu Tyr 5560	Gly Arg Tyr Pr	g gcg ttc gcc gag 16704 o Ala Phe Ala Glu 5565
Ala Leu Asp Ala 5570	Val Cys Ala Ala 5575	Leu Asp Ala Hi 558	
Leu Arg Asp Val 5585	Ile Trp Gly Glu 5590	Asp Ala Glu Le 5595	g ctg aac cgg acc 16800 u Leu Asn Arg Thr 5600
ggg tac gcc cag	aca ggg ctg ttc	gcc atc gag gt	g gcc ctg ttc cgc 16848

PCT/EP00/06227

WO 00/77222



Gly Tyr Ala Gln Thr Gly Leu Phe Ala Ile Glu Val Ala Leu Phe Arg 5605 5610 5615	
ctg ctg gag tcg tgg ggc gta cgc ccg gac cac ctg ctg ggg cac tcc Leu Leu Glu Ser Trp Gly Val Arg Pro Asp His Leu Leu Gly His Ser 5620 5625 5630	16896
atc gga gaa atc gcc gcg gcc cat gtg gcg ggc gtc ctc tcc ctc ccg Ile Gly Glu Ile Ala Ala Ala His Val Ala Gly Val Leu Ser Leu Pro 5635 5640 5645	16944
gac gcc tgt gcg ctg gtg gcc cga ggt cgg ctg atg cag caa ctg Asp Ala Cys Ala Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gln Leu 5650 5655 5660	16992
ccg tcc ggc ggc gcg atg atg gcg atc cgg gcg acc gag gac gag gtc Pro Ser Gly Gly Ala Met Met Ala Ile Arg Ala Thr Glu Asp Glu Val 5665 5670 5675 5680	17040
ctt ccg cat ctg gcg gaa ggc gtc tcg ctc gcg gcg gtc aac ggg ccg Leu Pro His Leu Ala Glu Gly Val Ser Leu Ala Ala Val Asn Gly Pro 5685 5690 5695	17088
tcg tcg gtc gtg gtc tcc ggc gcc gag gac gag gta ctc gcc ctc gcg Ser Ser Val Val Val Ser Gly Ala Glu Asp Glu Val Leu Ala Leu Ala 5700 5705 5710	17136
gcg cac ttc gag gaa gag gga cgc aag acc acc cga ctg cgg gtc tcg Ala His Phe Glu Glu Glu Gly Arg Lys Thr Thr Arg Leu Arg Val Ser 5715 5720 5725	17184
cac gcc ttc cac tcc ccg ctc atg gaa ccg atg ctg gcc gac ttc cgg His Ala Phe His Ser Pro Leu Met Glu Pro Met Leu Ala Asp Phe Arg 5730 5740	17232
gcc gtc gcc gac ggc atg acc tac gcc gcg ccg cgc atc ccc gtg gtc Ala Val Ala Asp Gly Met Thr Tyr Ala Ala Pro Arg Ile Pro Val Val 5745 5750 5760	17280
tcc aac gtc acc ggc cgg ccc gcc acc gcg gaa gag ctg tgc tgc gcc Ser Asn Val Thr Gly Arg Pro Ala Thr Ala Glu Glu Leu Cys Cys Ala 5765 5770 5775	17328
gag tac tgg gtc ggc cac gta cgc gag gcc gta cgg ttc gcc gac ggg Glu Tyr Trp Val Gly His Val Arg Glu Ala Val Arg Phe Ala Asp Gly 5780 5785 5790	17376
gtc ggc gcg ctc cgc gag cag ggt gtg acg acg ttc ctg gaa ctc ggc Val Gly Ala Leu Arg Glu Gln Gly Val Thr Thr Phe Leu Glu Leu Gly 5795 5800 5805	17424
Pro Asp Gly Ser Leu Ser Ala Leu Ala Ala Glu Ser Ala Ala Asp Asp	17472
5810 5815 5820	
tcc gta ctg gcc ccc gta ctg cgc aag aac cgc ccc gag gca ccg gca Ser Val Leu Ala Pro Val Leu Arg Lys Asn Arg Pro Glu Ala Pro Ala 5825 5830 5835 5840	17520

WO 00/77222

WO 00/77222 PCT/EP00/06227

5845 5850 5855 tgg tcc gcc gcc ttc gcc ggt acg ggt gcg cgg tgg gtg gac ctg ccg 17616 Trp Ser Ala Ala Phe Ala Gly Thr Gly Ala Arg Trp Val Asp Leu Pro acg tac gca ttc cag cac gag cgg ttc tgg ccg tcg ggc ggg gcg 17664 Thr Tyr Ala Phe Gln His Glu Arg Phe Trp Pro Ser Gly Gly Ala Ala cgc gca ggc gat gtg cgg tcc gcg ggc ctg ggc tcg gcc ggg cac ccg 17712 Arg Ala Gly Asp Val Arg Ser Ala Gly Leu Gly Ser Ala Gly His Pro 5890 5895 ctg ctg ggt gct gcg gtg gaa ctg gcg ggc tcc ggc ggg cgg ttg ctc 17760 Leu Leu Gly Ala Ala Val Glu Leu Ala Gly Ser Gly Gly Arg Leu Leu 5905 acc ggg egg etg tee etg tee teg eac eeg tgg etg geg gat eac gtg 17808 Thr Gly Arg Leu Ser Leu Ser Ser His Pro Trp Leu Ala Asp His Val gtg ctg ggc tcc gta ctg gtg ccc ggc acg gcg ctc atg gaa ctg gtg Val Leu Gly Ser Val Leu Val Pro Gly Thr Ala Leu Met Glu Leu Val 5940 ctg cgg gcg gcc gac gag gtg gac tgc gcc gcg gtg gac gaa ctc acg 17904 Leu Arg Ala Ala Asp Glu Val Asp Cys Ala Ala Val Asp Glu Leu Thr 5955 ctc gcc gcg cca ctg gtc ctg ccc gcc tcg ggc gcc gcg atc cag gta 17952 Leu Ala Ala Pro Leu Val Leu Pro Ala Ser Gly Ala Ala Ile Gln Val 5970 cag gta tgg gtg ggc gag ccc gat gag gcg ggc cgc cgg ccg gtc tcg 18000 Gln Val Trp Val Gly Glu Pro Asp Glu Ala Gly Arg Arg Pro Val Ser gte cat gea ege gag gge gag gge cea tgg aeg etg cae gee gae gge 18048 Val His Ala Arg Glu Gly Glu Gly Pro Trp Thr Leu His Ala Asp Gly ged ctg ged deg ged ged gag acg gtg deg ttd gat acc geg ata tqg 18096 Ala Leu Ala Pro Ala Ala Glu Thr Val Pro Phe Asp Thr Ala Ile Trp ecc ecg cag ggt gcc gag cac etg gac gcg gcg tgt tac gag egg 18144 Pro Pro Gln Gly Ala Glu His Leu Asp Ala Ala Gly Cys Tyr Glu Arg tte geg gae gee gga tte geg tae gge eeg gtg tte eag gge etg egg 18192 Phe Ala Asp Ala Gly Phe Ala Tyr Gly Pro Val Phe Gln Gly Leu Arg geg gee tgg aag ete gge gag gac ate tae gee gag gte gea ete eee 18240 Ala Ala Trp Lys Leu Gly Glu Asp Ile Tyr Ala Glu Val Ala Leu Pro gaa ggc acg gac ggc aac gcc tac ggc ctg cac ccc gca ctc ttc gac Glu Gly Thr Asp Gly Asn Ala Tyr Gly Leu His Pro Ala Leu Phe Asp

(PCT/EP00/06227


WO 00/77222

			gag gga acg Glu Gly Thr		
	o Phe Ser	y Val Thr	ctc cac gcc Leu His Ala 6125	Thr Gly	
			gaa ggc ggt Glu Gly Gly 6140		
	l Asp Thr	a Pro Val	gcc tcg gtg Ala Ser Val 6155	. Arg Ser	
			cag acc ggt Gln Thr Gly		
			cac ctc acc His Leu Thr		
	r Leu Ala	 Lys Asp	acc gag ggo Thr Glu Gly 6205	/ Ile Leu	_
	_	 	gac gac cto Asp Asp Lei 6220		-
	s Asp Thr	a Pro Leu	ccc acc cgg Pro Thr Arg 6235	Thr Ala	
	-	 -	ggg gca ctg Gly Ala Let	-	
			gcc tcg cgc Ala Ser Arg		
	g Gly Ala	 Thr Asp	ctc gcg ggt Leu Ala Gly 6285	Ala Ser	
,		 	cac ccg ggo His Pro Gly 6300	_	
	o Val Asp	n Asp Ala	gaa gtg ccg Glu Val Pro 6315	Leu Val	
			ttg gtg cgt Leu Val Arg		

WO 00/77222			PCT/EP00/06227
		cg cag tcc tcg gac acg la Gln Ser Ser Asp Thr 45 6350	
		tc acc ggc ggg acc ggt le Thr Gly Gly Thr Gly 6365	
		tg agc gag cac ggg gtg al Ser Glu His Gly Val 6380	
		cc gcc gcc gag ggt gtc ro Ala Ala Glu Gly Val 6395	
Leu Val Ala Glu I		gc gcg cag gtc acc gtc ly Ala Gln Val Thr Val 6410 6	
		tg gcc gat ctg gtg gct al Ala Asp Leu Val Ala 25 6430	
cgg atc agt gct g Arg Ile Ser Ala V 6435	gtg gtg cat acg g Val Val His Thr A 6440	cc ggt gtt ctg gat gac la Gly Val Leu Asp Asp 6445	ggt gtg 19344 Gly Val
gtg gag tcg ctg a Val Glu Ser Leu T 6450	acg ccg gag cgg c Thr Pro Glu Arg L 6455	tg tcg gcg gtg ctg cgt eu Ser Ala Val Leu Arg 6460	ccg aag 19392 Pro Lys
gtg gat gcg gcc t Val Asp Ala Ala T 6465	gg aac ctg cac g Trp Asn Leu His G 6470	ag gcg acc agg ggt ctg lu Ala Thr Arg Gly Leu 6475	gat ctg 19440 Asp Leu 6480
Asp Ala Phe Val V		tg gca ggc acc ttc ggc al Ala Gly Thr Phe Gly 6490 6	
ggt cag gcc aat t Gly Gln Ala Asn T 6500	ac gcg gcg ggt ac Yr Ala Ala Gly A 650	at gct ttc ctg gac gcg sn Ala Phe Leu Asp Ala 05 6510	ctg gcg 19536 Leu Ala
		cg gcg gtg tcg ctg gcg ro Ala Val Ser Leu Ala 6525	
cct tgg tcg cag g Pro Trp Ser Gln A 6530	gac ggt ggt atg ac Asp Gly Gly Met Ti 6535	cc ggc acc ttg agc gac hr Gly Thr Leu Ser Asp . 6540	gcc gat 19632 Ala Asp
		tg ccg ccg ctg acc gtc et et Pro Pro Leu Thr Val 6555	

ggt ctg gcc ctc ttc gac gcc gcg ctc ggc agc gcc gaa ccc atg gca Gly Leu Ala Leu Phe Asp Ala Ala Leu Gly Ser Ala Glu Pro Met Ala

ctc ccc gtc cgc ctg gac ctc gcg gcc cta cgg gca caa ggc gag ccc



<210> 4 <211> 6798 <212> PRT <213> Streptomyces natalensis

WO 00/77222 PCT/EP00/06227

Met Ser Asn Glu Glu Lys Leu Arg Glu Tyr Leu Lys Arg Ala Ile Ala 5 10 Asp Leu His Glu Thr Arg Gln Gln Leu Asp Glu Thr Glu Ala Lys Gln Arg Glu Pro Leu Ala Ile Val Ser Met Ala Cys Arg Phe Pro Gly Gly Val Arg Ser Pro Glu Glu Leu Trp Glu Leu Leu Arg Asp Gly Val Asp Ala Val Ser Ser Phe Pro Arg Asn Arg Gly Trp Asp Leu Asp Ala Leu Tyr His Ser Asp Pro Ala His Gln Gly Thr Ser Tyr Ala Arg Glu Gly Gly Phe Leu His Asp Ala Gly Glu Phe Asp Pro Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Leu Glu Thr Ala Trp Glu Ala Val Glu Arg Ala Gly Ile Asp Pro Glu Ser Leu Ala Gly Ser Arg Thr Gly Val Phe Val Gly Thr Gly His Gly Gly Tyr Asp Ala Glu Gly Arg Arg Ala Asp Glu Val Gly Gly His Leu Leu Thr Gly Asn His Ile Ser Ile Ala Ser Gly Arg Ile Ser Tyr Val Leu Gly Leu Glu Gly Pro Ala Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Ala Met His Ala Leu Arg Arg Asp Glu 215 Cys Ala Met Ala Leu Val Gly Gly Ala Thr Val Met Ser Thr Pro Gln Met Phe Val Glu Phe Ser Arg Gln Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Pro Phe Ala Ala Ala Ala Asp Gly Thr Gly Trp Ser Glu Gly Val Gly Leu Leu Val Glu Arg Leu Ser Asp Ala Val Arg Asn Gly Tyr Pro Val Leu Ala Val Leu Lys Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val 315



Ile	Arg	Gln	Ala	Leu 325	Thr	Gly	Ala	Gly	Leu 330	Ala	Ala	Ser	Asp	Ile 335	Asp
Ala	Val	Glu	Ala 340	His	Gly	Thr	Gly	Thr 345	Thr	Leu	Gly	Asp	Pro 350	Val	Glu
Ala	His	Ala 355	Leu	Leu	Ala	Thr	Tyr 360	Gly	Gln	Gln	Arg	Ala 365	Ala	Asp	Arg
Pro	Cys 370	Gly	Leu	Gly	Ser	Met 375	Lys	Ser	Asn	Ile	Gly 380	His	Thr	Gln	Ala
Ala 385		Gly	Ile	Ala	Gly 390	Val	Met	Lys	Met	Val 395	Leu	Ala	Met	Arg	His 400
Gly	His	Leu	Pro	Arg 405	Thr	Leu	His	Leu	Asp 410	Glu	Pro	Thr	Gly	His 415	Val
Asp	Trp	Ser	Glu 420	Gly	Asn	Ala	Arg	Leu 425	Leu	Ala	Glu	Pro	Glu 430	Pro	Trp
Pro	Ser	Ala 435	Gly	Arg	Pro	Arg	Arg 440	Ala	Ala	Val	Ser	Ser 445	Phe	Gly	Ile
	450		Asn			455					460				
465			Ala		470					475					480
			Ala	485					490					495	
			His 500			_	_	505	_				510		
		515	Leu		_		520					525	_		
	530		Gly			535					540		_		
545			Arg		550					555					560
			Ala	565					570					575	
			Glu 580					585					590		
		595	Cys				600				_	605			
	610		Phe			615					620				_
625			Tyr		630					635					640
rue	Arg	ьeu	Val	GIU	ser	Trp	GIA	val	Ala	Pro	Arg	Phe	val	Ala	Gly

WO 00/77222 PCT/EP00/06227

650 645 655 His Ser Ile Gly Glu Leu Thr Ala Ala His Val Ser Gly Val Leu Thr 665 Leu His Asp Ala Ala Arg Leu Val Ala Ala Arg Gly Thr Leu Met Gln 675 680 Ala Leu Pro Ala Gly Gly Ala Met Val Ala Val Gln Ala Thr Glu Asp Glu Ile Arg Glu Arg Leu Ala Gly His Glu Asp His Val Ala Leu Ala Ala Ala Asn Gly Pro Asp Ser Thr Val Ile Ser Gly Asp Glu Gln Ala Val Thr Glu Ile Ala Ala His Trp Glu Ala Gln Gly Arg Arg Thr Lys Arg Leu Arg Val Ser His Ala Phe His Ser Pro His Met Asp Asp Met Leu Glu Asp Phe Arg Arg Val Ala Arg Gly Leu Thr Phe His Ala Pro Arg Ile Pro Val Val Ser Thr Val Thr Gly Ala Leu Ala Thr Glu Asp Glu Leu Arg Ser Pro Asp Tyr Trp Val Arg Gln Val Arg Glu Thr Val Arg Phe Cys Ala Ala Val Arg Thr Leu Glu Ala Glu Gly Val Thr Thr Phe Val Glu Ile Gly Thr Gly Gly Val Leu Thr Pro Met Val Gln Asp Cys Leu Thr Thr Leu Glu Glu Pro Val Leu Val Pro Leu Leu Arg Thr Gly Arg Pro Glu Thr Val Ala Leu Thr Glu Gly Val Ala Thr Ala Phe Val His Gly Val Pro Val Asp Arg Ser Ala Phe Pro Gly Ala Pro Gly Thr Ser Arg Ala Asp Leu Pro Thr Tyr Ala Phe Gln Arg Gln Trp Tyr Trp Leu Asp Pro Ala Asp His Asp Glu Gly Glu Ala Ala Ala Glu Ala Gly Glu Ala Gly Phe Trp Ala Ala Val Glu Arg Glu Asp Leu Gln Glu Leu Ser Ala Val Leu Ala Ile Asp Gly Ser Glu Ala Asp Ser Leu Gly Ser Phe Leu Pro Thr Leu Ser Ser Trp Arg Arg Gln Arg Arg Thr



- Gln Ala Ala Asp Arg Phe Ser Tyr Arg Thr His Trp Ala Pro Arg 980 985 990
- Thr Ala Ser Gly Gly Pro Thr Ala Thr Gly His Trp Leu Val Val Leu 995 1000 1005
- Pro Glu Gly Gly Thr Asp Asp Pro Trp Thr Ala Arg Leu Leu Asp Ala 1010 1015 1020
- Leu Asn Asp Gln Gly Leu His Thr Asp Val Arg Glu Leu Pro Ala Asp 025 1030 1035 1040
- His Glu Pro Asp Ala Trp Gly Arg His Pro Val Asp Gly Val Leu Cys
 1045 1050 1055
- Leu Leu Ala Leu Asp Glu Arg Pro Thr Arg Ser Cys Pro Pro Tyr Arg 1060 1065 1070
- Arg Gly Leu Ala Ala Thr Thr Asn Ala Ala Ala Arg Pro Glu Gly Ala 1075 1080 1085
- Gly Ile Gln Ala Pro Leu Trp Cys Val Thr Arg Gly Ala Val Ala Val 1090 1095 1100
- Asp Arg His Glu Ala Leu Lys Ser Pro Leu Gln Ala Gln Thr Trp Gly 105 1110 1115 1120
- Leu Gly Arg Val Ala Ala Leu Glu Ser Pro Gln Ser Trp Gly Gly Leu 1125 1130 1135
- Ile Asp Leu Pro Asp Asn Leu Asp Gly Arg Ala Val Ser Ala Leu Leu 1140 1145 1150
- Ser Thr Leu Ala Gly Glu Glu Asp Gln Val Ala Val Arg Pro Ala Gly 1155 1160 1165
- Val Phe Ala Arg Arg Leu Glu Arg Ile Thr Pro Gly Gly Asp Thr Gly 1170 1180
- Asp Arg Trp Ser Thr His Gly Thr Val Leu Val Thr Gly Gly Thr Gly 185 1190 1195 1200
- Ala Leu Gly Ala His Leu Ala His Trp Leu Ala Asp Ala Gly Ala Glu 1205 1210 1215
- His Leu Val Leu Thr Gly Arg Arg Gly Pro Gln Ala Pro Gly Ala Pro 1220 1225 1230
- Glu Leu Ala Ala Leu Thr Asp Arg Gly Val Lys Val Thr Leu Ala 1235 1240 1245
- Ala Cys Asp Ala Ala Asp Arg Asp Ala Leu Ala Ala Val Leu Ala Asp 1250 1260
- Ile Pro Pro His Leu Pro Leu Thr Gly Val Val His Ala Ala Gly Val 265 1270 1275 1280
- Leu Asp Asp Gly Val Leu Asp Ala Leu Thr Pro Glu Arg Phe Glu Thr 1285 1290 1295



- Val Leu Arg Pro Lys Ala Arg Ala Ala Gln Asn Leu His Glu Leu Thr 1300 1305 1310
- Gln Asp Leu Asp Leu Asp His Phe Val Leu Phe Ser Ser Ile Val Gly 1315 1320 1325
- Val Leu Gly Asn Ala Gly Gln Ala Asn Tyr Ala Ala Asn Ala Tyr 1330 1335 1340
- Leu Asp Ala Leu Ala Glu His Arg Leu Ala Gln Gly Leu Pro Ala Thr 345 1350 1355 1360
- Ser Val Ser Trp Gly Pro Gly Gln Ala Ala Ala Trp His Asp Ser Asp 1365 1370 1375
- Ala Ala Asp Arg Met Ser Arg Asp Gly Leu Leu Pro Met Ala Ala Ala 1380 1385 1390
- Pro Arg Arg Pro Ala Pro Ala Leu Ala Gln Gly Met Thr Gln Val 1395 1400 1405
- Thr Val Ala Asp Ile Asp Trp Ser Ala Tyr Ala Pro Ala Leu Thr Ala 1410 1415 1420
- Val Arg Pro Ser Pro Leu Ile Gly Asp Leu Pro Glu Ala Arg Arg Ala 425 1430 1435 1440
- Leu Gly Pro Ala Glu Gly Pro Arg Arg Glu Arg Ser Pro Leu Arg Asp 1445 1450 1455
- Arg Ile Gly Ala Leu Pro Pro Ala Glu Gln Glu Lys Ala Phe Leu Thr 1460 1465 1470
- Met Val Arg Glu Glu Ala Ala Arg Val Leu Gly His Pro Ser Pro Asp 1475 1480 1485
- Thr Val Asp Ala Gln Arg Ala Phe Arg Glu Gln Gly Phe Asp Ser Leu 1490 1495 1500
- Met Ala Val Asp Leu Arg Asn Arg Leu Ser Ala Ala Thr Gly Leu Arg 505 1510 1515 1520
- Leu Pro Ala Thr Leu Leu Phe Asp His Pro Thr Pro Leu Ala Ala Ala 1525 1530 1535
- Ala Cys Leu Arg Ser Glu Val Leu Gly Ala Ala Gly Pro Ala Thr Val
- Val Gln Ala Ser Thr Ala Ala Leu Asp Glu Pro Val Ala Ile Ile Gly 1555 1560 1565
- Met Ala Cys Arg Phe Pro Gly Gly Val His Ser Pro Glu Ala Leu Trp 1570 1575 1580
- Arg Leu Leu Ala Glu Gly Gly Asp Ala Ile Thr Pro Met Pro Ala Asp 585 1590 1595 1600
- Arg Gly Trp Asp Leu Asp Arg Leu Tyr His Pro Asp Pro Asp His Gln
 1605 1610 1615
- Gly Thr Ser Tyr Ala Arg Gly Gly Gly Phe Leu Asp Gly Ala Ala Asp

PCT/EP00/06227

1620 1625 1630

Phe Asp Ala Asp Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met 1635 1640 1645

Asp Pro Gln Gln Arg Leu Leu Glu Thr Trp Glu Val Leu Glu Gln 1650 1655 1660

Ala Gly Ile Asp Pro Glu Ser Leu Arg Gly Ser Ser Thr Gly Val Phe
665 1670 1675 1680

Ala Gly Thr Asn Thr Gln Asp Tyr Gly Thr Ala Leu Asp Ala Ala Gln
1685 1690 1695

Asp Glu Ala Gly Gly His Arg Leu Thr Gly Asn Ala Met Ser Val Val 1700 1705 1710

Ser Gly Arg Val Ser Tyr Thr Phe Gly Phe Glu Gly Pro Ala Leu Thr 1715 1720 1725

Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Leu His Met Ala Ala 1730 1735 1740

Gln Ala Leu Arg Gln Gly Glu Cys Ser Leu Ala Val Ala Gly Gly Val 745 1750 1755 1760

Thr Val Met Ala Thr Pro Ser Ser Phe Val Glu Phe Ala Arg Gln Arg 1765 1770 1775

Gly Leu Ala Pro Asp Gly Arg Cys Lys Pro Phe Ala Ala Ala Asp 1780 1785 1790

Gly Thr Gly Trp Ser Glu Gly Val Gly Leu Leu Leu Val Glu Arg Leu 1795 1800 1805

Ser Asp Ala Arg Arg Asn Gly His Gln Val Leu Ala Val Val Arg Gly 1810 1815 1820

Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Ser Ala Pro Ser 825 1830 1835 1840

Gly Pro Ser Gln Gln Arg Val Ile Arg Gln Ala Leu Ala Asn Ala Arg 1845 1850 1855

Val Ala Ala Ser Glu Val Asp Ala Val Glu Ala His Gly Thr Gly Thr 1860 1865 1870

Thr Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly 1875 1880 1885

Gln Glu Arg Pro Leu Leu Gly Ala Val Lys Ser Asn Leu Gly His 1890 1895 1900


Thr Gln Ala Ala Gly Val Ala Gly Val Met Lys Met Val Leu Ala 905 1910 1915 1920

Met Arg His Gly Met Leu Pro Arg Thr Leu His Val Asp Glu Pro Thr 1925 1930 1935

Gly His Val Asp Trp Thr Ala Gly Ala Val Glu Leu Leu Thr Glu His 1940 1945 1950



- Thr Asp Trp Pro Glu Thr Gly His Pro Arg Arg Ala Ala Val Ser Ala 1955 1960 1965
- Phe Gly Ile Ser Gly Thr Asn Ala His Val Val Leu Glu Leu Pro Ala 1970 1975 1980
- Ala Glu Gln Pro Leu Val Glu Gln Pro Ser Ala Ala Glu Pro Asp Ala 985 1990 1995 2000
- Pro Ala Thr Ala Pro Asp Arg Thr Pro Thr Ala Ser Asp Gly Thr Ala 2005 2010 2015
- Pro Leu Leu Ser Ala Lys Ser Glu Ser Ala Leu Arg Ala Gln Ala 2020 2025 2030
- Ala Arg Leu His Ser His Leu Glu Arg Asp Pro Ala Leu Arg Leu Thr 2035 2040 2045
- Asp Ala Ala Tyr Thr Leu Met Thr His Arg Thr Ala Phe Ala His Arg 2050 2055 2060
- Ala Ala Val Arg Ala Ala Asp His Glu Ala Ala Leu Arg Ala Leu Thr 065 2070 2075 2080
- Ala Leu Ala Ala Gly Glu Ala Asp Pro Ala Val Asp Thr Gly Thr Ala 2085 2090 2095
- His Thr Gly Arg Asp Ala Val Leu Phe Ser Gly Gln Gly Ser Gln Arg 2100 2105 2110
- Ile Gly Met Gly Arg Glu Leu Ser Gly Arg Tyr Pro Val Phe Ala Glu 2115 2120 2125
- Ala Phe Asp Thr Val Cys Ala Ala Leu Asp Glu His Leu Asp Arg Pro 2130 2135 2140
- Leu Arg Asp Val Val Arg Gly Glu Asp Glu Glu Leu Leu Asn Arg Thr 2150 2155 2160
- Val Tyr Ala Gln Ala Gly Leu Phe Ala Ile Glu Val Ala Leu Phe Arg 2165 2170 2175
- Leu Val Glu Ser Trp Gly Val Arg Pro His Tyr Val Ala Gly His Ser 2180 2185 2190
- Val Gly Glu Ile Ala Ala Ala His Val Ala Gly Val Phe Ser Leu Ala 2195 2200 2205
- Asp Ala Cys Ala Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu 2210 2215 2220
- Pro Ala Gly Gly Ala Met Ala Ala Ile Arg Ala Thr Glu Asp Glu Val 225 2230 2235 2240
- Leu Pro His Leu Ala Asp Ser Val Ser Ile Ala Ala Val Asn Gly Pro 2245 2250 2255
- Ser Ser Val Val Val Ser Gly Ala Glu His Ala Val Leu Ser Ile Ala 2260 2265 2270



- Ala His Phe Glu Gly Ala Gly Arg Lys Thr Thr Arg Leu Arg Val Ser 2275 2280 2285
- His Ala Phe His Ser Pro Leu Met Asp Pro Met Leu Ala Asp Phe Arg 2290 2295 2300
- Ala Val Ala Glu Gly Leu Thr Tyr Gly Glu Pro Glu Leu Ala Val Val 305 2310 2315 2320
- Ser Asn Val Thr Gly Gln Leu Ala Thr Pro Asp Gln Leu Arg Thr Pro 2325 2330 2335
- Glu Tyr Trp Val Thr His Val Arg Ala Ala Val Arg Phe Ala Asp Gly
 2340 2345 2350
- Ile Arg Ala Leu Gly Ala Glu Gly Val Thr Arg Phe Leu Glu Leu Gly 2355 2360 2365
- Pro Asp Gly Val Leu Ser Ala Leu Ala Arg Glu Ser Ala Pro Asp Asp 2370 2375 2380
- Ala Val Cys Thr Pro Val Leu Arg Lys Asp Arg Ser Glu Ala Ala Thr 385 2390 2395 2400
- Leu Leu Ala Ala Leu Thr His Leu His Val His Gly Thr Glu Ile Asp 2405 2410 2415
- Trp Thr Ala Phe Leu Ala Gly Arg Asp Ala His Ala Val Asp Leu Pro 2420 2425 2430
- Thr Tyr Ala Phe Gln His Gln Arg Phe Trp Pro Thr Pro Asp His Thr 2435 2440 2445
- Arg Thr Gly Asp Leu Gly Ala Val Gly Leu Glu Ala Thr Gly His Pro 2450 2455 2460
- Leu Leu Ser Ala Ala Val Glu Leu Pro Asp Gly Glu Gly Leu Phe 465 2470 2475 2480
- Thr Thr Arg Leu Ser Leu Gln Thr His Pro Trp Leu Ala Gly His Val 2485 2490 2495
- Val Met Gly Ser Val Leu Leu Pro Gly Thr Ala Phe Ala Glu Leu Ala 2500 2505 2510
- Leu Arg Ala Ala Asp Glu Val Gly Cys Asp Arg Val Asp Glu Leu Thr 2515 2520 2525
- Leu Ala Ala Pro Leu Val Leu Pro Glu His Gly Gly Val Gln Leu Gln 2530 2535 2540
- Leu Arg Val Gly Pro Ala Asp Ala Ser Gly Arg Arg Thr Leu Thr Ala 545 2550 2555 2560
- Arg Ser Arg Ala Glu Gly Asp Gly Asp Arg Pro Trp Val Gln His Ala 2565 2570 2575
- Thr Gly Val Leu Ala Glu Gly Glu Ser Thr Pro Glu Pro Gly Tyr Asp 2580 2585 2590
- Phe His Thr Glu Ser Trp Pro Pro Ala Asp Ala Aro Val Glu Leu

2595 2600 2605

Ser Gly Leu Tyr Pro Asp Phe Ala Ala His Gly Phe Asp Tyr Gly Pro 2610 2615 2620

PCT/EP00/06227

- His Phe Gln Gly Leu Arg Thr Ala Trp Arg Arg Gly Asp Glu Val Phe 625 2630 2635 2640
- Ala Glu Val Ala Leu Pro Ala Glu Ala Glu Gly Glu Ala Ser Ala Tyr 2645 2650 2655
- Gly Leu His Pro Ala Leu Leu Asp Ala Ala Leu His Val Val Ala Phe 2660 2665 2670
- Asn Gly Val Asp Arg Gly Val Val Pro Phe Ser Trp Glu Ser Val Ala 2675 2680 2685
- Leu His Ala Thr Gly Ala Ser Ala Val Arg Ile Arg Val Val Arg His 2690 2695 2700
- Ser Gly Asp Thr Val Ser Val Asp Val Ala Asp Thr Thr Gly Glu Pro
 705 2710 2715 2720
- Val Ala Ser Ile Gly Thr Leu Val Leu Arg Ala Val Ser Ala Asp Gln 2725 2730 2735
- Leu Ala Gly Gly Ala Asp Pro Ala Val Arg Asp Ala Leu Phe Arg Val 2740 2745 2750
- Gln Trp Asn Pro Val Arg Leu Pro Pro Ala Gly Ala Ala Val Thr Val 2755 2760 2765
- Ala Thr Leu Gly Ser Leu Ala Gly Ala Pro Phe Asp Gly Tyr Pro Asp 2770 2780
- Leu Ala Ser Leu Ala Arg Ser Gly Arg Val Ala Gly Ala Val Leu Val
 785 2790 2795 2800
- Pro Val Glu Ala Gly Ala Gly Glu Val Val Ala Asp Asp Val Val Gly
 2805 2810 2815
- Ala Thr His Ala Thr Ala Ala Arg Ala Leu Asp Leu Ala Arg Ser Trp 2820 2825 2830
- Leu Ala Asp Asp Arg Phe Ala Ala Ser Arg Leu Val Phe Val Thr Arg 2835 2840 2845
- Gly Ala Val Ser Gly Ala Asp Leu Ala Gly Ala Ala Val Trp Gly Leu 2850 2855 2860
- Val Arg Ser Ala Leu Ser Glu His Pro Gly Arg Phe Gly Leu Val Asp 865 2870 2875 2880
- Leu Asp Asp Asp Ala Glu Leu Ala Leu Val Pro Arg Val Leu Ala Ser 2885 2890 2895
- Asp Glu Pro Gln Leu Leu Val Arg Gly Glu Val Leu Ala Ala Arg 2900 2905 2910
- Leu Ala Arg Ala Gln Ser Ser His Ala Val Thr Trp Asp Pro Ser Gly 2915 2920 2925



- Thr Val Leu Val Thr Gly Gly Thr Gly Gly Leu Gly Arg Val Met Ala 2930 2935 2940
- Arg His Leu Val Val Glu His Gly Val Arg Asn Leu Leu Leu Val Ser 2955 2960
- Arg Arg Gly Pro Ala Ala Glu Gly Ala Glu Glu Leu Val Thr Glu Leu 2965 2970 2975
- Arg His Ser Gly Ala Glu Val Ala Val Glu Ala Cys Asp Val Thr Asp 2980 2985 2990
- Ala Ala Val Ala Asp Leu Val Ala Arg His Arg Ile Ser Ala Val 2995 3000 3005
- Val His Thr Ala Gly Val Leu Asp Asp Gly Val Val Glu Ser Leu Thr 3010 3015 3020
- Pro Glu Arg Leu Ser Ala Val Leu Arg Pro Lys Val Asp Ala Ala Trp 025 3030 3035 3040
- Asn Leu His Glu Ala Thr Arg Asp Leu Asp Leu Asp Ala Phe Val Val 3045 3050 3055
- Phe Ser Ser Val Ala Gly Thr Ile Gly Ser Pro Gly Gln Ala Asn Tyr 3060 3065 3070
- Ala Ala Gly Asn Ala Phe Leu Asp Ala Leu Ala His His Arg Arg Ala 3075 3080 3085
- Ala Gly Leu Pro Ala Ala Ser Leu Ala Trp Gly Pro Trp Ser Arg Asp 3090 3095 3100
- Gly Gly Met Thr Gly Thr Leu Thr Asp Val Asp Ser Ser Ala Ser Pro 105 3110 3115 3120
- Gly Arg His Ala Arg Thr His Pro Arg Thr Gly Arg Gly Leu Phe Asp 3125 3130 3135
- Ala Ala Leu Ala Ala Gly Asp Ala His Leu Leu Pro Val Arg Phe Asp 3140 3145 3150
- Trp Ala Ser Leu Arg Ala Gln Gly Glu Val Pro Pro Leu Leu Arg Gly 3155 3160 3165
- Leu Ile Arg Thr Arg Ala Arg Ser Ala Val Gly Gly Ser Ala Ala 3170 3175 3180
- Ala Ala Gly Leu Val Gly Arg Leu Ser Gly Arg Gly Thr Val Glu Arg
 185 3190 3195 3200
- Arg Glu Val Leu Leu Asp Leu Val Arg Ala Gln Ile Ala Val Val Leu 3205 3210 3215
- Gly His Ala Asn Pro Glu Thr Ile Glu Ser Thr Arg Val, Phe Gln Asp 3220 3225 3230
- Leu Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu Asn 3235 3240 3245



- Asn Ala Thr Gly Leu Arg Leu Ser Ala Thr Ala Val Phe Asp Tyr Pro 3250 3255 3260
- Thr Ala Asp Ala Leu Val Asp Phe Leu Leu Asp Glu Leu Phe Gly Ala 265 3270 3275 3280
- Gln Glu Glu Ala Glu Leu Pro Ala Pro Val Pro Ser Pro Ala Gly Ala 3285 3290 3295
- Ala Asp Asp Pro Val Val Ile Val Gly Met Ser Cys Arg Tyr Pro Gly
 3300 3305 3310
- Gly Val Gly Ser Pro Glu Asp Leu Trp Arg Leu Val Ser Glu Gly Val 3315 3320 3325
- Asp Ala Val Ser Asp Phe Pro Thr Asp Arg Gly Trp Asp Val Glu Ser 3330 3335 3340
- Leu Tyr Ser Pro Asp Pro Glu Ala Leu Gly Thr Ser Tyr Thr Arg Ser 345 3350 3355 3360
- Gly Gly Phe Leu His Glu Ala Ala Glu Phe Asp Pro Asp Phe Phe Gly 3365 3370 3375
- Met Ser Pro Arg Glu Ala Leu Ala Thr Asp Ala Gln Gln Arg Leu Leu 3380 3385 3390
- Leu Glu Thr Trp Glu Ala Ile Glu Arg Thr Gly Ile Asp Pro Ala 3395 3400 3405
- Ser Leu Arg Gly Ser Arg Thr Gly Val Phe Ala Gly Val Met Tyr Thr 3410 3415 3420
- Asp Tyr Gly Asp Leu Leu Val Gly Asp Gln Phe Glu Gly Tyr Arg Ser 425 3430 3435 3440
- Asn Gly Ser Ala Ala Ser Ile Ala Ser Gly Arg Val Ser Tyr Thr Phe 3445 3450 3455
- Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser 3460 3465 3470
- Leu Val Ala Leu His Trp Ala Ala Gln Ser Leu Arg Ser Gly Glu Cys 3475 3480 3485
- Ser Leu Ala Val Ala Gly Gly Val Thr Val Met Ser Thr Pro Thr Thr 3490 3495 3500
- Phe Val Glu Phe Ser Arg Gln Arg Gly Leu Ser Ala Asp Gly Arg Cys 3515 3520
- Lys Ala Phe Ala Asp Ala Ala Asp Gly Val Gly Trp Gly Glu Gly Val 3525 3530 3535
- Gly Met Leu Val Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His 3540 3545 3550
- Arg Val Leu Ala Val Val Arg Gly Ser Ala Val Asn Gln Asp Gly Ala 3555 3560 3565
- Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ala Gln Gln Arg Val Ile

3570 3575 3580

WO 00/77222

Arg Gln Ala Leu Ala Ser Ala Gly Leu Ser Ala Ala Asp Val Asp Ala 585 3590 3595 3600

- Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ala 3605 3610 3615
- Gln Ala Leu Leu Ala Thr Tyr Gly Gln Glu Arg Pro Glu Asp Arg Pro 3620 3625 3630
- Leu Leu Cly Ser Val Lys Ser Asn Ile Cly His Ala Gln Ala Ala 3635 3640 3645
- Ser Gly Val Ala Gly Val Ile Lys Met Val Leu Ala Met Arg His Gly 3650 3660
- Val Leu Pro Arg Thr Leu His Val Asp Glu Pro Ser Ser His Val Asp 665 3670 3675 3680
- Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Ser Glu Ala Glu Trp Pro 3685 3690 3695
- Gln Gly Glu Gly Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser 3700 3705 3710
- Gly Thr Asn Ala His Val Ile Leu Glu Gln Pro Gly Pro Asp Ala Ala 3715 3720 3725
- Asp Ala Ala Pro Asp Ala Thr Val Thr Asp Pro Gly Ala Leu Ala Trp 3730 3735 3740
- Val Leu Ser Ala Arg Asn Glu Ala Ala Leu Arg Cys Gln Ala Ala Arg 745 3750 3755 3760
- Leu Leu Ser Leu Val Ala Gly Ser Asp Ala Leu Cys Ala Arg Asp Ile 3765 3770 3775
- Gly His Ser Leu Val Thr Gly Arg Ser Ser Phe Ala His Arg Ala Val 3780 3785 3790
- Val Trp Gly Gln Asp Arg Asp Ala Leu Val Arg Ala Leu Ser Ala Leu 3795 3800 3805
- Ala Val Gly Glu Ala Asp Ala Gly Leu Ala Glu Gly Ala Ser Gly Ala 3810 3815 3820
- Gly Arg Thr Ala Phe Leu Phe Ser Gly Gln Gly Ser Gln Arg Leu Gly 825 3830 3835 3840
- Met Gly Trp Glu Leu Tyr Ala Arg Tyr Pro Val Phe Ala Asp Ala Phe 3845 3850 3855
- Asp Ala Val Cys Ala Ala Leu Asp Glu His Leu Glu Arg Pro Leu Arg 3860 3865 3870
- Asp Val Val Trp Gly Glu Asp Ala Glu Leu Leu Asn Gln Thr Ala Tyr 3875 3880 3885
- Ala Gln Ala Gly Leu Phe Ala Ile Glu Val Ala Leu Tyr Arg Leu Ala 3890 3895 3900



Glu Ser Trp Gly Met Arg Pro Asp Phe Val Ala Gly His Ser Ile Gly 905 3910 3915 3920

- Glu Val Ala Ala Ala His Val Ser Gly Val Phe Ser Leu Pro Asp Ala 3925 3930 3935
- Cys Ala Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gln Leu Pro Ser 3940 3945 3950
- Gly Gly Ala Met Met Ala Ile Arg Ala Thr Glu Asp Glu Val Leu Pro 3955 3960 3965
- His Leu Ala Glu Gly Val Ser Leu Ala Ala Val Asn Gly Pro Ser Ser 3970 3975 3980
- Val Val Ile Ser Gly Ala Glu Asp Ala Val Leu Ala Ile Ala Ala His 985 3990 3995 4000
- Phe Ala Gly Glu Gly Arg Lys Thr Thr Arg Leu Arg Val Ser His Ala 4005 4010 4015
- Phe His Ser Pro Leu Met Glu Pro Met Leu Glu Phe Arg Ala Val 4020 4025 4030
- Val Thr Arg Leu Ser Phe Gly Thr Pro Thr Ile Pro Val Val Ser Asn 4035 4040 4045
- Leu Thr Gly Arg Leu Ala Glu Pro Glu Gln Leu Ala His Ala Asp Tyr 4050 4055 4060
- Trp Val Arg His Val Arg Glu Ala Val Arg Phe Ala Asp Gly Ile Gln 065 4070 4075 4080
- Ala Leu Arg Ala Glu Gly Val Thr Arg Phe Leu Glu Leu Gly Pro Asp 4085 4090 4095
- Gly Val Leu Ser Ala Met Ala Arg Glu Ser Ala Ser Asp Asp Ala Val 4100 4105 4110
- Leu Ala Pro Val Leu Arg Arg Asp Arg Pro Glu Glu Thr Ala Leu Leu 4115 4120 4125
- Gly Ala Leu Ala Gln Leu Tyr Val Arg Gly Ala His Val Asp Trp Thr 4130 4135 4140
- Val Pro Phe Ala Gly Ser Gly Ala Arg Trp Ala Asp Leu Pro Thr Tyr 145 4150 4155 4160
- Ala Phe Gln His Glu Arg Phe Trp Pro Ser Gly Gly Val Ala Arg Pro 4165 4170 4175
- Gly Asp Val Arg Ser Ala Gly Leu Gly Ser Ala Gly His Pro Leu Leu
 4180 4185 4190
- Gly Ala Ala Val Glu Leu Ala Gly Ser Gly Gly Leu Leu Phe Thr Gly
 4195 4200 4205
- Arg Leu Ser Val Ser Ser His Pro Trp Leu Ala Asp His Val Val Leu 4210 4215 4220



Gly Ser Val Leu Val Pro Gly Thr Ala Leu Val Glu Leu Val Leu Arg 225 4230 4235 4240

- Ala Ala Asp Glu Ala Gly Cys Asp Leu Leu Glu Glu Leu Thr Leu Ala 4245 4250 4255
- Ala Pro Leu Val Leu Pro Ala Ser Gly Ala Ala Val Gln Val Gln Val 4260 . 4265 4270
- Ala Val Gly Glu Pro Asp Glu Ala Gly Arg Pro Val Ser Val His 4275 4280 4285
- Ala Arg Glu Gly Glu Gly Pro Trp Thr Leu His Ala Ser Gly Ala Val 4290 4295 4300
- Thr Ser Gly Ala Glu Val Pro Pro Phe Asp Ala Thr Val Trp Pro Pro 305 4310 4315 4320
- Lys Gly Ala Glu Pro Val Asp Val Ala Asp Cys Tyr Asp Val Leu Ala 4325 4330 4335
- Asp Ala Gly Leu Thr Tyr Gly Pro Ala Phe His Gly Leu Gln Ala Ala 4340 4345 4350
- Trp Lys Leu Gly Gly Asp Val Tyr Ala Glu Ala Lys Leu Pro Glu Ser 4355 4360 4365
- Thr Asp Gly Asp Ala Tyr Gly Leu His Pro Ala Leu Phe Asp Ala Ala 4370 4375 4380
- Leu His Ala Ser Ala Leu Gly Gly Ala Glu Ala Gly Gly Val Pro Phe 385 4390 4395 4400
- Ser Trp Ala Gly Val Ser Leu His Ala Thr Gly Ala Ser His Leu Arg 4405 4410 4415
- Val Arg Ile Arg Glu Ala Gly Gly Ala Leu Ser Val Ala Ile Ala Asp 4420 4425 4430
- Thr Ser Gly Ala Pro Val Ala Ser Val Glu Ser Leu Val Ile Arg Pro 4435 4440 4445
- Leu Ser Ala Gly Gln Val Gln Ala Ala Asp Arg Asp Ala Leu Phe Lys 4450 4455 4460
- Ala Asp Trp Val Pro Val Pro Leu Thr Asp Glu Arg Val Glu Pro Gly 465 4470 4475 4480
- Thr Gly Pro Glu Gly Glu Pro Leu Arg Thr Tyr Ala Asp Leu Asp Ser 4485 4490 4495
- Leu Glu Gly Ala Ala Val Pro Gly Thr Val Leu Val Ala Pro Pro Ser 4500 4505 4510
- Gly Ala Ala Gly Thr Val Glu Ser Val His Ala Ala Thr Val Trp Ala 4515 4520 4525
- Leu Glu Met Val Gln Ala Trp Leu Ala Asp Asp Arg Phe Ala Thr Ser 4530 4540
- Arg Leu Val Phe Val Thr Arg Gly Ala Ala Phe Gly Ala Asp Leu Ala

4550 4555 4560

- Ala Ala Val Arg Gly Leu Val Arg Ser Ala Gln Ser Glu Asn Pro 4565 4570 4575
- Gly Arg Phe Gly Leu Val Asp Met Asp Gly Asp Ala Asp Thr Thr Val 4580 4585 4590
- Pro Ala Gln Ala Leu Ala Thr Asp Glu Pro Glu Leu Leu Val Arg Gly
 4595 4600 4605
- Gly Glu Val Leu Ala Ala Arg Leu Val Arg Ala Gln Ser Ser His Thr 4610 4615 4620
- Val Thr Trp Asp Pro Ser Gly Thr Val Leu Ile Thr Gly Gly Thr Gly 625 4630 4635 4640
- Gly Leu Gly Arg Ser Val Ala Arg His Leu Val Ser Glu His Gly Val
 4645 4650 4655
- Arg Ser Leu Leu Val Ser Arg Gly Pro Ala Ala Glu Gly Ala 4660 4665 4670
- Gly Glu Leu Val Ala Glu Leu Arg Gly Ser Gly Ala Glu Val Val Ile 4675 4680 4685
- Glu Ala Cys Asp Val Thr Asp Ala Val Ala Val Ala Asp Leu Val Ala 4690 4695 4700
- Arg His Arg Ile Ser Ala Val Val His Thr Ala Gly Val Leu Asp Asp 705 4710 4715 4720
- Gly Val Val Glu Ser Leu Thr Pro Glu Arg Leu Ala Val Val Leu Arg 4725 4730 4735
- Pro Lys Val Asp Ala Ala Trp Asn Leu His Glu Ala Thr Arg Gly Leu 4740 4745 4750
- Asp Leu Asp Ala Phe Val Val Phe Ser Ser Val Ala Gly Thr Phe Gly 4755 4760 4765
- Ser Ala Gly Gln Ala Asn Tyr Ala Ala Gly Asn Ala Phe Leu Asp Ala 4770 4775 4780
- Leu Ala Tyr His Arg Arg Ala Val Gly Leu Pro Ala Val Ser Leu Ala 785 4790 4795 4800
- Trp Gly Pro Trp Ser Gln Asp Gly Gly Met Thr Gly Thr Leu Ser Asp 4805 4810 4815
- Ala Asp Val Gln Arg Ile Ala Arg Gln Gly Met Pro Pro Leu Thr Val 4820 4825 4830
- Glu Glu Gly Leu Ala Leu Phe Asp Ala Ala Leu Gly Ser Ala Glu Pro 4835 4840 4845
- Met Ala Leu Pro Val Arg Leu Asp Leu Ala Ala Leu Arg Ala Gln Gly 4850 4855 4860
- Glu Pro Gln Pro Leu Leu Arg Gly Leu Ile Arg Thr Arg Thr Arg Arg 865 4870 4875 4880



- Ser Gly Ala Ala Ala Ser Gly Ile Ala Gln Arg Leu Ala Gly Leu 4885 4890 4895
- Ser Thr Ala Glu Arg Arg Glu Ala Leu Leu Asp Val Val Arg Ala Gln
 4900 4905 4910
- Ile Ala Thr Val Leu Gly His Ala Gly Pro Glu Thr Ile Ala Pro Asp 4915 4920 4925
- Arg Ala Phe Gln Asp Leu Gly Leu Asp Ser Leu Thr Ala Ile Glu Leu 4930 4935 4940
- Arg Asn Leu Leu Gly Lys Ala Thr Gly Leu Arg Leu Pro Ala Thr Thr 945 4950 4955 4960
- Val Phe Asp Tyr Pro Thr Val Asp Ala Leu Ala Ala His Leu Leu Asp
 4965 4970 4975
- Glu Leu Phe Gly Ala Glu Thr Gly Thr Ala Thr Glu Thr Pro Leu Pro 4980 4985 4990
- Val Pro Gly Leu Pro Ser Leu Ala Asp Asp Pro Val Val Ile Val Gly
 4995 5000 5005
- Met Ser Cys Arg Phe Pro Gly Gly Val Ala Ser Pro Glu Asp Leu Trp 5010 5020
- Arg Leu Val Ala Asp Gly Val Asp Ala Val Ser Ala Phe Pro Thr Asp 025 5030 5035 5040
- Arg Gly Trp Glu Ile Asp Asp Thr Tyr Asp Pro Glu Arg Glu Gly Ala 5045 5050 5055
- Ile Ala Thr Arg Ser Gly Gly Phe Leu His Asp Ala Ala Glu Phe Asp 5060 5065 5070
- Pro Glu Phe Phe Gly Met Ser Pro Arg Glu Ala Leu Thr Thr Asp Ala 5075 5080 5085
- Gln Gln Arg Leu Leu Glu Thr Thr Trp Glu Ala Leu Glu Arg Ala 5090 5095 5100
- Gly Met Asp Pro Ala Thr Leu Arg Gly Ser Arg Thr Gly Val Phe Ala 105 5110 5115 5120
- Gly Val Met Tyr His Asp Tyr Ser Thr Leu Leu Ser Gly Arg Glu Phe 5125 5130 5135
- Glu Gly Tyr Gln Gly Ser Gly Ser Ala Gly Ser Val Ala Ser Gly Arg 5140 5145 5150
- Val Ser Tyr Thr Phe Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr 5155 5160 5165
- Ala Cys Ser Ser Leu Val Ala Leu His Leu Ala Ala Gln Ser Leu 5170 5180
- Arg Ser Gly Glu Cys Ser Leu Ala Leu Ala Gly Gly Val Thr Val Met 185 5190 5195 5200



- Ser Thr Pro Leu Thr Phe Val Glu Phe Ser Arg Gln Gly Gly Leu Ser 5205 5210
- Ala Asp Gly Arg Cys Lys Ala Phe Ala Asp Ala Ala Asp Gly Val Gly 5220 5230
- Trp Ala Glu Gly Ala Gly Ile Leu Val Leu Glu Arg Leu Ser Asp Ala 5235 5240 5245
- Arg Arg Asn Gly His Arg Ile Leu Ala Thr Val Arg Gly Ser Ala Val 5250 5255 5260
- Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ala 265 5270 5275 5280
- Gln Gln Arg Val Ile Arg Gln Ala Leu Ala Ser Ala Gly Leu Ser Ala 5285 5290 5295
- Ala Asp Val Asp Ala Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly 5300 5310
- Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Glu Arg 5315 5320 5325
- Pro Glu Asp Arg Pro Leu Leu Gly Ser Val Lys Ser Asn Ile Gly 5330 5335 5340
- His Ala Gln Ala Ala Ser Gly Val Ala Gly Val Ile Lys Met Val Leu 345 5350 5355 5360
- Ala Met Arg His Gly Val Leu Pro Arg Thr Leu His Val Asp Glu Pro 5365 5370 5375
- Ser Ser His Val Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Ser 5380 5385 5390
- Glu Ala Glu Trp Pro Gln Gly Glu Gly Pro Arg Arg Ala Gly Val Ser
 5395 5400 5405
- Ser Phe Gly Ile Ser Gly Thr Asn Ala His Val Ile Leu Glu Gln Pro 5410 5415 5420
- Glu Pro Val Ala Ala Glu Thr Glu Ser Ile Thr Pro Asp Thr Ala Pro 425 5430 5435 5440
- Asp Ala Ala Glu Asp Glu Ala Ala Asp Ser Gly Thr Pro Val Pro Ala 5445 5450 5455
- Leu Leu Ser Gly Arg Ser Ala Ser Ala Leu Arg Ala Gln Ala Arg 5460 5465 5470
- Leu Leu Ser Arg Leu Asp Gly Asp Pro Gly Pro Arg Ile Thr Asp Val 5475 5480 5485
- Ala Tyr Ser Leu Ala Thr Gly Arg Ser Ala Phe Pro His Arg Ala Val 5490 5495 5500
- Ile Leu Ala Ala Asn Arg Ala Asp Leu Leu His Ser Leu Ser Ala Leu 505 5510 5515 5520
- Ala Glu Gly His Thr Glu Ala Pro Ala Val Val Ala Gln Asp Arg Ala

5525 5530 5535

Arg Ser Gly Lys Leu Ala Phe Leu Phe Ser Gly Gln Gly Ser Gln Arg
5540 5555

Leu Gly Met Gly Arg Glu Leu Tyr Gly Arg Tyr Pro Ala Phe Ala Glu 5555 5560 5565

Ala Leu Asp Ala Val Cys Ala Ala Leu Asp Ala His Leu Asp Arg Pro 5570 5580

Leu Arg Asp Val Ile Trp Gly Glu Asp Ala Glu Leu Leu Asn Arg Thr 585 5590 5595 5600

Gly Tyr Ala Gln Thr Gly Leu Phe Ala Ile Glu Val Ala Leu Phe Arg
5605 5610 5615

Leu Leu Glu Ser Trp Gly Val Arg Pro Asp His Leu Leu Gly His Ser 5620 5625 **\$**630

Ile Gly Glu Ile Ala Ala Ala His Val Ala Gly Val Leu Ser Leu Pro 5635 5640 5645

Asp Ala Cys Ala Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gln Leu 5650 5660

Pro Ser Gly Gly Ala Met Met Ala Ile Arg Ala Thr Glu Asp Glu Val 565 5670 5675 5680

Leu Pro His Leu Ala Glu Gly Val Ser Leu Ala Ala Val Asn Gly Pro
5685 5690 5695

Ser Ser Val Val Ser Gly Ala Glu Asp Glu Val Leu Ala Leu Ala 5700 5705 5710

Ala His Phe Glu Glu Glu Gly Arg Lys Thr Thr Arg Leu Arg Val Ser 5715 5720 5725

His Ala Phe His Ser Pro Leu Met Glu Pro Met Leu Ala Asp Phe Arg 5730 5735 5740

Ala Val Ala Asp Gly Met Thr Tyr Ala Ala Pro Arg Ile Pro Val Val 745 5750 5755 5760

Ser Asn Val Thr Gly Arg Pro Ala Thr Ala Glu Glu Leu Cys Cys Ala 5765 5770 5775

Glu Tyr Trp Val Gly His Val Arg Glu Ala Val Arg Phe Ala Asp Gly
5780 5785 5790

Val Gly Ala Leu Arg Glu Gln Gly Val Thr Thr Phe Leu Glu Leu Gly 5795 5800 5805

Pro Asp Gly Ser Leu Ser Ala Leu Ala Ala Glu Ser Ala Ala Asp Asp 5810 5820

Ser Val Leu Ala Pro Val Leu Arg Lys Asn Arg Pro Glu Ala Pro Ala 825 5830 5835 5840

Leu Leu Thr Ala Leu Ala Arg Leu His Ala Gln Gly Thr Pro Val Asp 5845 5850 5855



- Trp Ser Ala Ala Phe Ala Gly Thr Gly Ala Arg Trp Val Asp Leu Pro 5860 5865 5870
- Thr Tyr Ala Phe Gln His Glu Arg Phe Trp Pro Ser Gly Gly Ala Ala 5875 5880 5885
- Arg Ala Gly Asp Val Arg Ser Ala Gly Leu Gly Ser Ala Gly His Pro 5890 5895 5900
- Leu Leu Gly Ala Ala Val Glu Leu Ala Gly Ser Gly Glý Arg Leu Leu 905 5910 5915 5920
- Thr Gly Arg Leu Ser Leu Ser Ser His Pro Trp Leu Ala Asp His Val 5925 5930 5935
- Val Leu Gly Ser Val Leu Val Pro Gly Thr Ala Leu Met Glu Leu Val 5940 5945 5950
- Leu Arg Ala Ala Asp Glu Val Asp Cys Ala Ala Val Asp Glu Leu Thr 5955 5960 5965
- Leu Ala Ala Pro Leu Val Leu Pro Ala Ser Gly Ala Ala Ile Gln Val 5970 5975 5980
- Gln Val Trp Val Gly Glu Pro Asp Glu Ala Gly Arg Arg Pro Val Ser 985 5990 5995 6000
- Val His Ala Arg Glu Gly Glu Gly Pro Trp Thr Leu His Ala Asp Gly 6005 6010 6015
- Ala Leu Ala Pro Ala Ala Glu Thr Val Pro Phe Asp Thr Ala Ile Trp
 6020 6025 6030
- Pro Pro Gln Gly Ala Glu His Leu Asp Ala Ala Gly Cys Tyr Glu Arg 6035 6040 6045
- Phe Ala Asp Ala Gly Phe Ala Tyr Gly Pro Val Phe Gln Gly Leu Arg 6050 6060
- Ala Ala Trp Lys Leu Gly Glu Asp Ile Tyr Ala Glu Val Ala Leu Pro 065 6070 6075 6080
- Glu Gly Thr Asp Gly Asn Ala Tyr Gly Leu His Pro Ala Leu Phe Asp 6085 6090 6095
- Ala Ala Leu His Ala Ala Leu Leu Gly Gly Glu Gly Thr Asp Glu Ala 6100 6105 6110
- Ala Val Pro Phe Ser Trp Asn Gly Val Thr Leu His Ala Thr Gly Ala 6115 6120 6125
- Ser Arg Val Arg Val Arg Ile Arg Pro Thr Glu Gly Gly Thr Ser Ile 6130 6135 6140
- Ala Leu Val Asp Thr Ala Gly Ala Pro Val Ala Ser Val Arg Ser Leu 145 6150 6155 6160
- Thr Ala Arg Pro Ile Thr Ala Gly Gln Leu Gln Thr Gly Asp Arg Asp 6165 6170 6175

- Ser Leu Phe Gln Val Asp Trp Thr Thr Leu His Leu Thr Asp Glu Arg 6180 6185 6190
- Ala Asn Ser Leu Ala Leu Leu Gly Lys Asp Thr Glu Gly Ile Leu Asp 6195 6200 6205
- Thr Leu Ser Leu Gln Pro His Ala Asp Leu Asp Asp Leu Ala Ala Thr 6210 6220
- Gly Val His Asp Thr Val Leu Ala Pro Leu Pro Thr Arg Thr Ala Gly 6230 6235 6240
- Thr Val Glu Ser Val His Ala Ala Thr Thr Gly Ala Leu Ala Leu Ile 6245 6250 6255
- Arg Ser Trp Leu Ala Asp Asp Arg Phe Ala Ala Ser Arg Leu Val Phe 6260 6265 6270
- Val Thr Arg Gly Ala Val Ser Gly Thr Asp Leu Ala Gly Ala Ser Val 6275 6280 6285
- Trp Gly Leu Val Arg Ser Ala Leu Leu Glu His Pro Gly Arg Phe Gly 6290 6295 6300
- Leu Val Asp Val Asp Val Asp Gln Asp Ala Glu Val Pro Leu Val Pro 305 6310 6315 6320
- Arg Ala Leu Ala Ser Asp Glu Pro Gln Val Leu Val Arg Gly Glu 6325 6330 6335
- Val Leu Ala Arg Leu Val Arg Ala Gln Ser Ser Asp Thr Val Thr
 6340 6345 6350
- Trp Asp Pro Ser Gly Thr Val Leu Ile Thr Gly Gly Thr Gly Gly Leu 6355 6360 6365
- Gly Arg Ser Val Ala Arg His Leu Val Ser Glu His Gly Val Arg Ser 6370 6375 6380
- Leu Leu Leu Val Ser Arg Arg Gly Pro Ala Ala Glu Gly Val Asp Ala 385 6390 6395 6400
- Leu Val Ala Glu Leu Ala Glu Cys Gly Ala Gln Val Thr Val Glu Ala 6405 6410 6415
- Cys Asp Val Thr Asp Ala Val Ala Val Ala Asp Leu Val Ala Arg His
 6420 6425 6430
- Arg Ile Ser Ala Val Val His Thr Ala Gly Val Leu Asp Asp Gly Val 6435 6440 6445
- Val Glu Ser Leu Thr Pro Glu Arg Leu Ser Ala Val Leu Arg Pro Lys 6450 6455 6460
- Val Asp Ala Ala Trp Asn Leu His Glu Ala Thr Arg Gly Leu Asp Leu 465 6470 6475 6480
- Asp Ala Phe Val Val Phe Ser Ser Val Ala Gly Thr Phe Gly Ser Ala 6485 6490 6495
- Gly Gln Ala Asn Tyr Ala Ala Gly Asn Ala Phe Leu Asp Ala Leu Ala

*6*E10

- Tyr His Arg Arg Ala Val Gly Leu Pro Ala Val Ser Leu Ala Trp Gly
 6515 6520 6525
- Pro Trp Ser Gln Asp Gly Gly Met Thr Gly Thr Leu Ser Asp Ala Asp 6530 6540
- Val Gln Arg Ile Ala Arg Gln Gly Met Pro Pro Leu Thr Val Glu Glu 545 6550 6555 6560
- Gly Leu Ala Leu Phe Asp Ala Ala Leu Gly Ser Ala Glu Pro Met Ala 6565 6570 6575
- Leu Pro Val Arg Leu Asp Leu Ala Ala Leu Arg Ala Gln Gly Glu Pro 6580 6585 6590
- Gln Pro Leu Leu Arg Gly Leu Ile Arg Thr Pro Gly Arg Arg Thr Ala 6595 6600 6605
- Ala Ala Ala Thr Glu Gly Asp Thr Ala Ala Ala Phe Ala Gly Arg Leu 6610 6620
- Thr Gly Leu Ser Ala Ala Glu Gly Arg Glu Val Val Leu Gly Ala Val 625 6630 6635 6640
- Arg Ser Gln Ile Ala Gly Val Leu Gly His Ala Glu Ala Thr Glu Ile 6645 6650 6655
- Asp Gln Asp Arg Ala Phe Leu Asp Leu Gly Phe Asp Ser Leu Thr Ala 6660 6670
- Val Glu Leu Arg Asn Arg Leu Gly Ala Val Thr Gly Ile Arg Leu Pro 6675 6680 6685
- Ala Thr Leu Leu Phe Asp Tyr Pro Thr Pro Ala Glu Leu Val Ala His 6690 6695 6700
- Leu His Ala Arg Ile Ala Pro Glu Pro Thr Val Gly Pro Glu Ala Leu 705 6710 6715 6720
- Leu Gly Glu Leu Glu Arg Met Glu Lys Ser Phe Gly Gly Leu Asp Leu 6725 6730 6735
- Thr Glu Glu Met His Glu Gln Ile Ala Gly Arg Leu Glu Val Leu Arg 6740 6750
- Ala Lys Trp Asp Ala Leu Arg Asp Thr Ala Ala Ala Ala Gly His Asp 6755 6760 6765
- Gly Ser Pro Ser Asp Glu Asp Phe Asp Phe Glu Ser Ala Ser Asp Asp 6770 6780
- Glu Val Phe Asp Leu Leu Asp Asn Glu Leu Gly Leu Ser 785 6790 6795
- <210> 5
- <211> 1650
- <212> DNA
- <213> Streptomyces natalensis

PCT/EP00/06227

WO 00/77222

<220> <221> CDS <222> (1) .. (1650) <223> ORF1 <400> 5 atg ttc gag aac cag cat ctg tca cgg cgc cgt ctg ctc gga ctg gcc 48 Met Phe Glu Asn Gln His Leu Ser Arg Arg Leu Leu Gly Leu Ala gee ete gge gge gee gea gee gga atg ace acg ate ace tee gee 96 Ala Leu Gly Gly Ala Ala Ala Gly Met Thr Thr Ile Thr Ser Ala cet cat gee geg gee gee gae egg ege agt eeg cag gee ege age gge 144 Pro His Ala Ala Ala Ala Asp Arg Ser Pro Gln Ala Arg Ser Gly teg tte gta eeg gee gtg gtg ate ggt aeg gga tae gge gee geg gte 192 Ser Phe Val Pro Ala Val Val Ile Gly Thr Gly Tyr Gly Ala Ala Val tee geg etg egg ete gge gag gee gga att eee aeg ete atg ete gaa 240 Ser Ala Leu Arg Leu Gly Glu Ala Gly Ile Pro Thr Leu Met Leu Glu atg ggc cag ctg tgg aac aag ccc gcc gac gac ggc aac gtc ttc tgc 288 Met Gly Gln Leu Trp Asn Lys Pro Ala Asp Asp Gly Asn Val Phe Cys gga atg ctc tcg ccc gac cgc ccc agc tcg atc aag tcc cgc acc 336 Gly Met Leu Ser Pro Asp Arg Arg Ser Ser Trp Phe Lys Ser Arg Thr 100 105 gag gee eeg ete gge teg tte etg tgg etg gat gtg ate aac ege gae 384 Glu Ala Pro Leu Gly Ser Phe Leu Trp Leu Asp Val Ile Asn Arg Asp 115 ate gae eeg tae geg gga gtg etg gae aag gtg cae tte gae eag atg 432 Ile Asp Pro Tyr Ala Gly Val Leu Asp Lys Val His Phe Asp Gln Met 130 teq qtq tac qtq ggg cgg ggt gtc ggc ggc tcg ctg gtc aac ggc 480 Ser Val Tyr Val Gly Arg Gly Val Gly Gly Gly Ser Leu Val Asn Gly ggg atg gcc gtc gta ccg aag cgc tcg tac ttc gag gag gtc ctc ccg 528 Gly Met Ala Val Val Pro Lys Arg Ser Tyr Phe Glu Glu Val Leu Pro egg gtg gac gee gee gag atg tae gae egg tae tte eeg ege gee aac 576 Arg Val Asp Ala Ala Glu Met Tyr Asp Arg Tyr Phe Pro Arg Ala Asn 180 tcc atg ctc aag gtg aac cac atc gac aag ggg tgg ttc gag gag acg 624 Ser Met Leu Lys Val Asn His Ile Asp Lys Gly Trp Phe Glu Glu Thr 195 gag tgg tac aag ttc gcg cgg gtc tcg cgc gag cag gcg ggc aag gcg Glu Trp Tyr Lys Phe Ala Arg Val Ser Arg Glu Gln Ala Gly Lys Ala

210 215 220 gge etg gge ace ace tte gte ece aac gte tac gae tte gae tac atg Gly Leu Gly Thr Thr Phe Val Pro Asn Val Tyr Asp Phe Asp Tyr Met 225 230 235 cgg cgc gag gcg aac ggt gag tcg ccc aag tcc gcg ctg gcg acc gag Arg Arg Glu Ala Asn Gly Glu Ser Pro Lys Ser Ala Leu Ala Thr Glu 250 gtc atc tac ggc aac aac cac ggc aaa cag agc ctg gac aag acc tac 816 Val Ile Tyr Gly Asn Asn His Gly Lys Gln Ser Leu Asp Lys Thr Tyr 260 265 ctg gcc gcc gcg ctc ggc acc ggc aag gtc acc atc gag acc ctg cac 864 Leu Ala Ala Leu Gly Thr Gly Lys Val Thr Ile Glu Thr Leu His 275 cag gtc agg gcg atc cac cag cag ccg gac ggc agc tac gtg ctg tcc 912 Gln Val Arg Ala Ile His Gln Gln Pro Asp Gly Ser Tyr Val Leu Ser 290 gtg gac cag atc gac acg gcc ggc cag acc gtc gcc cac aag gag atc Val Asp Gln Ile Asp Thr Ala Gly Gln Thr Val Ala His Lys Glu Ile 305 310 315 tcc tgc cgt cac ctg ttc ctc ggc gcc ggc agc ctc ggc tcc acc gaa 1008 Ser Cys Arg His Leu Phe Leu Gly Ala Gly Ser Leu Gly Ser Thr Glu 325 330 ctg ctg gtg cgc gcc cgg gac acc ggc gcg ctg ccc gac ctc aac gcc 1056 Leu Leu Val Arg Ala Arg Asp Thr Gly Ala Leu Pro Asp Leu Asn Ala 340 345 gag gtc ggc gcg ggc tgg ggc ccc aac ggc aac atc atg acc ggc cgq 1104 Glu Val Gly Ala Gly Trp Gly Pro Asn Gly Asn Ile Met Thr Gly Arg 355 gcc aac cac gtc tgg aac ccc acc ggg gcc cac cag tcc tcq atc ccc 1152 Ala Asn His Val Trp Asn Pro Thr Gly Ala His Gln Ser Ser Ile Pro 370 get etg gge ate gae gae tgg aac aac eec ace gee eeg gte tte gee 1200 Ala Leu Gly Ile Asp Asp Trp Asn Asn Pro Thr Ala Pro Val Phe Ala 385 390 gaa atc gcc ccg atg ccc gcc ggg ttg gag acc tgg gtc agc ctc tat 1248 Glu Ile Ala Pro Met Pro Ala Gly Leu Glu Thr Trp Val Ser Leu Tyr 405 ctg gcg atc acc aag aac ccc gag cgc ggc acc ttc gtc tac gac aaq 1296 Leu Ala Ile Thr Lys Asn Pro Glu Arg Gly Thr Phe Val Tyr Asp Lys 420 gcc acc gac cgg gcc gcg ctg cgc tgg acg cgg gac cag aac acg ccc 1344 Ala Thr Asp Arg Ala Ala Leu Arg Trp Thr Arg Asp Gln Asn Thr Pro 435 gcg gtc aac gcc gcc agg tcg ctc ttc gac cgc atc aac aag gcc aac 1392 Ala Val Asn Ala Ala Arg Ser Leu Phe Asp Arg Ile Asn Lys Ala Asn

	acg Thr															1440
	gac Asp															1488
	acc Thr															1536
	gac Asp															1584
	atc Ile 530															1632
_	gtc Val	_	_	_	tag 550											1650
<21 <21	.0> 6 .1> 5! .2> PI	₹Ţ	comy	ces i	natal	lensi	is									
	0> 6 Phe	Glu	Asn	Gln 5	His	Leu	Ser	Arg	Arg 10	Arg	Leu	Leu	Gly	Leu 15	Ala	
Ala	Leu	Gly	Gly 20	Ala	Ala	Ala	Ala	Gly 25	Met	Thr	Thr	Ile	Thr 30	Ser	Ala	
Pro	His	Ala 35	Ala	Ala	Ala	Asp	Arg 40	Arg	Ser	Pro	Gln	Ala 45	Arg	Ser	Gly	
Ser	Phe 50		Pro	Ala		Val 55		Gly	Thr	Gly	Tyr 60	Gly	Ala	Ala	Val	
Ser 65	Ala	Leu	Arg	Leu	Gly 70	Glu	Ala	Gly	Ile	Pro 75	Thr	Leu	Met	Leu	Glu 80	
Met	Gly	Gln	Leu	Trp 85	Asn	Lys	Pro	Ala	Asp 90	Asp	Gly	Asn	Val	Phe 95	Cys	
Gly	Met	Leu	Ser 100	Pro	Asp	Arg	Arg	Ser 105	Ser	Trp	Phe	Lys	Ser 110	Arg	Thr	
		D	T	C1	Sar	Phe	Leu	Trp	Leu	Asp	Val	Ile	Asn	Arg	Asp	
Glu	Ala	115	Leu	GIY	Jei		120					125			-	
	Ala Asp 130	115					120	Asp	Lys	Val	His 140		Asp	Gln	Met	



Gly	Met	Ala	Val	Val 165	Pro	Lys	Arg	Ser	Tyr 170	Phe	Glu	Glu	Val	Leu 175	Pro
Arg	Val	Asp	Ala 180	Ala	Glu	Met	Tyr	Asp 185	Arg	Tyr	Phe	Pro	Arg 190	Ala	Asn
Ser	Met	Leu 195	Lys	Val	Asn	His	Ile 200	Asp	Lys	Gly	Trp	Phe 205	Glu	Glu	Thr
Glu	Trp 210	Tyr	Lys	Phe	Ala	Arg 215	Val	Ser	Arg	Glu	Gln 220	Ala	Gly	Lys	Ala
Gly 225	Leu	Gly	Thr	Thr	Phe 230	Val	Pro	Asn	Val	Tyr 235	Asp	Phe	Asp	Tyr	Met 240
Arg	Arg	Glu	Ala	Asn 245	Gly	Glu	Ser	Pro	Lys 250	Ser	Ala	Leu	Ala	Thr 255	Glu
Val	Ile	Tyr	Gly 260	Asn	Asn	His	Gly	Lys 265	Gln	Ser	Leu	Asp	Lys 270	Thr	Tyr
Leu	Ala	Ala 275	Ala	Leu	Gly	Thr	Gly 280	Lys	Val	Thr	Ile	Glu 285	Thr	Leu	His
Gln	Val 290	Arg	Ala	Ile	His	Gln 295	Gln	Pro	Asp	Gly	Ser 300	Tyr	Val	Leu	Ser
Val 305	Asp	Gln	Ile	Asp	Thr 310	Ala	Gly	Gln	Thr	Val 315	Ala	His	Lys	Glu	Ile 320
Ser	Cys	Arg	His	Leu 325	Phe	Leu	Gly	Ala	Gly 330	Ser	Leu	Gly	Ser	Thr 335	Glu
Leu	Leu	Val	Arg 340	Ala	Arg	Asp	Thr	Gly 345	Ala	Leu	Pro	Asp	Leu 350	Asn	Ala
Glu	Val	Gly 355	Ala	Gly	Trp	Gly	Pro 360	Asn	Gly	Asn	Ile	Met. 365	Thr	Gly	Arg
Ala	Asn 370	His	Val	Trp	Asn	Pro 375	Thr	Gly	Ala	His	Gln 380	Ser	Ser	Ile	Pro
Ala 385	Leu	Gly	Ile	Asp	Asp 390	Trp	Asn	Asn	Pro	Thr 395	Ala	Pro.	Val	Phe	Ala 400
Glu	Ile	Ala	Pro	Met 405	Pro	Ala	Gly	Leu	Glu 410	Thr	Trp	Val	Ser	Leu 415	Tyr
Leu	Ala	Ile	Thr 420	Lys	Asn	Pro	Glu	Arg 425	Gly	Thr	Phe	Val	Tyr 430	Asp	Lys
Ala	Thr	Asp 435	Arg	Ala	Ala	Leu	Arg 440	Trp	Thr	Arg	Asp	Gln 445	Asn	Thr	Pro
Ala	Val 450	Asn	Ala	Ala	Arg	Ser 455	Leu	Phe	Asp	Arg	Ile 460	Asn	Lys	Ala	Asn
Gly 465	Thr	Met	Tyr	Arg	Tyr 470	Asp	Leu	Phe	Gly	Pro 475	Gln	Leu	Lys	Asn	Phe 480

WO 00/77222 PCT/EP00/06227

Ser Asp Asp Phe Cys Tyr His Pro Leu Gly Gly Cys Val Leu Gly Lys 485 Ala Thr Asp Gly Tyr Gly Arg Val Ala Gly Tyr His Asn Leu Tyr Val Thr Asp Gly Ala Leu Ile Pro Gly Ser Ile Gly Val Asn Pro Phe Val 520 Thr Ile Thr Ala Leu Ala Glu Arg Asn Ile Glu Arg Ile Ile Ala Glu 535 Asp Val Lys Ala Ala <210> 7 <211> 1197 <212> DNA <213> Streptomyces natalensis <220> <221> CDS <222> (1)..(1197) <223> ORF2 <400> 7 atg acg tac aca gac eeg gee geg eec gag acg gat eeg eeg gee gte 48 Met Thr Tyr Thr Asp Pro Ala Ala Pro Glu Thr Asp Pro Pro Ala Val 15 gae ttt eeg cag ege aag eee gge gtg eeg tte eeg eeg eec gae tae Asp Phe Pro Gln Arg Lys Pro Gly Val Pro Phe Pro Pro Pro Asp Tyr 20 25 gcc gac tac cgc gac cgg aag ggg ctc gtc ctc tcg cag ctg tcc gac Ala Asp Tyr Arg Asp Arg Lys Gly Leu Val Leu Ser Gln Leu Ser Asp 144 35 ggc aaa cgg gta tgg ctg gtc acc cgg cac gag gac gta cgc gcc gta 192 Gly Lys Arg Val Trp Leu Val Thr Arg His Glu Asp Val Arg Ala Val 50 ctg acc agc ccg agc atc agc tcg aac ccc gag cac aag gga ttt ccc 240 Leu Thr Ser Pro Ser Ile Ser Ser Asn Pro Glu His Lys Gly Phe Pro 65 aac gtc ggg aac ctg ggt gtg ccc aag cag gac cag atc ccg ggc tgg 288 Asn Val Gly Asn Leu Gly Val Pro Lys Gln Asp Gln Ile Pro Gly Trp 95 ttc gtg ggc atg gac tcc ccc gag cac gac cgg ttc cgc aag gcc ctc Phe Val Gly Met Asp Ser Pro Glu His Asp Arg Phe Arg Lys Ala Leu 100 110 atc ccg gag ttc acc gtc cgg cgg gta cgc gcg atg aag ccc gcg atc Ile Pro Glu Phe Thr Val Arg Arg Val Arg Ala Met Lys Pro Ala Ile 115 gaa cgc acg gtg gac gcc caa ctg gac gcc atg ctg gcc gcg ggc aac Glu Arg Thr Val Asp Ala Gln Leu Asp Ala Met Leu Ala Ala Gly Asn

	130					135					140					
acc Thr 145	gcc Ala	gac Asp	ctc Leu	gtc Val	gcc Ala 150	gac Asp	ttc Phe	gcc Ala	ctg Leu	ccc Pro 155	atc Ile	ccc Pro	tcc Ser	ctg Leu	gtg Val 160	480
atc Ile	tcc Ser	gca Ala	ctg Leu	ctc Leu 165	ggc Gly	gtg Val	ccg Pro	ccc Pro	gcc Ala 170	gac Asp	cgc Arg	gag Glu	ttc Phe	ttc Phe 175	gag Glu	528
tcc Ser	agg Arg	acc Thr	cgc Arg 180	gtc Val	ctg Leu	gtc Val	tcc Ser	ctc Leu 185	cgc Arg	tcc Ser	tcc Ser	acc Thr	gac Asp 190	gac Asp	gac Asp	576
cgg Arg	atg Met	gcc Ala 195	gcc Ala	gcc Ala	aag Lys	gac Asp	ctc Leu 200	ctg Leu	cgg Arg	tac Tyr	atc Ile	aac Asn 205	cgg Arg	ctc Leu	gtg Val	624
gag Glu	atc Ile 210	aaa Lys	cag Gln	aag Lys	tgg Trp	ggc Gly 215	ggc Gly	gac Asp	gac Asp	ctc Leu	atc Ile 220	acc Thr	cgg Arg	ctg Leu	ctg Leu	672
gcc Ala 225	acc Thr	ggt Gly	gcc Ala	atc Ile	gcc Ala 230	ccc Pro	cac His	gaa Glu	atg Met	tcc Ser 235	ggc	gtg Val	ctg Leu	atg Met	ctc Leu 240	720
ctg Leu	ctc Leu	atc Ile	gcc Ala	ggc Gly 245	cac His	gag Glu	acc Thr	acg Thr	gcc Ala 250	aac Asn	aac Asn	atc Ile	gcc Ala	ctc Leu 255	ggc Gly	768
gtg Val	gtc Val	acc Thr	ctg Leu 260	ctg Leu	gcg Ala	aac Asn	ccc Pro	caa Gln 265	tgg Trp	atc Ile	ggc	gac Asp	gac Asp 270	cgg Arg	gcc Ala	816
gtg Val	gag Glu	gag Glu 275	acc Thr	ctg Leu	cgc Arg	ttc Phe	cac His 280	tcc Ser	gtc Val	gcc Ala	gac Asp	ctg Leu 285	gtg Val	tcc Ser	ctg Leu	864
cgc Arg	gtc Val 290	gcg Ala	gtc Val	cag Gln	gac Asp	gtg Val 295	gaa Glu	atc Ile	gcc Ala	gjà aaa	cag Gln 300	ctc Leu	atc Ile	aag Lys	gcg Ala	912
ggc Gly 305	gag Glu	gga Gly	atc Ile	gtg Val	ccg Pro 310	ctg Leu	gtc Val	gcc Ala	gcc Ala	gcc Ala 315	aat Asn	cat His	gac Asp	gag Glu	aac Asn 320	960
gcc Ala	ttc Phe	gaa Glu	tgc Cys	ccc Pro 325	cac His	gcc Ala	ttc Phe	gac Asp	ccg Pro 330	tcc Ser	cgg Arg	tcc Ser	gcc Ala	cgc Arg 335	cac His	1008
cat His	gtg Val	gcc Ala	ttc Phe 340	ggc	tac Tyr	ggc Gly	gta Val	cac His 345	caa Gln	tgc Cys	ctg Leu	gga Gly	cag Gln 350	aac Asn	ctg Leu	1056
gtg Val	cgg Arg	atc Ile 355	gag Glu	atg Met	gaa Glu	gtc Val	gcg Ala 360	tac Tyr	cgg Arg	aaa Lys	ctc Leu	ttc Phe 365	gag Glu	cgc Arg	atc Ile	1104
ccg Pro	aac Asn 370	ctc Leu	gaa Glu	ctc Leu	gcc Ala	gtg Val 375	ccc Pro	acc Thr	gac Asp	gly aaa	ttg Leu 380	gac Asp	atc Ile	aag Lys	tac Tyr	1152

: ` '



gac ggc gtg ctc tac ggc ctg aac gag ctg ccc gtc cgc tgg tag 1197 Asp Gly Val Leu Tyr Gly Leu Asn Glu Leu Pro Val Arg Trp 390 <210> 8 <211> 399 <212> PRT <213> Streptomyces natalensis Met Thr Tyr Thr Asp Pro Ala Ala Pro Glu Thr Asp Pro Pro Ala Val Asp Phe Pro Gln Arg Lys Pro Gly Val Pro Phe Pro Pro Pro Asp Tyr Ala Asp Tyr Arg Asp Arg Lys Gly Leu Val Leu Ser Gln Leu Ser Asp Gly Lys Arg Val Trp Leu Val Thr Arg His Glu Asp Val Arg Ala Val 50 Leu Thr Ser Pro Ser Ile Ser Ser Asn Pro Glu His Lys Gly Phe Pro Asn Val Gly Asn Leu Gly Val Pro Lys Gln Asp Gln Ile Pro Gly Trp Phe Val Gly Met Asp Ser Pro Glu His Asp Arg Phe Arg Lys Ala Leu Ile Pro Glu Phe Thr Val Arg Arg Val Arg Ala Met Lys Pro Ala Ile . 115 120 Glu Arg Thr Val Asp Ala Gln Leu Asp Ala Met Leu Ala Ala Gly Asn 135 Thr Ala Asp Leu Val Ala Asp Phe Ala Leu Pro Ile Pro Ser Leu Val 145 150 Ile Ser Ala Leu Leu Gly Val Pro Pro Ala Asp Arg Glu Phe Phe Glu Ser Arg Thr Arg Val Leu Val Ser Leu Arg Ser Ser Thr Asp Asp Asp 180 Arg Met Ala Ala Lys Asp Leu Leu Arg Tyr Ile Asn Arg Leu Val Glu Ile Lys Gln Lys Trp Gly Gly Asp Asp Leu Ile Thr Arg Leu Leu 210 215 Ala Thr Gly Ala Ile Ala Pro His Glu Met Ser Gly Val-Leu Met Leu 230 Leu Leu Ile Ala Gly His Glu Thr Thr Ala Asn Asn Ile Ala Leu Gly 245 Val Val Thr Leu Leu Ala Asn Pro Gln Trp Ile Gly Asp Asp Arg Ala

WO 00/77222

PCT/EP00/06227

Val Glu Glu Thr Leu Arg Phe His Ser Val Ala Asp Leu Val Ser Leu 275 280 285

Arg Val Ala Val Gln Asp Val Glu Ile Ala Gly Gln Leu Ile Lys Ala 290 295 300

Gly Glu Gly Ile Val Pro Leu Val Ala Ala Ala Asn His Asp Glu Asn 305 310 315 320

Ala Phe Glu Cys Pro His Ala Phe Asp Pro Ser Arg Ser Ala Arg His 325 330 335

His Val Ala Phe Gly Tyr Gly Val His Gln Cys Leu Gly Gln Asn Leu 340 345 350

Val Arg Ile Glu Met Glu Val Ala Tyr Arg Lys Leu Phe Glu Arg Ile 355 360 365

Pro Asn Leu Glu Leu Ala Val Pro Thr Asp Gly Leu Asp Ile Lys Tyr 370 375 380

Asp Gly Val Leu Tyr Gly Leu Asn Glu Leu Pro Val Arg Trp 385 390 395

<210> 9

<211> 1194

<212> DNA

<213> Streptomyces natalensis

<220>

<221> CDS

<222> (1)..(1194)

<223> ORF3

<400> 9

atg acc gcc gcc tcc cac gac ctg ccc tgc ctc aac ctc gaa ccg ccc 48
Met Thr Ala Ala Ser His Asp Leu Pro Cys Leu Asn Leu Glu Pro Pro

1 5 10 15

aaa atg ctg aaa ctg agc ccg ctg ctg cgc gcc ttg cag gac cgg ggg 96
Lys Met Leu Lys Leu Ser Pro Leu Leu Arg Ala Leu Gln Asp Arg Gly
20 25 30

ccg atc cac cgg gtg cgc aca ccc gcc ggg gac gag gcg tgg ctg gtg
Pro Ile His Arg Val Arg Thr Pro Ala Gly Asp Glu Ala Trp Leu Val

acc cgc cac gcc gag ctc aag cag ctg ctg cac gac gag cgc atc ggc 192
Thr Arg His Ala Glu Leu Lys Gln Leu Leu His Asp Glu Arg Ile Gly
50 55 60

cgc acg cac ccc gac ccg ccc tcc gcc gcc cag tac gta cgc agc ccc 240
Arg Thr His Pro Asp Pro Pro Ser Ala Ala Gln Tyr Val Arg Ser Pro
65 70 75 80

ttc ctg gac ctg ctg atc agc gac gcc gac gcc gag tcc ggg cgt cgg
Phe Leu Asp Leu Leu Ile Ser Asp Ala Asp Ala Glu Ser Gly Arg Arg
85 90 95

Cag Gl:	g cac n His	gcc Ala	gag Glu 100	acc Thr	cgc Arg	cgc Arg	ctg Leu	ctc Leu 105	act Thr	ccg Pro	ttg Leu	ttc Phe	tcg Ser 110	gcc Ala	cgg Arg	336
Arg	gtt Val	ctg Leu 115	gaa Glu	atg Met	cag Gln	ccg Pro	aag Lys 120	gtg Val	gag Glu	gag Glu	gcc Ala	gcg Ala 125	gac Asp	acc Thr	ctg Leu	384
ct <u>s</u> Lei	gac Asp 130	gcg Ala	ttc Phe	atc Ile	gcc Ala	cag Gln 135	ggg Gly	cct Pro	ccc Pro	ggc Gly	gac Asp 140	ctg Leu	cac His	ggc	gag Glu	432
Cto Let 145	acc Thr	gtg Val	ccg Pro	ttc Phe	gcc Ala 150	ctc Leu	acg Thr	gtc Val	ctc Leu	tgc Cys 155	gag Glu	gtc Val	atc Ile	ggc Gly	gtg Val 160	480
	ccg Pro															528
aag Lys	ctg Leu	gac Asp	gac Asp 180	cgc Arg	gag Glu	ggc Gly	gcc Ala	gta Val 185	cgg Arg	gca Ala	cag Gln	gac Asp	gac Asp 190	ctg Leu	ttc Phe	576
G17 aaa	tac Tyr	gtg Val 195	gca Ala	Gly aaa	ctg Leu	gtc Val	gag Glu 200	cac His	aag Lys	cgg Arg	gcc Ala	gag Glu 205	ccc Pro	ggc	cca Pro	624
gad Asi	atc Ile 210	atc Ile	tcc Ser	cgg Arg	ctg Leu	aac Asn 215	gac Asp	ggc	gag Glu	ctg Leu	acc Thr 220	gag Glu	gac Asp	cgc Arg	gtg Val	672
gca Ala 225	cac His	ctg Leu	gcc Ala	atg Met	ggc Gly 230	ctg Leu	ctg Leu	ttc Phe	gcc Ala	999 Gly 235	ctg Leu	gac Asp	agc Ser	gtc Val	gcg Ala 240	720
ago Ser	atc Ile	atg Met	gac Asp	aac Asn 245	Gly aaa	gtg Val	gtg Val	ctg Leu	ctg Leu 250	gcc Ala	gcc Ala	cac His	ccc Pro	gat Asp 255	cag Gln	768
cgc Arc	gcg Ala	gcg Ala	gcg Ala 260	ctg Leu	gcc Ala	gac Asp	ccc Pro	gac Asp 265	gtg Val	atg Met	gcg Ala	cgt Arg	gcc Ala 270	gtg Val	gag Glu	816
gag Glu	gtg Val	ctg Leu 275	cgg Arg	acc Thr	gcc Ala	cgg Arg	gcc Ala 280	ggc Gly	gly aaa	tcg Ser	gtc Val	ctg Leu 285	ccg Pro	ccg Pro	egc Arg	864
tac Tyr	gcc Ala 290	agc Ser	gag Glu	gac Asp	atg Met	gaa Glu 295	ttc Phe	ggc	gjà aaa	gtg Val	acg Thr 300	ata Ile	cgg Arg	gcc Ala	gga Gly	912
gac Asp 305	ctg Leu	gtc Val	ctg Leu	ttc Phe	gac Asp 310	ctc Leu	ggc Gly	ctg Leu	ccc Pro	aac Asn 315	ttc Phe	gac Asp	gag Glu	cgg Arg	gcg Ala 320	960
tto Phe	aca Thr	Gly 999	ccg Pro	gag Glu 325	gaa Glu	ttc Phe	gac Asp	gcc Ala	gcc Ala 330	agg Arg	acc Thr	ccc Pro	aat Asn	ccc Pro 335	cat His	1008

WO 00/77222		
WO 00///222		PCT/EP00/06227

ctg Leu	acc Thr	ttc Phe	ggc Gly 340	cac His	ggc Gly	atc Ile	tgg Trp	cac His 345	tgc Cys	atc Ile	ggc	gcc Ala	ccc Pro 350	ctc Leu	gcg Ala	1056
cgc Arg	ctg Leu	gaa Glu 355	ctc Leu	agg Arg	acg Thr	atg Met	ttc Phe 360	acc Thr	aag Lys	ctg Leu	ttc Phe	acc Thr 365	cgc Arg	ctg Leu	ccg Pro	1104
gaa Glu	ctg Leu 370	cgc Arg	ccg Pro	gaa Glu	ctt Leu	ccg Pro 375	gtg Val	gag Glu	caa Gln	ctg Leu	cgc Arg 380	ctg Leu	aag Lys	gag Glu	ggc Gly	1152
cag Gln 385	ctg Leu	tcg Ser	ggc Gly	ggc Gly	ttc Phe 390	gcc Ala	gag Glu	ctc Leu	cgg Arg	gtg Val 395	gtc Val	tgg Trp	tag			1194
<213	0> 10 L> 39 2> PI 3> St	98 RT	comyc	ces 1	nata]	lensi	is									
	0> 10 Thr		Ala	Ser	Hic	Aen	T.e.u	Pro	Cve	Len	A cn	Ton	C1	Dwo	Dwo	
1				5			Lea	110	10	Deu	ASII	Deu	GIU	15	PIO	
Lys	Met	Leu	Lys 20	Leu	Ser	Pro	Leu	Leu 25	Arg	Ala	Leu	Gln	Asp 30	Arg	Gly	
Pro	Ile	His 35	Arg	Val	Arg	Thr	Pro 40	Ala	Gly	Asp	Glu	Ala 45	Trp	Leu	Val	
Thr	Arg 50	His	Ala	Glu	Leu	Lys 55	Gln	Leu	Leu	His	Asp 60	Glu	Arg	Ile	Gly	
Arg 65	Thr	His	Pro	qaA	Pro 70	Pro	Ser	Ala	Ala	Gln 75	Tyr	Val	Arg	Ser	Pro 80	
Phe	Leu	Asp	Leu	Leu 85	Ile	Ser	Asp	Ala	Asp 90	Ala	Glu	Ser	Gly	Arg 95	Arg	
Gln	His	Ala	Glu 100	Thr	Arg	Arg	Leu	Leu 105	Thr	Pro	Leu	Phe	Ser 110	Ala	Arg	
Arg	Val	Leu 115	Glu	Met	Gln	Pro	Lys 120	Val	Glu	Glu	Ala	Ala 125	Asp	Thr	Leu	
Leu	Asp 130	Ala	Phe	Ile	Ala	Gln 135	Gly	Pro	Pro	Gly	Asp 140	Leu	His	Gly	Glu	
Leu 145	Thr	Val	Pro	Phe	Ala 150	Leu	Thr	Val	Leu	Cys 155	Glu	Val	Ile	Gly	Val 160	
Pro	Pro	Gln	Arg	Arg 165	Ala	Glu	Leu	Thr	Thr 170	Leu	Leu	Ala	Gly	Ile 175	Ala	
Lys	Leu	Asp	Asp 180	Arg	Glu	Gly	Ala	Val 185	Arg	Ala	Gln	Asp	Asp 190	Leu	Phe	
Gly	Tyr	Val 195	Ala	Gly	Leu	Val	Glu 200	His	Lys	Arg	Ala	Glu 205	Pro	Gly	Pro	



- Asp Ile Ile Ser Arg Leu Asn Asp Gly Glu Leu Thr Glu Asp Arg Val 210 215 220
- Ala His Leu Ala Met Gly Leu Leu Phe Ala Gly Leu Asp Ser Val Ala 225 230 235 240
- Ser Ile Met Asp Asn Gly Val Val Leu Leu Ala Ala His Pro Asp Gln 245 250 255
- Arg Ala Ala Leu Ala Asp Pro Asp Val Met Ala Arg Ala Val Glu 260 265 270
- Glu Val Leu Arg Thr Ala Arg Ala Gly Gly Ser Val Leu Pro Pro Arg 275 280 285
- Tyr Ala Ser Glu Asp Met Glu Phe Gly Gly Val Thr Ile Arg Ala Gly 290 295 300
- Asp Leu Val Leu Phe Asp Leu Gly Leu Pro Asn Phe Asp Glu Arg Ala 305 310 315 320
- Phe Thr Gly Pro Glu Glu Phe Asp Ala Ala Arg Thr Fro Asn Pro His 325 330 335
- Leu Thr Phe Gly His Gly Ile Trp His Cys Ile Gly Ala Pro Leu Ala 340 345 350
- Arg Leu Glu Leu Arg Thr Met Phe Thr Lys Leu Phe Thr Arg Leu Pro 355 360 365
- Glu Leu Arg Pro Glu Leu Pro Val Glu Gln Leu Arg Leu Lys Glu Gly 370 375 380
- Gln Leu Ser Gly Gly Phe Ala Glu Leu Arg Val Val Trp 385 390 395
- <210> 11
- <211> 40
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: Forward primer ermE promoter
- <400> 11
- aaactgcagc tctagaggcg gcttgcgccc gatgctagtc

- <210> 12
- <211> 70
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: Reverse primer ermE promoter
- <400> 12

WO 00/77222



aaactgcagc tctagatggc ccgggtatcg atcgtcgacg gcatgcggat cctaccaacc	60							
ggcacgattg	70							
<210> 13 <211> 30 <212> DNA <213> Artificial Sequence								
<pre><220> <223> Description of Artificial Sequence: Forward primer ORF1</pre>								
<400> 13 aggattaccc atatgttcga gaaccagcat								
<210> 14 <211> 20 <212> DNA <213> Artificial Sequence								
<220> <223> Description of Artificial Sequence: Reverse primer ORF1								
<400> 14 qcatqaqcqt qqqaattccq	20							

??

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/53 C12N C12N15/52 C12N9/02 C12N9/04 C12P19/62 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N C12P C07H IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, STRAND, EMBL C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category ' Relevant to claim No. APARICIO ET AL.: "The biosynthetic gene X 1-13. cluster for the 26-membered ring polyene 15 - 27macrolide pimaricin. A new polyketide synthase organization encoded by two subclusters separated by functionalization genes' JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 274, no. 15, 9 April 1999 (1999-04-09), pages 10133-10139, XP002120719 page 10134, column 2; figure 2 page 10137, column 2 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docucitation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means "P" document published prior to the international filing date but later than the priority date claimed "8" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 27 October 2000 08/11/2000 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2

1

NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016

van Klompenburg, W

	FC1/EF 00/0622/
(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Itegory Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
W0 95 01098 A (MONSANTO CO) 12 January 1995 (1995-01-12) page 15, line 25 -page 16, line 29 page 16, line 15 - line 29 page 19, line 23 -page 24, line 31 seq id no 8 page 30 -page 32 table 3	1-6,12, 13,15, 17,20, 21,23-27
US 5 672 497 A (COX KAREN L ET AL) 30 September 1997 (1997-09-30) column 9, line 35 - line 64; figure 1; table 11	1-7,9, 10,12, 13, 15-17, 19-21, 23-27
W0 98 11230 A (SQUIBB BRISTOL MYERS CO) 19 March 1998 (1998-03-19) seq id no 22 page 25, line 9 -page 27, line 30; claims 1-27; table 1	1-27
BRAUTASET ET AL: "Biosynthesis of the polyene antifungal antibiotic nystatin in Streptomyces noursei ATCC 11455: analysis of the gene cluster and deduction of the biosynthetic pathway" CHEMISTRY AND BIOLOGY, vol. 7, no. 6, 23 May 2000 (2000-05-23), pages 395-403, XP000953274 nysL page 401 -page 402; figure 4; table 2 -& DATABASE EMBL 'Online! EBI; ACC.NO.:AF263912, 25 May 2000 (2000-05-25 BRAUTASET ET AL.: "Streptomyces noursei ATCC 11455 nystatin biosynthetic gene cluster, complete sequence" XP002151299 nysL abstract	1-6,12, 13,24-27

Ontont danimant		Outlinester	101/21 00/0022/				
Patent document cited in search report	1	Publication date		Patent family member(s)	Publication date		
WO 9501098	Α	12-01-1995	US	5518908 A	21-05-1996		
			AT	147231 T	15-01-1997		
			AU	686200 B	05-02-1998		
			AU	7214094 A	24-01-1995		
		•	BR	9406965 A	27-08-1996		
			CA	2163120 A	12-01-1995		
			CN	1126423 A	10-07-1996		
			DE	69401436 D	20-02-1997		
			DE	69401436 T	26-06-1997		
			DK	706320 T	07-07-1997		
			EP	0706320 A	17-04-1996		
			ES	2097656 T	01-04-1997		
			GR	3023050 T	30-07-1997		
			HÜ	73324 A	29-07-1996		
			JP	9500528 T	21-01-1997		
			NZ	268794 A	27-08-1996		
			PL	312277 A	15-04-1996		
			US	5554369 A	10-09-1996		
			US	5558862 A	24-09-1996		
			US	5763245 A	09-06-1998		
US 5672497	Α	30-09-1997	AT	116364 T	15-01-1995		
·			AU	603088 B	08-11-1990		
			AU	7040587 A	24-09-1987		
			BG	60053 A	16-08-1993		
			CN	87102137 A	04-11-1987		
			DE	3750907 D	09-02-1995		
			DE	3750907 T	18-05-1995		
		•	DK	135787 A	22-09-1987		
			EP	0238323 A	23-09-1987		
	•		ES	2067443 T	01-04-1995		
			GR	3015151 T	31-05-1995		
			HU	43631 A,B	30-11-1987		
			ΙE	65709 B	15-11-1995		
			IL	81892 A	31-10-1995		
			JP	2674998 B	12-11-1997		
			JP	62275686 A	30-11-1987		
			KR	9206350 B	03-08-1992		
			NZ	219694 A	29-01-1992		
			NZ	232685 A	29 - 01-1992		
			PT	84489 A,B	01-04-1987		
			RU	2043416 C	10-09-1995		
			ZA 	8701862 A	26-10-1988 		
WO 9811230	Α	19-03-1998	NONE	_			